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Abstract 
 
Protection of neurons against oxidative stress is crucial during neuronal 
development, maintenance and for the treatment of neurodegenerative 
diseases. However, little is known about the molecular mechanisms 
underlying sex-specific maturation and survival of neurons. In the present 
study, we demonstrated NF-B-p65 mediated neuroprotection in human 
glutamatergic neurons differentiated from inferior turbinate stem cells 
(ITSCs) in a sex-dependent manner. For this we successfully differentiated 
ITSCs into MAP2+/NF200+/Synaptophysin+/vGlut2+-glutamatergic 
neurons in vitro and validated their functionality. TNF-α-dependent NF-
B-p65 activation was accompanied by significant neuroprotection against 
oxidative stress-induced neuronal death, which was unexpectedly higher in 
neurons from female donors. Accordingly, sex-specific neuroprotection of 
female neurons was followed by an increased expression of special NF-B 
target genes SOD2 and IGF2. Among these, SOD2 is a well known gene 
protecting cells against oxidative stress resulting in longevity. While, IGF2 
is known to promote synapse formation and spine maturation, and it has 
antioxidant and neuroprotective effects against oxidative damage.  
In addition, little is known about the role of NF-κB signaling in the 
regulation of neuronal differentiation particularly in human neural stem 
cells. In order to shed light on the understanding of NF-κB mechanisms 
during neuronal differentiation we efficiently differentiated ITSCs into 
glutamatergic and dopaminergic neurons as well, and we characterized their 
NF-κB subunit distribution during early neuronal differentiation, to 
establish the relevant subunits involved in their regulation. In this work, we 
demonstrated for the first time a major function of NF-κB during early 
human neuronal differentiation of ITSCs. We discovered that during 
glutamatergic differentiation, NF-κB pattern showed a nuclear activation of 
RelB/p52 heterodimers during an early phase, and a nuclear c-Rel 
activation peak during a later phase of differentiation. While the classical 
NF-κB subunits, RelA and p50 had no part during this differentiation. In 
contrast, during dopaminergic differentiation RelA had an important 
nuclear activity during an initial phase, whereas c-Rel showed a clear 
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nuclear peak at a medial phase of differentiation, and RelA and RelB were 
both strongly increased at a final phase of dopaminergic differentiation. 
These results confirmed that NF-κB activity is strictly regulated during 
neuronal differentiation, and thus NF-κB-signalling might have a particular 
temporal pattern during the differentiation towards different cell fates. 
Furthermore, our findings revealed that pentoxifylline directly induced a 
shift from glutamatergic fate towards the oligodendrocyte fate, due to c-Rel 
nuclear inhibition, and also demonstrated that c-Rel has a key role in cell 
survival and neuronal fate. These results strongly suggested that NF-κB-c-
Rel is essentially necessary for glutamatergic fate commitment during 
ITSCs differentiation. 
Moreover, we further analyzed differences in the ability of female and 
male-derived ITSCs to differentiate into dopaminergic neurons, and we 
determined sex-specific differences in the neuronal complexity. In addition, 
we chemically stimulated dopaminergic neurons using TNF-α, 6-
hydroxydopamine (6OHDA) and their combination, to study their 
functionality. We found out that TNF-α-treatment induced a significant 
NF-κB-p65 nuclear activation, demonstrating a crucial role of NF-κB in 
dopaminergic function. Furthermore, stimulation using 6OHDA, exhibited a 
strong alteration in the neuronal morphology in both sexes, however there 
was a higher death tendency in male-derived neurons, compared to their 
female counterparts. Although the death rate differences between female- 
and male-derived neurons were not significantly different, these trend is in 
line with gender differences observed in Parkinson's disease, where more 
men are diagnosed with the disease than women. Also, our results introduce 
a neuroprotective effect induced by the activation of NF-κB-p65 mediated 
by TNF-α-pretreatment upon 6-OHDA stimulation of dopaminergic 
neurons derived from both sexes. Further analysis needs to be done to 
demonstrate this neuroprotective effect, and also the potential sex-specific 
differences that might be related to it. 
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1.1 Stem cells 
Stem cells are undifferentiated cells with the potential to self-renew, 
which is to produce daughter cells with identical properties, and they also 
have the capacity to differentiate into highly specialized cell types (Fig. 1-
1). Stem cells play an essential role at different stages of development and 
also within the postnatal organism5. There are distinct kinds of stem cells 
according to their differentiation potential. After fertilization, the zygote is 
the unique cell to be totipotent, which is to be capable to form all cell 
lineages of an organism including the extraembryonic tissues like the 
placenta, this characteristic is present until the stage of 4 blastomeres6. 
Pluripotent stem cells are more specialized cells, being capable to give rise 
to cells from all three germ layers: endoderm, mesoderm, ectoderm and 
germ cells, but they do not form extraembryonic tissues. Examples of 
pluripotent stem cells are the embryonic stem cells (ESCs) and the induced 
pluripotent stem cells (iPSCs). In contrast, multipotent stem cells are more 
restricted in their differentiation potential and can develop multiple cell 
types but only within a specific lineage. Ultimately, unipotent cells can 
differentiate only into one cell type. Adult stem cells (ASCs), also called 
somatic stem cells can be either multipotent or unipotent stem cells5,7.  
 
 
 
 
Figure 1-1. Stem cells celf-renew and differentiation. Stem cells have the potential to 
self-renew and are able to differentiate into highly specialized cell types. 
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1.1.1 Embryonic stem cells and induced pluripotent stem cells 
Embryonic stem cells (ESCs), which are derived from the inner cell 
mass of the blastocyst, are defined by their capacity for unlimited self-
renewal and their ability to differentiate into somatic cells of all three 
embryonic lineages and germ cells8-9. Since the first description of mouse 
ESCs10-11, it has been clear that the derivation of human ESCs (hESCs) 
could provide a unique model to study early human development and 
differentiation, as well as drug screening for treating multiple diseases12. 
hESCs were established in 199813, and were capable of unlimited 
undifferentiated proliferation in vitro. They were also able to give rise to 
teratomas including cells from all three germ layers in vivo, when grafted 
into immunodeficient mice12. hESCs showed normal karyotypes, expressed 
high levels of telomerase activity, and expressed cell surface markers that 
characterize primate embryonic stem cells13. There are some exclusive 
surface markers in hESCs such as SSEA-3, SSEA-4, TRA-1-60 and TRA-1-
81 and transcription factors like OCT4, SOX2 and NANOG that identify 
them as pluripotent8,12,14-16. These undifferentiated cells also show a high 
alkaline phosphatase activity, a high nucleus to cytoplasm ratio, prominent 
nucleoli, as well as a short G1 phase of the cell cycle and form multi-layered 
colonies17-20. There are many differences among mouse and human 
embryonic stem cells, in particular they respond differently to extrinsic 
signals and express different markers. Nevertheless, microRNA expression 
profiles in both revealed that ESCs express a distinctive set of miRNAs and 
that some of these are conserved among both species21-22. 
Moreover with the arrival of new cellular reprogramming techniques, 
Yamanaka and Takahashi demonstrated that ectopic expression of four 
transcription factors normally expressed in ESCs (OCT4, SOX2, KLF4 and 
c-MYC) was enough to reset a somatic cell like a fibroblast back to an 
embryonic-like stem cell23, achieving the derivation of induced pluripotent 
stem cells (iPSCs). This accomplishment had strong clinical implications, 
such as the possibility to derive disease-specific and patient-specific iPSCs 
in order to study them in vitro, and to perform genetic and drug screening 
for patient-specificity treatments. However, the use of human ESCs and 
IPSCs in clinical applications for cell replacement therapies to treat a 
variety of diseases remains limited for ethical and practical reasons13. Due 
to the potential tumorigenicity, as well as the risk of the expression of 
Introduction 
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introduced genes at the genome level in the case of iPSCs24. Furthermore 
the contribution of hESCs or iPSCs to the germ line in chimeras or by 
tetraploid complementation is not feasible13. Thus, demonstration of 
pluripotency, the capacity to form cell types representing all germ layers 
had to be determined by teratoma formation and by using protocols for 
directed differentiation in vitro 12,25.  
1.1.2 Adult stem cells 
Adult stem cells (ACSs) are resident stem cells within different tissues, 
which persist in the adult organism and whose primary role is to proliferate 
and differentiate in order to replace damaged or dying cells when necessary, 
ensuring their own self-renewal26-27. Thus, these cells commit to become the 
functional cells of their tissue of origin depending on the tissue turnover.  
ASCs have the capability for self-renewal and differentiation, being either 
multipotent or unipotent5,7, depending in their differentiation potential. 
They represent a valuable source for regenerative cell based therapies, being 
easy to handle in contrast to ESCs or iPSCs, also they do not confer risk 
for teratomas and they confer low immunogenicity, having no major ethical 
concerns28. These cells can be isolated from different tissues from the same 
patient, however as they are lineage-restricted and tissue-specific, they do 
not provide a source for all potential tissue therapies within the adult 
organism5,9, having a strong preference for differentiation into specific cell 
lineages. Nevertheless, only a limited number of cells can be isolated from 
their tissue of origin. 
Most investigated adult stem cells are the neural crest derived stem cells 
(NCSCs), hematopoietic and mesenchymal stem cells derived from the bone 
marrow, and neural stem cells derived from the brain3,7,28. Other tissue-
specific stem cells have limited differentiation potential and they are 
unipotent, like muscle satellital cells. However, the multipotency or 
unipotency of ASCs do not impede their therapeutic application, being a 
rather favourable feature. Nevertheless depending on their potential they 
should be applied in a tissue specific manner7. In the following, this thesis 
will especially focus in neural crest-derived stem cells and neural stem cells. 
Introduction 
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1.1.3 Neural crest derived stem cells  
During vertebrate development, neural crest (NC) cells migrate from the 
border between the neural plate and the prospective epidermis and give rise 
to a wide variety of cell types such as neurons, glial cells, and melanocytes29 
(Fig. 1-2). The induction of early NC territory depends upon the 
coordinated action of a set of signalling molecules and transcription factors 
during gastrulation and neurulation stages30. The integration of these 
diffusible signalling molecules: bone morphogenetic proteins (BMPs) 
produced by the ectoderm, anti-BMPs derived from the neural plate, like 
chordin, noggin and follistatin (neural inducers), Wnt proteins and retinoic 
acid (RA) originated from the posterior mesoderm that caudalize the neural 
tissue, and FGF (fibroblast growth factor) and Notch that originate from 
the paraxial mesoderm, produce a gradient that initiates the neural crest 
transcription program at the neural plate border. These transcription 
factors activate another set of genes that are expressed specifically in the 
prospective neural crest and play important roles in the establishment and 
maintenance of the neural crest. As part of NC induction, neural crest cells 
undergo an epithelial-to-mesenchymal transition and delaminate along 
almost the entire length of the embryo31. Snail, a neural crest specifier, 
plays a crucial role in this transformation, because it directly represses E-
Cadherin, an important cell adhesion molecule promoting delamination32. 
Upon delamination, activation of patterning genes such as Sox10 begins and 
neural crest cells migrate extensively to colonize their prospective tissue, 
and they are progressively restricted in their potential as they settle down. 
The pre-migratory neural crest is subdivided into four distinct axial 
populations, the cranial, cardiac, vagal and trunk neural crest, each of them 
migrate along distinct pathways and contribute to different tissues at 
distinct axial levels31. Cranial neural crest cells give rise to cartilage and 
bone, as well as connective tissue, pigment cells and sensory and 
parasympathetic ganglia. Cardiac neural crest cells contribute to the 
aorticopulmonary septum, the aortic arch and parasympathetic cardiac 
ganglia. Vagal neural crest cells populate the gut and neurons and glia from 
the enteric nervous system. The trunk neural crest cells differentiate into 
neurons and glia of the peripheral nervous system, caudal enteric nervous 
system and pigment cells31.    
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The persistence of these neural crest-derived stem cells (NCSCs) into 
adulthood was found within various craniofacial tissues, such as the skin, 
cornea, periodontal ligament, palate, pulp of teeth and nasal turbinates1,33-38. 
Adult NCSCs have the capacity for self-renewal and the ability to 
differentiate into multiple lineages under appropriate conditions, and they 
represent a promising stem cell population for cell-based therapies3. NCSCs 
express high levels of nestin, an intermediate filament essential for self-
renewal in neural stem cells39, as well as several additional neural crest 
markers like the low-affinity nerve growth factor receptor (p75), that vary 
between different populations of NCSCs. 
1.1.4 Inferior turbinate stem cells 
Among neural crest-derived stem cells, inferior turbinate stem cells 
(ITSCs) were localized within the respiratory epithelium of the adult 
human inferior turbinate (Figure 1-3). Within their endogenous niche, 
ITSCs are located within the lamina propia, near the nerve fibers between 
 
 
Figure 1-2. Neural crest. Schematic overview showing neural crest formation, 
delamination and migration, and their ability to differentiate into cells of both mesodermal 
and ectodermal cell types. NCSCs also persist as uncommitted cells within the adult, 
Modified from Kaltschmidt et al. 20123. 
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the glands, and they express NCSCs specific markers Nestin, S100 and 
p75NTR, being glial in nature. When cultured in vitro, they also showed high 
expression levels of Nestin, S100, SLUG and SOX10, and they form spheres 
under serum-free conditions1. Furthermore, ITSCs have a great 
differentiation capability; they are able to differentiate into diverse 
mesodermal and neuro-ectodermal cell types such as adipocytes, 
chondrocytes, osteocytes and glutamatergic and dopaminergic neurons 1,40. 
Thus, ITSCs differentiate into neural stem cells, which can give rise to 
neurons, astrocytes and oligodendrocytes (Fig. 1-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, these cells do not form teratomas and are a very easily 
accessible stem cell population, which makes them a promising candidate 
for the potential clinical use. Considering this, and their capability to 
efficiently differentiate into functional mature glutamatergic and 
dopaminergic neurons in vitro, ITSCs harbour an immense potential as a 
model for drug screening and for the treatment of neurodegenerative 
diseases as well as for other cell-based therapies1. Also, as shown by 
previous findings, transplanted ITSCs functionally improved a parkinsonian 
rat model, as demonstrated by behavioural tests40. After transplantation, 
cells were able to survive and migrate towards the damaged brain area, and 
they differentiated into functional neurons. Therefore, ITSCs have a 
tremendous potential for clinical use. However, little is known about the 
 
Figure 1-3. Inferior turbinate stem cells localization within the respiratory epithelium 
of the inferior turbinate of human nose. (A) Schema of the internal structure of the 
nasal cavity showing the superior, middle and inferior turbinates respectively. (B) 
hematoxylin-eosin staining of a human inferior turbinate section showing the epithelium 
and its ciliated surface. C) Inferior turbinate section immunostained against nestin, 
showing putative stem cells found within the LP and the basal cells of the RE. RE: 
respiratory epithelium, LP: lamina propria. Modified from Hauser 20121.  
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molecular mechanisms regulating their fate decisions during differentiation, 
especially into the neuronal fate.  
 
 
1.1.5 Neural stem cells 
Neural stem cells are present in neurogenic niches in discrete regions of 
the adult brain, in the subventricular zone of the lateral ventricle and in 
the subgranular zone of the dentate gyrus in the hippocampus41-42. Other 
types of neural stem cells are also found in the peripheral nervous system 
(PNS), and originate from the neural crest during embryogenesis43. NSCs 
are self-renewing cells capable of differentiating into neurons, astrocytes and 
oligodendrocytes44-45, within the embryo they are also known as radial glial 
cells, and in the adult brain as astrocyte-like stem cells45. Both embryonic 
and adult neural stem cells are glial in nature and share an epithelial 
morphology essential to their stem cell properties. They had a long process 
that extends radially from the ventricular apical surface, to the outer pial 
surface (basal), and expressed high levels of nestin and glial fibrillary acidic 
protein42. Notch signalling maintains their proliferative state, while its 
withdrawal promotes neural differentiation46. NSCs undergo distinct modes 
of cell division, giving rise to a great diversity of glial and neuronal cell 
types in the central nervous system (CNS) 41.  As well as they become 
restricted in their potential to produce specific subtypes of neurons and glial 
cells, which are defined by their position within the embryo, due to regional 
specific transcription factors that are expressed in different rostro-caudal 
and dorso-ventral positions44,47. NSCs also generate neuronal and glial 
intermediate progenitor cells that are capable of generating various 
 
 
 
Figure 1-4. Inferior turbinate stem cells differentiation in the neural 
lineage. ITSC are able to differentiate into neural stem cells (NSCs), which 
can further differentiate into neurons, astrocytes and oligodendrocytes. 
NCSCs:neural crest stem cells. 
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neuronal or glial cell types41, such as oligodendroglial progenitor cells 
(OPCs) which can also differentiate into astrocytes, schwann cells, neurons 
and oligodendrocytes48.                          
1.2 Differentiation 
1.2.1 Fate specification   
The stem cell decision to self-renew or to differentiate is intrinsically 
controlled by the interplay of specific transcription factors and chromatin 
regulators49. As mentioned before, several key transcription factors are 
responsible for the self-renewal including OCT4, NANOG and SOX250-51. 
During development in mammals, the first fate decision occurs during 
compaction where the cells from the outer layer of the 8-cell embryo 
develop tight junctions and the cells from the center develop gap junctions, 
thus the outer cells are specified into the trophectoderm and the central 
cells into the inner cell mass respectively52. Moreover, after blastocoel 
formation, during gastrulation, cell movements allow the interaction of 
different cell populations segregated until then, and these interactions 
together with the expression of genes induce the specification of different 
cell populations into the three germ layers, endoderm, mesoderm and 
ectoderm. These extrinsic and intrinsic factors are also used for the 
specification in vitro of embryonic and adult stem cells. Bone 
morphogenetic proteins (BMPs), WNT and Activin/Nodal pathways which 
are implied in germ layer development are manipulated to obtain these 
lineages in vitro53-54. Both WNT and Activin/Nodal signalling are required 
for the beginning of gastrulation and favour differentiation into specific 
derivatives in vitro. In particular, high levels of Activin were shown to 
induce endoderm formation in culture55, while BMP4 (bone morphogenetic 
protein 4) signalling is necessary for mesoderm specification. Thus, cell fate 
decisions occurring in vitro resemble those occurring during development. 
1.2.2 Neuronal fate specification  
Neurons share many features, but they have different phenotypic 
characteristics that define their function, localization and connectivity. The 
diversification in different neuronal subtypes in nervous system 
development involves the integration of extrinsic and intrinsic instructive 
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signals that result in the expression of distinct regulatory molecules in a 
spatial and temporal manner. Thus, neuronal induction and differentiation 
follow a common pattern, of activation and inhibition of various signalling 
pathways which are strongly regulated epigenetically, in particular by 
histone modifications and DNA methylation56. At the end of gastrulation 
the prospective neural tissue is already induced and has began to be 
patterned. The neuronal specification takes place along the rostral-caudal 
and the dorsal-ventral axes of the neural tube, being coordinated by 
patterning molecules that confer positional identity. Neural stem cells and 
other neural progenitor cells (NPCs) respond differently to distinct 
concentrations of the same molecule, and therefore they differentiate into 
region-specific progenitors in response to locally positioned/derived 
signals42,44,57. For example, Sonic hedgehog (SHH), is secreted by the 
notochord and the floor plate of the neural tube (ventralizing activity), 
whereas WNT proteins and bone morphogenetic proteins (BMPs) are 
secreted from dorsal regions, by the roof plate and the ectoderm, 
establishing the dorsal-ventral axis42. Thus, treatment with increasing 
concentrations of SHH promote the ventralization, while retinoic acid (RA), 
FGF and β-catenin promote specification of more posterior fates58. WNT 
gradient helps to establish the rostral/caudal axis, and its signalling 
activation produces a dose-dependent effect where increasing levels are 
patterning the NPCs to forebrain, midbrain, hindbrain and anterior spinal 
cord identities, respectively42,58-60. The resulting morphogen gradient specifies 
neurons into different subtypes along both dorsal-ventral and anterior-
posterior axes, leading to CNS morphogenesis. Neuronal differentiation in 
vitro recapitulates this regional patterning principle from in vivo 
morphogenesis61. 
Moreover, a specific neurotransmitter subtype is usually produced in 
different parts of the brain at different stages of development, 
demonstrating that different spatiotemporal signalling molecules converge 
inducing a similar fate62. Then, once specified cells are patterned into 
specific regional fates, and they finally differentiate into neurons and glia42. 
Cells specified to a neuronal fate express a series of proneural genes either 
alone or in concert with additional neuronal differentiation genes, which 
activate Notch signalling pathway, cell cycle withdrawal and pan-neuronal 
and cell type-specific gene expression63.  
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Glutamatergic neuronal fate 
Excitatory glutamatergic neurons are found throughout the central 
nervous system, in the cerebral cortex, in the subcortical regions and within 
the spinal cord 58,64-65. Despite the differences in their specification during 
development, the strategies that have been established to successfully 
generate glutamatergic neurons are mainly based on the derivation of 
cortical glutamatergic neurons that originate from the dorsal telencephalic 
region66. Also, forebrain identity is known as a default programme for 
neuronal differentiation, and existing protocols yield neurons with a 
glutamatergic identity without the need of a series of patterning 
molecules67. Neural progenitors differentiated from NSCs in vitro will adopt 
a regional identity depending in the morphogens present at the time the 
precursors are responsive. During development the neuroectoderm at the 
head region form first, thus neuroepithelial cells initially express forebrain 
homeobox transcription factors such as OTX1/2 (Orthodenticle homeobox 
1 and 2) and brain factor 1 (BF1), but no hox genes that are present in the 
hindbrain and spinal cord. With the exposure to morphogens like WNTs, 
RA and FGFs, which caudalize the neuroepithelial cells, less forebrain 
progenitors are present in neural differentiation cultures. Thus, Neuronal 
progenitors differentiated by treatment with RA usually display hindbrain 
and spinal cord identities. RA promotes the expression of Hox genes but 
suppresses the expression of OTX2 and BF1 in a dose dependent manner. 
In contrast FGF8 (fibroblast growth factor 8) favours the differentiation of 
neural progenitors with mid/hindbrain characteristics, while FGF2 
(fibroblast growth factor 2) favours differentiation into a mixed population 
with a range of identities from forebrain to spinal cord phenotypes47. 
Further restriction by dorsal-ventral morphogens limits the differentiating 
neurons to a specific state in the dorsal-ventral domain of the neural tube. 
Therefore, glutamatergic neurons are produced by a series of genetically 
programmed fate choices, applied by developmental transcription factors 
which are expressed sequentially during glutamatergic neurogenesis, PAX6 
(paired box 6), TBR2 (T-box brain protein 2), NEUROD (neuronal 
differentiation 1), and TBR1 (T-box brain protein 1), which are initially 
conserved in neocortex, cerebellum, and adult hippocampus. However, 
subtypes of glutamatergic neurons are further induced by other 
combinations of transcription factors expressed afterwards in each region68. 
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Neurogenin2 (NGN2) regulates glutamatergic differentiation of early-born 
neurons in the developing forebrain, and expression of TBR1 and TBR2. 
Whereas MATH1 regulates glutamatergic neuron development and TBR1 
expression in the cerebellum. In addition, MATH1 was found to be 
necessary for TBR2 and PAX6 expression in the cerebellum68. Furthermore, 
molecules that orchestrate neurogenesis not only include transcription 
factors, but also environmental factors. 
 
Dopaminergic neuronal fate 
Dopaminergic neurons are localized in the diencephalon, mesencephalon 
and the olfactory bulb69. Protocols differentiating cells into dopaminergic 
neurons have focused in particular in the neurons originating from the 
midbrain54,70 due to their applicability for the treatment of Parkinson’s 
disease. The molecular patterning and specification of these dopaminergic 
neurons has been largely studied, over the last decades. Midbrain 
dopaminergic neurons are specified from the floor plate in the 
mesencephalon, regulated by WNT, SHH and FGF-8 signalling, essential 
morphogens for dopaminergic specification71-72. Neuronal progenitors in the 
midbrain are characterized by the expression of LMX1A (LIM homeobox 
transcription factor 1 alpha), FOXA2 (forkhead box A2), EN1 (Engrailed 
Homeobox 1) and OTX2 72. WNT1 (Wnt family member 1) induces the 
expression of OTX2, which in turn represses GBX2 (Gastrulation brain 
homeobox 2) to maintain the mid-hindbrain organizer and also represses 
NKX2-2 (NK2 homeobox 2), which is a negative regulator that replaces the 
dopaminergic neurons by serotonergic neurons in the absence of OTX273. 
OTX2 induces LMX1A expression, which in turn induces the pro-neural 
gene NGN2 through MSX1 (msh homeobox 1) or represses NKX6-1 (NK6 
homeobox 1) to inhibit differentiation into alternative neuronal fates74-75. 
This principle also guides the differentiation of human midbrain 
dopaminergic neurons in vitro, as shown by different protocols based on 
chemically defined systems. A diversity of this systems that rely on the 
activation of FGF8 and SHH signalling pathways, have shown the efficient 
differentiation into the dopaminergic phenotype, of neurons expressing 
tyrosine hydroxylase (TH)76-79. However, the combination of FGF8 and SHH 
alone was not sufficient to restrict their specification to the midbrain fate76. 
The addition of WNT signalling by using GSK3β inhibitor CHIR99021, 
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improve the efficiency in the specification into midbrain dopaminergic 
neurons4,59,76,80-81. A short WNT induction with CHIR99021, during early 
dopaminergic differentiation of human epidermal NCSCs, allowed their 
restriction into a midbrain dopaminergic neuronal fate, showing a great 
potential for the use of directed dopaminergic differentiation in vitro for 
modelling neurodegenerative diseases 4,40. 
1.3 Nuclear Factor kappa B  
1.3.1 NF-κB signalling  
NF-B (nuclear factor kappa-light-chain-enhancer of activated B-cells) 
is a ubiquitously expressed, inducible transcription factor that regulates the 
expression of a broad number of genes and is involved in diverse cellular 
processes such as cell survival, growth, stress, immune and inflammatory 
responses 82. Furthermore, within the nervous system NF-B has special 
functions, being involved in neuroprotection/degeneration, in neurite 
growth 83, in dendritic spine formation and functionality 84, in axonal 
outgrowth 85 and synaptic plasticity 86-87.  
In mammalian cells the NF-B family consists of five subunits, 
p50/p105, p52/p100, p65 (RelA), c-Rel and RelB, which share an N-
terminal domain known as the Rel homology domain (RHD) which allows 
their dimerization into different NF-B complexes as homo or heterodimers, 
as well as DNA binding and nuclear localization 88 (Fig. 1-5). Furthermore, 
only Rel subfamily members RelA, RelB and c-Rel contain a C-terminal 
transactivation domain, allowing them to initiate transcription. In most of 
the cells, NF-B complexes are sequestered in the cytoplasm by the 
association with an inhibitory protein of the inhibitor of B family (IB). 
Activation of NF-B is triggered by multiple stimuli (cytokines, 
neurotransmitters, mitogens and growth factors) and involves the activation 
of a kinase cascade, which ends in the activation of the IB kinase complex 
(IKK & IKK), which in turn phosphorylates specific serines within the 
inhibitory IB-alpha subunit (IB), leading to its ubiquitination and 
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proteosomal degradation. Upon release, NF-B dimers can translocate to 
the nucleus and regulate the expression of their target genes 88-90. 
Considering that NF-B has multiple roles in very diverse cellular 
processes and also within the nervous system, we hypothesized that NF-B 
may have a role during the differentiation of ITSCs, especially into the 
neuronal phenotype. Therefore in the present work, we explored the 
distribution of NF-B family members during early stages of neuronal 
glutamatergic differentiation in ITSCs. 
1.3.2 NF-κB signalling in nervous system 
Acute and chronic nervous system damage in response to an insult such 
as oxidative stress is directly associated to neuronal death and degeneration 
91. Thus, appropriate neuroprotection remains as a crucial parameter for 
effective treatment of neurodegenerative diseases. Interestingly, increasing 
evidences point towards sex-specific differences in risk, severity and 
progression of neurodegenerative diseases such as Parkinson’s (PD) or 
Alzheimer’s disease (AD) or in case of Ischemic stroke 92-94. In particular, 
female AD patients were reported to not only have an increased risk of 
developing AD compared to age-matched men 95, but also showed a 
significantly elevated age-related faster decline of cognition 93,96. On the 
contrary, PD was shown to have a greater prevalence and occurs in an 
earlier age in men compared to woman 92. Although neurodegenerative 
diseases and preventive neuroprotective mechanisms 97 seem to be subjected 
to sex-dependent differences, little is known about the underlying molecular 
mechanisms particularly regarding maturation and survival of neurons 
differentiated from human stem cells. 
The transcription factor NF-B is involved in a broad range of cellular 
processes such as cell survival, growth, stress, immune and inflammatory 
responses 82. Within the murine nervous system, the NF-B heterodimers 
cRel/p65 and p50/p65, and p50 homodimers play an important role during 
development 98, while the activity of p50/p65 was shown to be predominant 
in the adult brain99. 
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Figure 1-5. NF-κB members and signaling cascades. A) Schematic view of 
the NF-κB family members. Relevant domains are indicated and alternative 
nomenclatures are provided in parenthesis. RHD, rel homology domain; TAD, 
transactivation domain; ANK, ankirin repeats; DD, death domain. C) Schema 
showing simplified NF-κB canonical and non-canonical signaling pathways. 
NF-κB activation is triggered by multiple stimulus and involves the 
activation of a kinase cascade that ends in the IκB kinase complex activation, 
which causes the degradation of an inhibitory protein or the partial 
degradation of a NF-κB precursor. The resulting NF-κB dimers translocate 
into the nucleus and regulate the expression of different target genes.  
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Activation of NF-B can be triggered by multiple stimuli such as 
cytokines like tumour necrosis factor-α (TNF-α) or neurotransmitters like 
AMPA (agonist α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) or 
glutamate in mouse and rat cerebellar granule cells100-101. In murine neurons, 
NF-B signalling and its target genes are involved in 
neuroprotection/degeneration 86, neurite growth 83, the formation of 
dendritic spines and their functionality 84, axonal outgrowth 85 and synaptic 
plasticity87-88,102. Activation of NF-B in human and murine cells is also 
known to be caused by oxidative stress, an increase in intracellular reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2), superoxide (O2
-), 
or hydroxyl radical (OH)103. Whithin the nervous system, oxidative stress 
leads to activation of NF-B with a direct linkage to several neurologic 
diseases and brain damage104. In functional neurons from humans or mice, 
activation of various glutamate receptors also induces oxidative stress 105. 
On the contrary, reactive oxygen intermediate H2O2 is known to act as 
second messenger despite its cytotoxicity 104,106. In primary rat cerebellar 
granule cells, the direct exogenous addition of H2O2 to culture medium 
activates NF-B107, as well as it was observed previously in different human 
cell lines106,108-109. In human and mouse embryonic stem cells, metabolic 
oxidation is known to directly regulate embryonic stem cell 
differentiation110. Maintenance of redox balance was further shown to be 
crucial for stemness and self-renewal of hematopoietic stem cells (HSCs) 
and neural stem cells (NSCs)111 from mice and humans. On the other hand, 
NF-B signalling is directly linked to proliferation of rat NSCs112 and early 
neuronal differentiation of mouse NSCs113, although its direct role in 
protection of human stem cell-derived neurons against oxidative stress still 
remains unclear. 
1.3.3 Aim of the study  
The central aim of this project was to study the role of NF-κB subunits 
during the specification of inferior turbinate stem cells into the neuronal 
fate and during their maturation, in order to provide a better 
understanding of the molecular mechanisms underlying the regulation of 
stem cell properties during differentiation and neuronal physiology. 
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Therefore we initially tried to efficiently reproduce the neuronal 
differentiation of ITSCs into glutamatergic and dopaminergic neurons using 
directed differentiation assays. In addition, upon neuronal differentiation 
and maturation we verified the expression of characteristic neuronal 
subtype markers to further validate their differentiation. Also, upon their 
properly differentiation and maturation we analyzed their functionality in 
vitro by chemical stimulation. Afterwards we characterized the differential 
NF-κB subunit composition during early neuronal differentiation, to 
elucidate their role during differentiation. After we determined NF-κB 
distribution, we further studied the cell fates obtained after inhibition of the 
central subunit involved during glutamatergic differentiation, for this we 
analyzed a series of specific cellular markers, to recognize distinct cell fates. 
 20 
 
2 Materials and methods 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
 
21 
 
2.1 Isolation and Cultivation of ITSCs 
ITSCs were isolated from adult human inferior turbinate tissue obtained 
by biopsy during routine surgery after informed consent according to local 
and international guidelines and cultivated as described previously 1. The 
ethics board of the medical faculty of the University of Münster approved 
all the procedures described in this article (No. 2012-15-fS). All experiments 
were performed in accordance. For further cultivation of ITSCs within the 
3D blood plasma (BP) matrix 114, ITSCs were dissociated using pre-warmed 
Collagenase I (NB 4; Serva Electrophoresis, Heidelberg, Germany, 
http://www.serva.de) for 1 h at 37ºC on an orbital shaker (Edmund 
Bühler, Hechingen, Germany) and harvested by centrifugation at 300 g for 
10 min. ITSCs were resuspended in Dulbecco’s modified Eagle’s 
medium/Ham F-12 (DMEM/F-12; Biochrom, Berlin, Germany, 
http://www.biochrom.de) containing 2 mM L-glutamine (Sigma-Aldrich), 
penicillin/streptomycin (1x, Sigma-Aldrich), and supplemented with basic 
fibroblast growth factor-2 (FGF2; 40 ng/ml; Miltenyi Biotec), epidermal 
growth factor (EGF; 20 ng/ml; Miltenyi Biotec) and B27 supplement 
(Gibco) followed by supplementation with 10% of clinically accredited 
therapeutic human blood plasma (obtained from Institut für Laboratoriums 
und Transfusionsmedizin, Bad Oeynhausen, Germany) and cultivated at 
37C, 5% O2 and 5% CO2.  
2.2 Glutamatergic neuronal differentiation 
For neuronal differentiation, cells of three to six donors precultivated 
within the 3D BP matrix were removed from the matrix as described 
above, and resuspended in DMEM high glucose (Sigma-Aldrich) containing 
2 mM L-glutamine (Sigma-Aldrich), penicillin/streptomycin (1x, Sigma-
Aldrich) and 10 % FCS (Sigma-Aldrich) an plated at a density of 5x104 
cells per 24 well plate followed by cultivation at 37ºC, 5% CO2 and 
atmospheric O2 in a humidified incubator for 2 days. Afterwards, 1M 
dexamethasone (Sigma-Aldrich), 2 M insulin (Sigma-Aldrich), 500 M 3-
isobutyl-1-methylxanthine (Sigma-Aldrich), 200 M indomethacin (Sigma-
Aldrich) and 200 M ethanol were added to the medium to induce neuronal 
differentiation (neuronal induction medium, NIM) according to40. After 9 
Materials and methods 
 
22 
 
days of differentiation cells were induced adding 0.5 µM retinoic acid 
(Sigma Aldrich) and 1x N-2 supplement (Gibco, Darmstadt, Germany, 
http://www.invitrogen.com)115. Subsequently, the medium was changed by 
removing half of the volume, followed by addition of fresh pre-warmed NIM 
containing 1X N-2 supplement40. As a control, undifferentiated ITSCs 
within the 3D blood plasma matrix were used. ITSCs were differentiated for 
1 month, and further stimulated using different drugs, or treated for 
immunocytochemical and RT-PCR analysis (Reverse transcription 
Polymerase Chain Reaction).  
2.3 Neuronal stimulation of mature glutamatergic neurons 
After 30 days of differentiation neurons were exposed to the excitatory 
neurotransmitter glutamate (GLU) or its agonist α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate (AMPA), the cytokine Tumour Necrosis 
Factor α (TNF-α, Calbiochem®), hydrogen peroxide (H2O2), and the NF-κB 
inhibitor pyrrolidine dithiocarbamate (PDTC) 107. Before treatment with 
glutamate or AMPA, cells were washed three times with buffered control 
salt solution (CSS)116 containing 120 mM NaCl, 5.4 mM KCl, 1.8 mM 
CaCl2, 25 mM Tris HCl (pH 7.4), 15 mM D-glucose. For inhibitor controls 
cells were preincubated with either 1 μM dibenzocyclohepteneimine (MK-
801, Tochris Bioscience, UK)117 or 50 μM 6-cyano-7-nitroquinoxaline-2,3-
dione (CQNX, Tochris Bioscience, UK) 101 for 10 min at 37 °C, before 10 
min treatment with glutamate or AMPA respectively. After treatment, 
with different concentrations, cells were washed with CSS and incubated 
with complete medium for 45 min at 37ºC. Control cells received identical 
incubation times and washing steps with CSS 101. The pulse with 10 ng/ml 
TNF-α was performed for 30 min, 1 h, and 24 hours. For oxidative stress 
induction, 300 μM H2O2 were applied during 25 h and to analyze the 
neuroprotective role of NF-κB during oxidative stress, a pre-treatment with 
10 ng/ml TNF-α was performed for 2 hours previous to the treatment with 
hydrogen peroxide. Untreated control cells received identical incubation 
times in complete medium. In order to confirm NF-κB activation due to 
TNF-α, a pre-treatment using 100 μM PDTC for one hour was performed 
and afterwards samples were directly used or further treated with TNF-α 
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for at least one hour. For Indirect immunofluorescence assay cells were fixed 
for 15 min in phosphate-buffered 4% paraformaldehyde (PFA; 4% pH 7.4). 
For Smart-seq2, cells were directly used after treatment and treatment 
duration was slightly longer, PDTC and TNF-α treatment took 3h as well 
as the combination treatments.   
2.4 PTXF treatment - oligodendrocyte differentiation 
In order to inhibit c-Rel nuclear translocation during differentiation, 
cells were treated using pentoxifylline (PTXF), a known inhibitor of c-Rel2. 
For this, 500µg of PTXF per ml were added to the media, in parallel to the 
differentiation procedure. PTXF was refreshed every 1-2 days. For 
evaluating the stimulation of ITSCs using PTXF, differentiated ITSCs in 
the absence of PTXF were used as control. ITSCs were differentiated for a 
maximum of 1 month, and further treated for immunocytochemical and 
PCR analysis. 
2.5 Classical oligodendrocyte differentiation 
For classical oligodendrocyte differentiation, ITSCs were harvested and 
resuspended in DMEM high glucose (Sigma-Aldrich) containing 2 mM L-
glutamine (Sigma-Aldrich), penicillin/streptomycin (1X, Sigma-Aldrich) 
and 10% FCS (Sigma-Aldrich) an plated at a density of  25x104 cells per 6 
well plate followed by cultivation at 37ºC, 5% CO2 and atmospheric O2 in 
a humidified incubator. The next day, after attachment of the cells to the 
culture surface, medium was switched to oligodendrocyte enrichment 
medium (Millipore, OEM: DMEM/F12 with 1X NEAA, 2 mM glutamine, 
N21 medium supplement, a cocktail of growth factors recombinant human 
PDGF-AA (SRP3268), recombinant human neurotrophin-3 (N1905), and 
recombinant human basic FGF2 (F0291) to differentiate into 
olygodendrocyte progenitor cells (OPCs). Media was changed every 2-3 
days. 
2.6 In vitro myelination assay 
For in vitro myelination, olygodendrocytes derived from ITSCs cultured 
in oligodendrocyte enrichment medium (Millipore) and those derived from 
PTXF-treated differentiated ITSCs (cultured in neuronal induction media) 
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were transplanted after 20 days of differentiation and co-culture with ITSC-
derived neurons which were previously differentiated for 20 days. Cells were 
co-cultured for 10 days in NIM with N2 at 37ºC in a 5% CO2 incubator. 
Medium was changed every 2 to 3 days by replacing half of the media with 
fresh media. Afterwards cells were treated for immunocytochemical and 
RT-PCR analysis. 
2.7 Dopaminergic neuronal differentiation 
For dopaminergic differentiation, cells of six donors were expanded 
within the 3D BP matrix and further dissociated using collagenase, as 
described above. ITSCs were directly differentiated as previously reported40 
slightly modified from Sieber-Blum et al.4. Cells were seeded at a density of 
5x104 cells per 24 well plate and cultivated for 18 hours in DMEM high 
glucose containing 2 mM L-glutamine, penicillin/streptomycin and 10 % 
FCS. For neuronal induction (Fig. 2-2), cells were exposed to DMEM high 
glucose supplemented with 1% FCS, penicillin/streptomycin, β-
mercaptoethanol (10 µM), B27 without retinoic acid (1X; Life 
Technologies), purmorphamine (10 µM; Sigma-Aldrich), FGF8 (100 ng/ml; 
Peprotech), recombinant human glial cell line-derived neurotrophic factor 
(GDNF; 5 ng/ml; Peprotech), recombinant human brain-derived 
neurotrophic factor (BDNF; 20 ng/ml; Peprotech), nerve growth factor 
(NGF; 20 ng/ml; Peprotech), dibutyryl cAMP (1 mM; Sigma- Aldrich), 
ascorbic acid (200 µM; Sigma-Aldrich), SB-431542 (10µM; Sigma-Aldrich), 
LDN193189 (100 nM; Abcam, Cambridge, U.K., http://www.abcam.com), 
and CHIR99021 (0.5µM; Abcam). CHIR99021 was removed after 24 hours. 
On day 4 of differentiation, the WNT inhibitor IWP-4 (Miltenyi Biotec, 
Bergisch Gladbach, Germany, http://www.miltenyibiotec.com) was added 
to the media at a concentration of 100 nM, which was increased to 1 µM at 
day 6 of differentiation, followed by withdrawal of FCS at day 7. At day 9, 
the concentration of purmorphamine was decreased to 5 µM. Medium was 
replaced with prewarmed fresh medium daily. 
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2.8 Chemical stimulation of dopaminergic differentiated 
neurons  
After 20 days of differentiation, dopaminergic neurons were exposed to 6-
hydroxydopamine (6-OHDA), a neurotoxic synthetic organic compound 
used to selectively destroy dopaminergic neurons, the cytokine Tumour 
Necrosis Factor α (TNF-α, Calbiochem), as well as their combination. For 
the each treatment, drugs were applied in the differentiation media. The 
pulse with 10 ng/ml TNF-α was performed for 2 hours. For neurotoxic 
induction, 100 μM 6-OHDA were applied during 24 h and to analyze the 
neuroprotective role of NF-κB during it, a pre-treatment with 10 ng/ml 
TNF-α was performed for 2 hours previously. Untreated control cells 
received identical incubation times in complete medium. After treatment, 
cells were washed and directly fixated for immunocytochemical analysis.  
2.9 Immunocytochemistry 
Differentiated ITSCs were fixed in phosphate-buffered 4% 
paraformaldehyde (PFA; 4% pH 7.4) for 15 minutes at room temperature 
(RT) followed by 3 wash steps in phosphate-buffered saline (1xPBS). The 
cells were permeabilized with 0.02% Triton X-100 and blocked using 5% of 
appropriate serum or 3% BSA for 30 minutes at RT, followed by incubation 
with primary antibodies for 1 hour at RT. Primary antibodies used are 
listed in Table 1.  
 
Table 1: List of primary antibodies. 
Antibody Origin Dilution Company Code 
anti-c-Rel 
Rabbit 
polyclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-70x 
anti-c-Rel 
Rabbit 
monoclonal 
1:400 Cell Signaling #4727 
anti-RelB 
Rabbit 
polyclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-226 
anti-RelB 
Rabbit 
monoclonal 
1:1600 Cell Signaling #10544,  
anti-p65 
Mouse 
monoclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-8008 
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anti-NF-kappaB p65 
Rabbit 
monoclonal 
1:200 Cell Signaling D14E12 
anti-p50 
Mouse 
monoclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-8414 
anti p52 
Rabbit 
polyclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-298 
anti-IB 
Rabbit 
polyclonal 
1:100 
Santa Cruz 
Biotechnology 
sc-371 
anti-MAP-2 
(Microtubule-associated 
protein 2) 
Rabbit 
polyclonal 
1:100 
Santa Cruz 
Biotechnology 
Sc-20172 
Anti- Synaptophysin 
Rabbit 
monoclonal 
1:250 Merck Millipore MAB5258 
anti-vGlut2 
Mouse 
monoclonal 
1:200 Millipore MAB5504 
anti-Olig2 Goat polyclonal 1:250 R&D Systems AF2418 
anti-Nestin 
Mouse 
monoclonal 
1:200 Millipore MAB5326 
anti--III-tubulin 
Mouse 
monoclonal 
1:300 Promega G7121 
anti-neurofilament 200 
(NF200) 
Rabbit 
polyclonal 
1:200 Sigma-Aldrich N4142 
Calretinin 
Mouse 
monoclonal 
1:200 Swant 6B3 
GFAP 
Rabbit 
polyclonal 
1:500 Dako Z0334 
anti-αSMA 
Mouse 
monoclonal 
1:200 Sigma A5691 
anti-O4  
Mouse 
monoclonal IgM 
1:100 R&D Systems MAB1326 
NGFRp75 (c-20)  Goat polyclonal 1:100 
Santa Cruz 
Biotechnology 
sc-6188 
anti-clived caspase 3 
(Asp 175) 
Rabbit 
monoclonal 
1:300 Cell Signaling #9664 
anti-MOG (Myelin 
oligodendrocyte 
glycoprotein) 
Mouse 
monoclonal 
1:50 Millipore MAB5680 
anti-TH (tyrosine Rabbit 1:100 Santa Cruz SC-14007 
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hydroxylase) polyclonal 
anti-DA 
Rabbit 
polyclonal 
1:100 Millipore AB1225 
anti-PitX3 
Rabbit 
polyclonal 
1:100 Millipore AB5722 
 
The secondary fluorochrome-conjugated antibodies (1:300; goat anti-
mouse or goat anti-rabbit Alexa 555, donkey anti goat Alexa 555; and 
donkey anti-mouse or anti-rabbit Alexa 488; Life Technologies) were 
incubated for 1 hour at RT. Nuclear counterstaining was performed with 
49,6-diamidino-2-phenylindole (DAPI; 1 g/ml; Sigma-Aldrich) for 15 min 
at RT. Fluorescence imaging was performed using a confocal laser scanning 
microscopy (LSM 780; Carl Zeiss, Jena, Germany) and analyzed using ZEN 
software from the same provider or ImageJ 118. 
2.10 Reverse transcription Polymerase Chain Reaction 
Total RNA was isolated using the TRI Reagent (Sigma-Aldrich) or the 
NucleoSpin Kit (Macherey-Nagel) according to the manufacture’s 
guidelines. Quality and concentration of isolated RNA were assessed via 
Nanodrop ultraviolet spectrophotometry. cDNAs were synthesized by 
reverse transcription using the First Strand cDNA Synthesis Kit 
(Fermentas Life Sciences). PCR was performed using the GoTaq (Promega) 
according to the manufacturer’s guidelines and 10 µM primers (Sigma-
Aldrich). The cycling conditions comprised an initial denaturation of 1 min 
at 94ºC and 35–38 cycles of 15 s at 94ºC, 15 s at 60ºC, and 20 s at 72ºC 
followed by a final elongation for 1 min at 72ºC. For primer sequences see 
Table 2. 
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Table 2: Primer sequences for RT-PCR. 
Target Sequence 5'-3' 
Nestin CAGCGTTGGAACAGAGGTTG 
Rev-Nestin GCTGGCACAGGTGTCTCAAG 
MAP-2 GAGGATGAAGAGGGTGCCTT 
Rev-MAP-2 AGCTCTCCGTTGATCCCATTC 
Synaptophysin TGTAGTCTGGTCAGTGAAGCC 
Rev- Synaptophysin GCAGGGCTCAGACAGATAA 
AMPA receptor subunit 1 GGGCGATAATTCAAGTGTTCA 
Rev-AMPA receptor subunit 1 GGCTCCGTATTTTCCATCAC 
NMDA Receptor subunit 1 GCTCCTCGAGAAGGAGAACA 
Rev- NMDA Receptor subunit 1 GCCATTGTAGATGCCCACTT 
Vesicular glutamate transporter 1 CACAAGACTCGGGAGGAGTG 
Rev- Vesicular glutamate 
transporter 1 
GCCTCATCCTCCATTTCGCT 
Glutamate metabotropic receptor 
1 
AGCTGCTGATTTCTCAGCCAA 
Rev- Glutamate metabotropic 
receptor 1 
GCCTCCAACATTGGAATGGA 
Tyrosine Hydroxylase CCGTGCTAAACCTGCTCTTC 
Rev- Tyrosine Hydroxylase CGCACGAAGTACTCCAGGT 
Choline Transporter GGCACAGCTGAAGCAGTTTA 
Rev- Choline Transporter CCCATGCGTTTTCCATAGAT 
GABA transporter CAGTGGGATGTGCCTTCTCT 
Rev- GABA transporter CAGGGGTCATGATCATCCAG 
Serotonin transporter CTCCGAGGACAACATCACCT 
Rev- Serotonin transporter CAGAGGTCTTGACGCCTTTC 
RPLP0 (Ribosomal Protein 
Lateral Stalk Subunit P0) 
TGGGCAAGAACACCATGATG 
Rev-RPLP0 AGTTTCTCCAGAGCTGGGTTGT 
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2.11 SMART-Seq2 
For  full-length cDNA generation, the protocol recently described by 
Picelli et al119 slightly modified was applied. Approximately 20000 
cells/treatment of differently treated ITSC-derived glutamatergic neurons 
were used. Cells were harvested by centrifugation (5000 g for 5 min at RT) 
and directly lysed with an adjusted amount of lysis buffer (RNase inhibitor, 
0.2% Triton X-100). Afterwards the annealing mix containing AccuStart 
Taq Polymerase HiFi (Quanta bio), oligo-dT primer, dNTP-mix, was added 
to the cell lysate. Probes were incubated 3 min at 72ºC, and the reverse 
transcription-mix containing SuperScript II reverse transcriptase (Thermo 
Fisher Scientific) was added. Reverse transcription, relying on template-
switching reaction was performed. The cycling program comprised a initial 
denaturation of 90 min at 42°C, following by 9 cycles of 2 min at 50ºC and 
2 min at 42ºC followed by a final elongation for 15 min at 70ºC. The PCR 
pre-amplification mix was added  to the first-strand reaction. PCR pre-
amplification-cycling-program used comprised an initial denaturation of 3 
min at 98ºC and 21 cycles of 20 s at 98ºC, 15 s at 67ºC, and 6 min at 
72ºC followed by a final elongation for 5 min at 72ºC. 
2.12 Real-time PCR 
All Quantitative polymerase chain reaction (qPCR) reactions were 
performed in triplicate using PerfeCTa SYBR Green qPCR Super-Mix 
(Quantabio), according to the manufacturer’s guidelines, and assayed with a 
Rotor Gene 6000 (Qiagen). Primers used are listed in Table 3.  
 
Table 3. List of primer sequences used for qPCR. 
Target Sequence 5'-3' 
IGF1 ( Insulin-like growth 
factor 1) 
GAAGATGCACACCATGTCCT 
Rev- IGF1 TAAAAGCCCCTGTCTCCACA 
IGF2 ( Insulin-like growth 
factor 2) 
TGGACTTGAGTCCCTGAACC 
Rev- IGF2 GATGGCCAGTTTACCCTGAA 
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PKAcatα (c-AMP-dependent 
protein kinase catalytic subunit α) 
TACAACAAGGCCGTGGACTG 
Rev- PKAcatα AGATCTGGATGGGCTGGTCT 
SOD2 (Superoxide dismutase 2) TGGAAGCCATCAAACGTGACT 
Rev- SOD2 TTGAAACCAAGCCAACCCCA 
cIAP1 (Cellular inhibitor of 
apoptosis protein 1) 
CCA CTG GAG AAG AAA ATG CTG 
Rev- c-IAP1 CCA AGG CAG ATT TAA CCA CA 
c-IAP2 (Cellular inhibitor of 
apoptosis protein 2) 
GAC AGC CCA GGA GAT GAA AA 
Rev- c-IAP2 CAC GGC AGC ATT AAT CAC AG 
Fw-NG2 (transmembrane 
proteoglycan nerve-glia antigen 2*) 
CATCCCACTAGAGGCGCAAA 
Rev-NG2 CCCAGGAGAGTGGGGAAGTA 
Fw-MBP (Myelin basic protein) GCGTCACAGAAGAGACCCTC 
Rev-MBP CTCTGTGCCTTGGGAGGAAG 
Fw-PDGFRA (Platelet derived 
growth factor receptor alpha) 
GAAGAAAACAACAGCGGCCTT 
Rev-PDGFRA TGTACAACCCTGTGTGGGC 
Fw-RPLP0 (Ribosomal Protein 
Lateral Stalk Subunit P0) 
TGGGCAAGAACACCATGATG 
Rev-RPLP0 AGTTTCTCCAGAGCTGGGTTGT 
Fw-GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase) 
CATGAGAAGTATGACAACAGCCT 
Rev-GAPDH AGTCCTTCCACGATACCAAAGT 
* also known as Chondroitin sulfate proteoglycan 4 (CSPG4)  
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2.13 Cell Counting and Statistics 
For nuclear NF-κB analysis, quantification of indirect 
immunofluorescence was performed for a minimum of 3 different donors. 
For each time point 6-12 pictures were analyzed per donor, where the mean 
of the nuclear integrated density was measured by defining the region of 
interest (ROI) with the nuclear counterstaining (DNA channel) using 
ImageJ 118. For analysis of neuronal survival the same channel was used to 
study the nuclear chromatin morphology. Nonviable neurons were 
recognized by nuclear condensation and/or fragmented chromatin. In phase 
contrast images, those neurons were irregularly shaped with shrunken cell 
bodies and/or disrupted neurites, and in immunocytochemistry analyses 
they were shown to be positive for clived-caspase 3. The number of viable 
and nonviable neurons was counted in four to five field pictures and death 
rate was calculated.  
For analysis of positive cells for different markers, 3-4 pictures were 
analyzed per donor and per marker; positive cells were counted and plotted 
as the percentage of positive cells. For quantifying the level of intensity 
within the positive cells, the integrated density was measured by defining 
the ROI as the cellular contour, manually using ImageJ. The Mean 
integrated density for each cell was plotted normalized to the highest value 
of the data set compared (Highest value set to 100%) to better illustrate 
the differences. 
Data was further analyzed for statistics with Past3 120 and/or GraphPad 
Prism 5 (GraphPad software, La Jolla, CA, http:// www.graphpad.com). 
Normality of the data sets was refuted after analysis using Kolmogorov-
Smirnov and/or Shapiro-Wilk normality tests. Homogeneity of variance was 
tested using Levene's test and non-parametric Kruskal-Wallis test was used 
to compare the medians between the different data sets for the different 
donors (***p≤0.001). Bonferroni corrected post-test served to identify the 
significance of the differences between the groups, by comparing the 
population means (*p≤0.05, **p≤0.01; ***p≤0.001). Non-parametric Mann-
Whitney test was used to compare two pair of groups (***p≤0.001). 
Further differences were studied using Tukey's test (*p≤0.05, **p≤0.01, 
***p≤0.001).  
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2.14 Promoter analysis 
Sequence of promoter regions (3000 bp downstream and 100 bp 
upstream the ATG) of genes of interest were taken from Eukaryotic 
Promoter Database (epd.vital-ti.ch) for Homo sapiens. Binding sites for 
gene of interest in chosen promoter sequence were looked up using JASPAR 
Tool (jaspar.genereg.net). A relative score threshold of 85% was used. 
RELA, RELB and REL binding sites were compared in the promoter 
regions of target genes of interest. 
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3 Sex-specific neuroprotective role of NF-κB-p65 in 
human stem cell-derived neurons  
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3.1 Results 
3.1.1 Inferior turbinate stem cells efficiently differentiate into 
glutamatergic neurons in vitro 
In order to gain an appropriate model system for studying the role of 
NF-B in neuroprotection during maturation of human NCSC-derived 
neurons, ITSCs were cultivated following a directed neuronal differentiation 
procedure for 30 days (Fig. 3-1A) 1,40. Exposure of ITSCs to a neuronal 
induction medium for 28 days resulted in a neuronal-like morphology 
indicated by retraction of the cytoplasm towards the nucleus, extended 
cellular processes resulting in neurite outgrowth (Fig. 3-1B-D). 
Immunocytochemical analyzes confirmed the presence of the mature 
neuronal markers Neurofilament 200 (Fig. 3-1E, H; 92,28% ± 1,45%), MAP-
2 (92,28% ± 4,20%; Fig. 3-1F, H) and Synaptophysin (75,77% ± 11,55%; 
Fig. 3-1I, H). Interestingly, 19,77% ± 6,85% of ITSC-derived neurons were 
positive for Calretinin (Fig. 3-1G, H), while a small subpopulation of 
13,70% ± 8,74% differentiated ITSCs expressed the glial marker (Olig-2 Fig. 
3-1H). Further validating their successful differentiation, only 20,96% ± 
0,63% of ITSCs showed co-expression of Nestin (Fig. 3-1J) after directed 
differentiation. Accordingly, RT-PCR analyses depicted a decrease in 
expression of Nestin as well as an increased expression of MAP-2 and 
Synaptophysin in NCSC-derived neurons (Fig. 3-1I). Characterizing these 
neurons in more detail, we observed a low expression of GABA and 
serotonin transporter, whereas the AMPA receptor subunit 1, NMDA 
receptor subunit 1, glutamate metabotropic receptor 1 (GRM1) as well as 
the vesicular glutamate transporter 1 (VGLUT1) were robustly expressed 
(Fig. 3-1K). Immunocytochemistry further confirmed the glutamatergic 
phenotype of ITSC-derived neurons by revealing vGlut2-expression on the 
protein level (Fig. 3-1L, M). In addition to their efficient neuronal 
differentiation in vitro, ITSCs were able to integrate and differentiate 
within a neural environment by transplanting undifferentiated stem cells 
into murine organotypic hippocampal slices121. 
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Figure 3-1. Adult human neural crest-derived stem cells from the inferior turbinate 
(ITSCs) are able to efficiently differentiate into glutamatergic neurons. A: Schematic view of 
the neuronal differentiation procedure. B-D: ITSCs changed their morphology towards a 
neuronal phenotype during directed neuronal differentiation. D-G: Immunocytochemistry of 
ITSCs after 30 days of differentiation depicting the presence of NF200. MAP-2, and 
calretinin positive. H: Quantification of immunocytochemical analyses showing the 
percentage of Synaptophysin+ (75,77%±11,55%), Calretinin+ (19,77%±6,85%), MAP-2+ 
(92,28%±4,20%), NF-200+ (92,28%±1,45%), Olig 2+ (13,70%±8,74%) and Nestin+ 
(13,70%±0,63%) ITSC-derived neurons after 30 days of differentiation (Mean ± SEM, n=3). 
I-J: Differentiated ITSCs were positive for Synaptophysin, while small population of cells 
remained Nestin-positive. K: RT-PCR of differentiated ITSCs showing the down-regulation 
of Nestin, the up-regulation of MAP-2, Synaptophysin, AMPA receptor subunit 1, NMDA 
Receptor subunit 1, vesicular glutamate transporter 1, and glutamate metabotropic receptor 
1 after neuronal differentiation, and the low expression of GABA and serotonin transporter. 
RPLP0 served as housekeeping gene. NTC: non-template-control. L-M: Differentiated ITSCs 
positive for vGlut2, and merge with DNA staining. 
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3.1.2 ITSCs-derived glutamatergic neurons show AMPA or 
glutamate-dependent activation of NF-B-p65 
We next investigated the capability of ITSC-derived neurons to respond 
to the excitatory neurotransmitter glutamate (GLU) or its agonist α-amino-
3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA). Stimulation with 
GLU or AMPA resulted in a significant increase in nuclear translocation of 
NF-B-p65 in a dose-dependent manner (5 µM - 10 µM) in comparison to 
untreated neurons. On the contrary, treatment with 50 µM GLU or AMPA 
led to a significant decline in NF-B-p65 nuclear translocation compared to 
10 µM-treatment (Fig. 3-2A-D). We also observed high levels of basal NF-
B-activity (Fig. 3-2A-D), in accordance to the already described 
constitutive activation of NF-B particularly in glutamatergic neurons 122.  
Treatment of ITSC-derived neurons with their respective inhibitors 6-
cyano-7-nitroquinoxaline-2,3-dione (CQNX) or dibenzocyclohepteneimine 
(MK-801) prior to application of GLU (10 µM) or AMPA (10 µM) resulted 
in a significantly reduced translocation of NF-B-p65 into the nucleus 
compared to the stimulation approaches (Fig. 3-2E-F). These findings 
provide pharmacological evidence that both kinds of receptors were 
expressed in human ITSC-derived glutamatergic neurons, which in turn 
were observed to be fully functional after 30 days of differentiation.  
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Figure 3-2. Stimulation of glutamatergic neurons derived from ITSCs leads to significantly increased 
nuclear translocation of NF-B-p65. A-B: Immunocytochemistry and respective quantification of nuclear mean 
integrated density of NF-B-p65 revealed significantly increased nuclear translocation of NF-B-p65 in ITSC-
derived neurons after glutamate (GLU)-dependent stimulation (arrowheads) compared to control (arrows). 
Mean values were normalized to the highest value. C-D: AMPA-dependent stimulation resulted in significantly 
increased nuclear translocation of NF-B-p65 in ITSC-derived neurons (arrowheads) compared to control 
(arrows). Mean values were normalized to the highest value. E-F: Pre-treatment of ITSC-derived neurons with 
MK-801 or CQNX prior to GLU or AMPA-treatment led a significant decrease in nuclear translocation of NF-
B-p65 (arrows) compared to GLU or AMPA-dependent stimulation (arrowheads). Mean values were 
normalized to the highest value. Statistical analysis was performed using Graph Pad Prism 5. Normality of the 
data sets was refuted after analysis using Kolmogorov-Smirnov and Shapiro-Wilk normality tests. Non-
parametric Mann-Whitney test was further used (***p≤0.001), error bars indicate the standard error of the 
mean (SEM).  
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3.1.3 Stimulation with TNF-α leads to significantly increased 
nuclear translocation of NF-B-p65 in ITSC-derived 
glutamatergic neurons 
After validating human NCSC-derived neurons as a model system for 
studying the role of NF-B during maturation, we investigated the 
potential of TNF-α to stimulate NF-B in these neurons. Stimulation of 
ITSC-derived neurons with TNF-α  for 30 minutes or 1 hour resulted in 
nuclear translocation of NF-B-p65 subunit (Fig. 3-3A, arrowheads) in 
comparison to untreated neurons or 24 h of TNF-α-treatment (Fig. 3-3A, 
arrows). Quantification of the NF-B-p65 nuclear mean integrated density 
clearly validated these dynamics by showing a highly significant increase in 
nuclear NF-B-p65 fluorescence after 30 minutes (93,96% ± 6,04%) and 1 
hour (88,00% ± 12,00%) of TNF-α-treatment compared to untreated 
controls (≤20%) (Fig. 3-3B). Accordingly, stimulation of ITSC-derived 
neurons with TNF- α for 24 hours did not result in a significantly different 
nuclear NF-B-p65 fluorescence intensity compared to control (Fig. 3-3B). 
Furthermore we analyzed the activation of the other two Rel members 
RelB and c-Rel and we clearly evidenced that TNF-α stimulation for 30 
minutes activated nuclear c-Rel translocation in addition to p65, but not 
RelB, emphasizing their role in TNF-α stimulation. 
3.1.4 TNF-α-pre-treatment of human ITSC-derived 
glutamatergic neurons leads to increased NF-B-activity upon 
oxidative stress insult 
We further analyzed the effect of H2O2-mediated oxidative stress insult 
on the activity of NF-B-p65 in ITSC-derived neurons. Application of H2O2 
for 25 h on human glutamatergic neurons differentiated for 30 days led to 
significantly increased nuclear translocation of NF-B-p65 in comparison to 
control. In order to analyze a potential neuroprotective role of NF-B, we 
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performed a pre-treatment using 10 ng/ml TNF-α during 2 hours prior to 
oxidative stress insult. 
Notably, TNF-α-pre-treatment of ITSC-derived glutamatergic neurons 
followed by H2O2-mediated oxidative stress resulted in a significant increase 
in nuclear translocation of NF-B-p65 compared to the H2O2 alone or 
control (Fig. 3-4A-B, arrowheads). We further applied pyrrolidine 
dithiocarbamate (PDTC) as a control for guided inhibition of NF-B. Pre-
treatment of the cultivated neurons with PDTC for 1 hour followed by 
application of TNF-α or sole PDTC-treatment did not result in changes of 
nuclear translocation of NF-B-p65 (Fig. 3-4A-B, arrows). Quantification of 
the nuclear mean integrated density for p65 indicated a small but 
significant increase in nuclear NF-B-p65 in both treatments compared to 
the untreated negative control (Fig. 3-4B).  
 
3.1.5 ITSC-derived glutamatergic neurons are protected from 
oxidative stress-mediated cell death via TNF-α-dependent 
activation of NF-κB-p65 
Determining the physiological consequences of TNF-α-dependent 
activation of NF-κB-p65 during oxidative stress, we analyzed the death rate 
of ITSC-derived neurons after treatment with H2O2 or H2O2 after TNF-α-
pre-treatment. H2O2-mediated oxidative stress led to robust and significant 
apoptosis of glutamatergic neurons compared to untreated control (Fig. 3-
4C). Notably, this H2O2-mediated increase in apoptosis was significantly 
reduced down to a level similar to control upon TNF-α-pre-treatment prior 
to the oxidative stress insult (Fig. 3-4C). Application of TNF-α alone did 
not affect the survival of ITSC-derived neurons nor did the PDTC 
treatment, or the PDTC treatment followed by TNF-α  in comparison to 
control (Fig. 3-4C).  
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Figure 3-3. TNF-α-dependent stimulation of glutamatergic neurons derived from ITSCs 
leads to nuclear transloaction of NF-B-p65. A: Immunocytochemistry of ITSC-derived neurons 
(30 days of differentiation) showed nuclear translocation of NF-B-p65 after treatment with 
TNF-α for 30 min or 1 h (arrowheads), whereas control and 24 h-TNF-α-treatment did not 
result in nuclear translocation of NF-B-p65 (arrows). B: Quantification of nuclear mean 
integrated density of NF-B-p65 confirmed the significant increase in nuclear NF-B-p65 after 
TNF-α-treatment of ITSC-derived neurons for 30 min or 1h compared to  24h and untreated 
control. Mean values were normalized to the highest value. Statistical analysis was performed 
using GraphPad Prism 5. Normality of the data sets was refuted after analysis using 
Kolmogorov-Smirnov and Shapiro-Wilk normality tests. Non-parametric Mann-Whitney test 
was further used. ***p≤0.001, error bars indicate the standard error of the mean (SEM). C: 
Immunocytochemistry of ITSC-derived neurons (30 days of differentiation) showing nuclear 
translocation of NF-B-p65 and c-Rel after treatment with TNF-α for 30 minutes, but no 
nuclear translocation of NF-B-RelB, for a male and a female donor, and DNA staining. 
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3.1.6 Sensitivity of glutamatergic neurons to ROS-mediated cell 
death and neuroprotection via NF-κB-p65 is dependent on the sex 
of the ITSC-donor 
Investigating the effects of TNF-α-treatment on H2O2-mediated death of 
ITSC-derived neurons in more detail, we analyzed the amount of apoptotic 
cells after oxidative stress and TNF-α-dependent neuroprotection in 
dependence to the sex of the ITSC-donor. We observed a significant 
increase in cell death of neurons differentiated from female ITSC-donors 
compared to their male counterparts, indicating an elevated sensitivity of 
human female glutamatergic neurons to oxidative stress (Fig. 3-4D). Pre-
treatment of ITSC-derived neurons from female donors with TNF-α led to a 
significant and complete neuroprotection against H2O2-mediated cell death. 
Although neurons from male ITSC-donors were likewise protected against 
cell death via exposure to TNF-α, we observed a 2-fold increase in TNF-α-
dependent neuroprotection in female ITSCs-derived neurons compared to 
those differentiated from male ITSCs. These findings not only demonstrate 
a NF-B-dependent neuroprotection of ITSC-derived neurons against 
oxidative stress-mediated cell death, but emphazise the dependence on its 
sensitivity to the sex of the ITSC-donor. 
3.1.7 TNF-α-mediated neuroprotection of ITSC-derived neurons 
is accompanied by sex-specific expression of NF-B target genes 
To investigate the role NF-B-p65 in protection of ITSC-derived 
neurons from H2O2-mediated death in more detail, expression of NF-B 
target genes was assessed by qPCR.  Treatment of ITSC-derived neurons 
with H2O2 or TNF-α followed by H2O2 led to significantly increased 
expression levels of cAMP-dependent protein kinase catalytic subunit alpha 
(PKAcatα) compared to control. We further observed a significant increase 
in PKAcatα expression levels in male ITSCs-derived neurons compared to 
those differentiated from female ITSCs after TNF-α/H2O2-treatment (Fig. 
3-5A). On the contrary, we observed a significant increase in manganese 
superoxide dismutase (Mn-SOD, SOD2) mRNA levels only in female 
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ITSCs-derived neurons upon exposure to TNF-α, H2O2 and TNF-α/H2O2 
compared to control (Fig. 3-5B). Expression levels of cellular inhibitor of 
apoptosis protein-1 and 2 (c-IAP1 and c-IAP2) showed the tendency to be 
elevated in male ITSCs-derived neurons after TNF-α/H2O2-treatment 
compared to their female counterparts (Fig. 3-5C, D). Treatment with 
TNF-α, H2O2 and TNF-α/H2O2 further resulted in significantly increased 
expression levels of insulin-like growth factor 1 (IGF1) in ITSCs-derived 
neurons compared to control, although no significant sex-dependent 
differences were observable. Female ITSCs-derived neurons showed 
significantly increased expression levels of IGF2 after H2O2 and TNF-
α/H2O2-treatment compared to control, while no expression was detectable 
in male counterparts. However, sole treatment with TNF-α resulted in 
significantly increased expression levels of IGF2 in neurons from male and 
female donors compared to control. These findings strongly suggest a sex-
specific NF-κB-p65 target gene expression in dependence to TNF-α-
mediated neuroprotection during oxidative stress.  
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Figure 3-4. Treatment ITSC-derived glutamatergic neurons with TNFα prevents 
from oxidative stress-mediated cell death in a sex-dependent manner. A: 
Immunocytochemistry of ITSCs-derived neurons after 30 days of differentiation, after 
treatment with H2O2 alone, TNF-α-pretreatment prior to H2O2 and PDTC alone and 
PDTC followed by TNF-α against NF-B-p65 B: Quantification of 
immunocytochemical assays showed significantly increased nuclear translocation of NF-
B-p65 after treatment with TNF-α alone and TNF-α prior to H2O2 compared to H2O2 
alone and untreated control. Pretreatment of ITSC-derived neurons with PDTC for 
one hour followed by TNF-α-treatment did not result in significantly different amounts 
of nuclear NF-B-p65 compared to PDTC alone. Mean values were normalized to the 
highest value. C: Quantification of neuronal cell death showed significant death after 
oxidative stress insult (H2O2) compared to TNF-α/ H2O2, TNF-α, PDTC, PDTC/ 
TNF-α and untreated control (n=6). D: Quantification of neuronal cell death after 
oxidative stress (H2O2), TNF-α-pretreatment TNF-α, PDTC, PDTC/ TNF-α and 
untreated control comparing sex differences (n=3 males, n=3 females). Data were 
showed not to be normally distributed using Kolmogorov-Smirnov and Shapiro-Wilk 
normality tests. Non-parametric Kruskal-Wallis test was further used (p≤0.001), and 
Tukey's post-hoc test (**p≤0.01, ***p≤0.001). Mean ± SEM (standard error of the 
mean).  
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Figure 3-5. Quantitative polymerase chain reaction revealed sex-specific NF-κB-
p65 target gene expression after TNFα-dependent neuroprotection upon oxidative 
stress-insult. A: QPCR analysis  revealed increased PKAcatα mRNA levels after H2O2 
alone, TNF-α-pretreatment prior to H2O2 and TNF-α alone compared to untreated 
control, with a stronger effect for TNFα/H2O2 in male compared to female ITSCs-
derived neurons. B: SOD2 mRNA levels significantly increased in female ITSCs-
derived neurons compared to control and compared to their male counterparts. C: 
qPCR analysis showing c-IAP1 mRNA levels in male and female ITSCs-derived 
neurons. D: qPCR analysis showing c-IAP2 mRNA levels in male and female ITSCs-
derived neurons. E: qPCR analysis showing significant increased IGF1 mRNA levels 
compared to control in male and female ITSCs-derived neurons. F: IGF2 mRNA 
levels were significantly elevated only in female-derived neurons compared to control. 
Non-parametric Mann Whitney test (*p≤0.05), mean ± SEM (standard error of the 
mean). Nd: Not detectable. G: Promotor analysis using the JASPAR Tool 
(jaspar.genereg.net) validated SOD2, PRKACA and IGF2 to be direct RELA, RELB 
and REL target genes. RELA binding sites are shown in red, RELB binding sites  in 
green, and REL binding sites  in brown. Common RELA and REL binding sites are 
shown in blue. One promoter is shown for each gene, for more detail see 
supplementary material. 
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Figure 3-6. Sex-specific response to oxidative stress insult and NF-B-mediated 
neuroprotection in human NCSC-derived neurons. Female ITSCs-derived neurons 
responded with a higher sensitivity to oxidative stress-induced neuronal death, and TNF-
α-mediated neuroprotection compared to their male counterparts. TNF-α-mediated 
neuroprotection led to an increase in NF-κB-p65 nuclear translocation, triggering 
differential expression of sex-specific NF-κB target genes. 
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3.2 Discussion 
The present study describes for the first time a neuroprotective role of 
NF-κB-p65 in human NCSC-derived glutamatergic neurons after oxidative 
stress insult.  
We successfully differentiated human neural crest-derived inferior 
turbinate stem cells into MAP-2+/NF200+/Synaptophysin+/vGlut2+-
glutamatergic neurons by application of a directed differentiation assay or 
via transplantation into organotypic mouse hippocampal slice cultures121. 
Extending our previous findings depicting vesicle recycling and calcium 
spiking of ITSC-derived neurons40, we validated their functionality by 
showing an increased NF-B-activity upon stimulation with the excitatory 
neurotransmitter glutamate or its agonist AMPA. Accordingly, ITSC-
derived neurons showed expression of NMDA1- and AMPA1-receptors, 
which were shown to require an appropriate neuronal differentiation in 
neural stem cells123. Inhibitor controls using CQNX and MK-801 led to a 
decrease in glutamate or AMPA-dependent stimulation of NF-B-activity, 
further validating the specificity of the respective receptors. In accordance 
to our findings, stimulation of ionotropic glutamate receptors was shown to 
activate NF-B in primary rat cerebellar granule neurons100-101. Given the 
pivotal role of NF-B signalling in key elements for neuronal morphology 
like neurite growth83, dendritic spine formation84, axonal outgrowth85 and 
synaptic plasticity87-88,102, our data suggest the participation of NF-B in the 
normal physiology of the human nervous system. 
In addition to its AMPA- and glutamate-dependent stimulation, we also 
observed a significant increase in NF-B-activity in ITSC-derived neurons 
after treatment with TNF-α. In canonical NF-B-signalling, recognition of 
stimuli like cytokines or neurotransmitters leads to phosphorylation of IκB 
kinases124-125, in turn resulting in phosphorylation, polyubiquitylation and 
26S-proteasome-mediated degradation of IκBs. Demasking of the nuclear 
translocation signal region of p50/p65 by degradation of IκBs is 
subsequently followed by translocation of p50/p65 into the nucleus and 
activation of target gene expression by binding to B elements88-90,126-127. 
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TNF-α is one of the best characterized cytokines inducing this pathway, 
and its receptors TNFR1 and TNFR2 are widely expressed in the nervous 
system both in neurons and glia 128-130. Besides its modulatory effects of 
neuronal responses to excitotoxic and hypoxic insults in the nervous 
system131, the absence of TNFR was shown to result in an increased 
neuronal damage following either ischemic or kainic acid induced 
excitotoxic damage132. In mouse NSCs, TNF-α-mediated NF-κB signalling 
was reported to be required for initial neuronal differentiation113. Extending 
these findings, ITSC-derived human glutamatergic neurons revealed a 
significantly increased nuclear translocation of NF-B-p65, indicating the 
crucial role of NF-B-signalling during stem cell-based neuronal 
differentiation. We further demonstrated, in the present study that TNF-α 
stimulation for 30 minutes activated not only NF-B-p65, but also NF-B-
c-Rel nuclear translocation, emphasizing their role in TNF-α stimulation in 
neuronal glutamatergic physiology. 
Being a major cause of several neurologic diseases and brain damage104, 
oxidative stress is known to be directly caused by Alzheimer's disease via 
amyloid A beta peptide-dependent production of hydrogen peroxide 
through metal ion reduction133-134. In Parkinson’s disease, free radicals 
accumulate in the substantia nigra pars compacta, resulting in the 
formation of 6-hydroxydopamine, in turn leading to the generation of 
superoxide135-136. In the present study, H2O2-mediated oxidative stress led to 
cell death of human NCSC-derived glutamatergic neurons. Although NF-B 
is known to be activated by oxidative stress in the nervous system104, 
several studies indicated its neuroprotective role in murine cells. Here, Heck 
and colleagues demonstrated an Insulin-like growth factor-1-mediated 
neuroprotection of rat primary cerebellar neurons against oxidative stress 
directly associated to activation of NF-B137. Erythropoietin-mediated 
neuroprotection of rat cerebrocortical cultures from oxidative stress was 
also shown to occur in an NF-B-dependent manner138. On the contrary, 
Zou and colleagues demonstrated TNF-α-treatment of rat hippocampal-
entorhinal cortex slice cultures to result in increased neurotoxicity to both 
glutamate and oxidative stress139. In the present study, TNF-α-pre-
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treatment led to a significant decrease in H2O2-mediated cell death of 
NCSC-derived human neurons accompanied by a significantly increased 
nuclear translocation of NF-B-p65. Our data therefore demonstrate a key 
role of NF-B-p65 in protection of human stem cell-derived neurons from 
oxidative stress, further emphasizing the importance of NF-B-signalling in 
neuroprotection104,137-138.  
Interestingly, we further observed a significantly elevated sensitivity of 
ITSCs-derived neurons from female donors to oxidative stress-induced cell 
death and to NF-B-dependent neuroprotection compared to neurons from 
male donors. These findings were substantiated by a differential expression 
of NF-B target genes in a sex-dependent manner. Here, increased Mn-SOD 
mRNA levels observed in female but not in male ITSCs-derived neurons 
indicated a NF-B-dependent induction of Mn-SOD protecting against 
oxidative stress-induced neuronal apoptosis. Accordingly, Mn-SOD 
expression was described to be inducible by TNF-α, having an anti-
apoptotic role by directly reducing cellular ROS levels140. Next to -Mn-SOD, 
expression levels of IGF2 were significantly elevated only in female neurons 
after TNF-α/H2O2-treatment compared to control. IGF2 is known to 
promote synapse formation and spine maturation in the mouse brain141. 
Within a mouse model of Alzheimer's disease, IGF2 administration rescued 
spine formation and synaptic transmission in the hippocampus142. In 
accordance to the present findings, IGF2 was reported to have an 
antioxidant and neuroprotective effect on oxidative damage and 
mitochondrial function in cultured adult rat cortical neurons143-144. In 
contrast to their female counterparts, male ITSCs-derived neurons showed a 
significant increase in the expression level of PKAcatα after TNF-α/H2O2-
treatment. Interestingly, we observed no significantly altered expression 
levels of the antiapoptotic proteins c-IAP1 and c-IAP2, known mediators of 
TNF-α-dependent neuroprotection145. With PKAcatα being an essential 
regulator in learning and memory by transducing synaptic responses 
through CREB signaling102,146 and controlling synaptic incorporation of 
AMPA receptors147, PKA-activity may directly contribute to the 
neuroprotective effects observed here. Although being a matter of debate, 
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sex-dependencies in stem cell biology have already been shown in terms of 
autosomal gene expression148 and proliferation149, particularly regarding 
mouse NSCs150-151. Compared to their male counterparts, female muscle-
derived stem cells were reported to have higher muscle regeneration 
efficiency in mice152. In terms of neuroinflammation and neuroprotection, 
sex-dependent differences between patients have been likewise reported in 
ischemic stroke94, PD92, or AD93. While female AD patients were described 
to have an increased risk of developing AD93,96, PD was shown to have a 
greater prevalence in male patients92. In line with these findings, our data 
indicate for the first time a direct sex-dependent difference in 
neuroprotection of human stem cell-derived neurons against oxidative stress 
mediated by NF-B-signalling.  
In summary, the present study reveals NF-κB-p65 as a key player in 
neuroprotection of NCSC-derived neurons against oxidative stress in a sex-
dependent manner. We demonstrate a sex-dependent difference of stress 
response and TNF-α-mediated neuroprotection, with a strong increase of 
both H2O2-mediated cell death as well as neuroprotection against cell death 
in female NCSC-derived neurons (Fig. 3-6). These differences were 
emphasized by the sex-specific differential expression of NF-κB-p65 target 
genes SOD2 and IGF2. In line with our findings, increasing evidences 
pointing towards sex-specific differences in risk and severity of 
neurodegenerative diseases, such as Alzheimer’s disease. Since oxidative 
stress is directly associated to neurodegenerative diseases, but little is 
known about the underlying molecular mechanisms of neuroprotection, NF-
B-signalling may be a crucial parameter for treatment strategies and 
NCSC-based neuronal regeneration in vivo. 
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4 Role of NF-κB subunits in the glutamatergic 
differentiation of adult human stem cells 
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A version of this chapter is in preparation to be published: 
Ruiz-Perera, L. M., Greiner, J.F.W., Kaltschmidt, C., Kaltschmidt, B. 
in prep. Role of NF-B subunits in the glutamatergic differentiation of 
adult human stem cells. 
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4.1 Results 
4.1.1 NF-κB subunit distribution in early stages of glutamatergic 
differentiation of ITSCs 
In order to elucidate the possible role of NF-κB during glutamatergic 
differentiation, we first evaluated the NF-κB subunit composition during 
early stages of differentiation. For this, ITSCs were cultivated following a 
directed neuronal differentiation protocol (Fig. 4-1A), samples were taken 
at different time points (0, 1, 2, 5, 9.5, and 10 days of differentiation) and 
were analyzed by immunocytochemistry. Furthermore, as the NF-κB family 
is composed by five subunits, and among them three contain a 
transactivation domain (Fig. 4-1B) allowing DNA binding and gene 
expression, we focused specially on these to determine the predominating 
subunits involved within this process (Fig. 4-1C). 
 
 
Figure 4-1. Diagrams showing glutamatergic differentiation protocol and NF-B family members and 
their potential effects. A: Schematic representation of neuronal differentiation of ITSCs. Adult human 
inferior turbinate stem cells were differentiated into glutamatergic neurons as previously described1 and 
samples were taken at different time points to analyze the NF-κB subunit composition during early 
differentiation. B: Schematic view of the NF-κB family members. Relevant domains are indicated and 
alternative nomenclatures are provided in parenthesis. RHD, rel homology domain; TAD, transactivation 
domain; ANK, ankirin repeats; DD, death domain. C) Schema showing The NF-κB activation triggered 
during differentiation allowing nuclear translocation of a predominant NF-κB dimmer or a particular 
combination of NF-κB dimmers which would induce the gene expression program of a distinct cell fate or 
otherwise it could result in cell death. 
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Figure 4-2. Immunocytochemical analysis of NF-κB-p65 (RelA). A-F: ITSCs labeled 
against RelA after 0, 1, 2, 5, 9.5 and 10 days of glutamatergic differentiation respectively. 
Each panel shows RelA protein on the left-side and co-localization with DNA staining on 
the right-side. Intensity scale indicates white as highest intensity level and black as lowest 
intensity level. G: Quantification of immunocytochemical analyses showing nuclear mean 
integrated density of RelA/p65 during early differentiation (n=3, mean ± standard error of 
the mean (SEM)). Normality of the data was refuted using Shapiro-Wilk normality test. 
Non-parametric Kruskal-Wallis (***p≤0.001) and Bonferroni corrected post-test (**p≤0.01) 
revealed a significant nuclear translocation of NF-κB-p65 at day 0. H: Fluorescence 
intensity profiles measured at three different time points (0, 1, 2 days of differentiation), 
for different cells following transects as shown, to clearly reveal the difference between the 
nuclear and cytoplasmic fluorescence.  
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4.1.2 RelA distribution during early glutamatergic 
differentiation 
Immunocytochemistry against NF-κB-p65 (RelA), revealed a strong 
marked cytoplasmic signal and a faint p65 nuclear level during early 
differentiation (Fig. 4-2A-C). Little variation was observed on the intensity 
range for the later time points (Fig. 4-2D-F). Due to the slight nuclear 
activation observed, we quantified nuclear fluorescence using the nuclear 
mean integrated density (Fig. 4-2G). Statistical analysis clearly 
demonstrated significant differences for nuclear RelA between day 0 and all 
later time points (Non parametric Kruskal-Wallis test, ***p≤0.001, n=3), 
which might be due to the role of p65 in cell attachment; and also between 
day 1 and day 10 (Bonferroni corrected post-test, **p≤0.01, n=3). These 
differences were further analyzed with the fluorescence intensity profile, to 
discriminate fluctuations in p65 subcellular localization comparing cells 
during early differentiation (at 0, 1, and 2 days, Fig. 4-2H). No changes on 
nuclear fluorescence intensity were determined, but cytoplasmic level was 
clearly higher than nuclear level, indicating that RelA might have a role 
during cell attachment at day 0, but little or no role during early 
differentiation.  
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Figure 4-3. Immunocytochemical analysis of RelB. A-F: ITSCs labeled against RelB 
after 0, 1, 2, 5, 9.5 and 10 days of glutamatergic differentiation respectively. Each panel 
shows RelB protein on the left-side and co-localization with DNA staining on the right-side. 
Intensity scale indicates white as highest intensity level and black as lowest intensity level. 
G: Quantification of immunocytochemical analyses showing nuclear mean integrated density 
of RelB during early differentiation (n=3, mean ± SEM). Normality of the data was refuted 
using Shapiro-Wilk normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and 
Bonferroni corrected post-test (***p≤0.001) revealed a significant peak in nuclear 
translocation of NF-κB-RelB at day 0. H: Fluorescence intensity profiles measured at three 
different time points (0, 1 and 2 days of differentiation), for different cells following 
transects as shown, to clearly reveal the difference between the nuclear and cytoplasmic 
fluorescence.  
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4.1.3 RelB distribution during early glutamatergic 
differentiation 
Immunostaining analyses also confirmed that RelB had a gradual 
decrease during early stages of differentiation (Fig. 4-3A-F). ITSCs were 
strongly positive at day 0, with a robustly labeled cytoplasm; however 
nuclear RelB was not evident (Fig. 4-3A). At day 1 a slight increase in 
nuclear RelB was observed (Fig. 4-3B), which was remarkably reduced in 
the later time points (Fig. 4-3C-F). In these, cytoplasmic RelB was also 
reduced and gradually concentrated in the perinuclear region (Fig. 4-3F). 
To detect nuclear intensity changes we quantified nuclear mean integrated 
density (Fig. 4-3G). Statistical analysis demonstrated significant differences 
between day 0 and day 1 (Non parametric Kruskal-Wallis test, ***p≤0.001, 
n=3), and also between day 0 and day 5 (Bonferroni corrected post-test, 
***p≤0.001, n=3), indicating there was a short NF-κB-RelB activation peak 
between days 0 and 1. These differences are further illustrated with the 
fluorescence intensity profile (Fig. 4-3H). In these cells we directly 
distinguish the intensity fluctuations between nucleus and cytoplasm. At 
day 0, fluorescence intensity was especially high in the cytoplasm, and was 
completely negative in the nucleus; while at day 1 we observe exactly the 
opposite, cytoplasmic intensity was markedly reduced and nuclear RelB was 
increased. Finally, after 2 days, both cytoplasmic and nuclear fluorescence 
intensity levels were totally reduced. These findings suggested that RelB 
has a short function during early glutamatergic differentiation, being 
strongly inactivated afterwards and sequestered in the perinuclear region. 
4.1.4 c-Rel distribution during early glutamatergic 
differentiation 
We further analyzed NF-κB-c-Rel by immunocytochemistry, which 
determined a low c-Rel level at nuclear and cytoplasmic localization during 
early time points (Fig. 4-4A-B), and at day 2 experienced a strong increase 
especially at the nuclear level (Fig. 4-4C), which was maintained after 5 
days showing a clear nuclear activation (Fig. 4-4D). This strong c-Rel 
activation peak was remarkably reduced at later time points at nuclear and 
cytoplasmic level (Fig. 4-4E-F). Quantification of nuclear mean integrated 
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density for c-Rel confirmed this nuclear activation, which was statistically 
relevant (non parametric Kruskal-Wallis test ***p≤0.001, n=3, Fig. 4-4G) 
indicating that NF-κB-c-Rel activation peak occurred at day 2 (Bonferroni 
corrected post-test, ***p≤0.001, n=3). Furthermore, the differences in c-Rel 
expression were illustrated by measuring the fluorescence intensity profile of 
different cells at the relevant time points (Fig. 4-4H) where the fluorescence 
fluctuations are particularly apparent. At day 1, fluorescence intensity is 
extremely low at both cytoplasmic and nuclear level, while at day 2, 
nuclear and cytoplasmic c-Rel is strongly increased, and finally at day 5, 
total c-Rel was decreased and concentrated at the nuclear level. These 
results strongly support the existence of a nuclear c-Rel peak during early 
differentiation, suggesting that NF-κB-c-Rel might have a predominant role 
in the neuronal differentiation towards a glutamatergic fate. 
4.1.5 p50 and p52 distribution during early glutamatergic 
differentiation 
Similarly, immunostaining analysis of p50 (Fig. 4-5A-F) and p52 (Fig. 4-
6A-F), established that p50 had no particular role during early 
differentiation due to its very little variation, while p52 might have an 
important role due to a strong nuclear activation at day 1. ITSCs were p50 
positive during early time points, however the intensity range was strongly 
reduced from blue to black (Fig. 4-5C, E-F) and even if quantified 
differences were significant (Non parametric Kruskal-Wallis test 
***p≤0.001; Bonferroni corrected post-test *p≤0.05, n=3; Fig. 4-5G), it was 
not possible to determine a direct correlation between these and the 
intensity range, as well as with the differences illustrated by fluorescence 
intensity profile analyzed (Fig. 4-5H), thus discarding a possible role for p50 
during this differentiation. In contrast, p52 showed a robust increase in 
nuclear translocation after 1 day of differentiation, which was markedly 
reduced at day 2 (Fig. 4-6A-C), and was dramatically reduced in later time 
points (Fig. 4-6D-F). Quantification of nuclear mean integrated density and 
statistical analysis revealed a relevant significant difference between nuclear 
p52 peak at day 1 and all later time points (Kruskal-Wallis ***p≤0.001, 
Bonferroni corrected post-hoc ***p≤0.001), suggesting the importance of 
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p52 during early glutamatergic differentiation. This observation is further 
illustrated by the fluorescence intensity profile of three cells (Fig. 4-6H). 
Intensity fluctuations showed a key increase in nuclear p52, while 
cytoplasmic increase was not so remarkable. These findings further support 
that NF-κB-p52 subunit might have a central role during neuronal 
glutamatergic differentiation of ITSCs, suggesting the existence of p52/RelB 
heterodimers.  
4.1.6 IκBα distribution during early glutamatergic differentiation 
Furthermore analysis of IκBα, a negative regulator of NF-κB subunits, 
showed a similar distribution pattern to NF-κB-c-Rel. Cells were negative 
for IκBα at day 0 but protein levels were raised at day 1 (Fig. 4-7A, B), 
continuing to increase at day 2 especially within the nucleus (Fig. 4-7C). At 
day 5 nuclear IκBα was really concentrated (Fig. 4-7D), and was strongly 
decreased at later stages (Fig. 4-7E, F). Quantification and statistical 
analysis for IκBα, confirmed a strong significant increase of nuclear mean 
integrated density at 2 and 5 days (non parametric Kruskal-Wallis test, 
***p≤0.001, n=3), compared to earlier and later time points (Bonferroni 
corrected post-test, ***p≤0.001, n=3). Also a significant increase at day 2 
compared to day 5 was determined (Bonferroni corrected post-test, 
***p≤0.001, n=3), which demonstrated IκBα peak at day 2. IκBα differences 
were further exemplified for three cells at few patent time points to see the 
evident changes in fluorescence intensity (Fig. 4-7H). At day 2, intensity 
was extremely high at both cytoplasmic and nuclear level, while at day 5, it 
was kept strictly circumvented to the nucleus; lastly at day 9.5 the 
intensity was completely decreased. These findings confirmed IκBα 
distribution resembled that of NF-κB-c-Rel, having a strong peak at day 2 
which was gradually decreased, suggesting a strong regulatory mechanism 
modulated by IκBα.  
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Figure 4-4. Immunocytochemical analysis of c-Rel. A-F: ITSCs labeled against c-
Rel after 0, 1, 2, 5, 9.5 and 10 days of glutamatergic differentiation respectively. Each 
panel shows on the left c-Rel and co-localization with DNA on the right. Intensity 
scale indicates white as highest intensity level and black as lowest. G: Quantification 
of immunocytochemical analyses showing nuclear mean integrated density for c-Rel 
during early differentiation (n=3, mean ± SEM). Normality of the data was refuted 
using Shapiro-Wilk normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and 
Bonferroni corrected post-test (***p≤0.001) revealed significantly increased nuclear 
translocation of NF-κB-c-Rel at day 2 and day 5. H: Fluorescence intensity profiles 
measured at three different time points (1, 2 and 5 days of differentiation), for 
different cells following transects as shown, in order to clearly reveal the difference 
between the nuclear and cytoplasmic fluorescence. 
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Figure 4-5. Immunocytochemical analysis of p50. A-F: ITSCs labeled against p50 
after 0, 1, 2, 5, 9.5 and 10 days of glutamatergic differentiation respectively. Each panel 
shows p50 protein on the left-side and the co-localization with DNA staining on the 
right-side. Intensity scale indicates white as highest intensity level and black as lowest 
intensity level. G: Quantification of immunocytochemical analyses showing nuclear mean 
integrated density of p50 during early differentiation (n=3, mean ± SEM). Normality of 
the data was refuted using Shapiro-Wilk normality test. Non-parametric Kruskal-Wallis 
(***p≤0.001) and Bonferroni corrected post-test (*p≤0.05) showed some significant 
differences between day 0 and 2 and 10 days, and between day 1 and day 2. H: 
Fluorescence intensity profiles measured at different time points (0, 1 and 2 days of 
differentiation), for different cells following transects as shown, to clearly expose the 
difference between nuclear and cytoplasmic fluorescence. 
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Figure 4-6. Immunocytochemical analysis of p52. A-F: ITSCs labeled against p52 
after 0, 1, 2, 5, 9.5 and 10 days of glutamatergic differentiation respectively. Each panel 
shows p52 subunit on the left-side and the co-localization with DNA on the right-side. 
Intensity scale indicates white as highest intensity level and black as lowest intensity 
level. G: Quantification of immunocytochemical analyses showing nuclear mean 
integrated density of p52 during early differentiation (n=3, mean ± SEM). Normality of 
the data was refuted using Shapiro-Wilk normality test. Non-parametric Kruskal-Wallis 
(***p≤0.001) and Bonferroni corrected post-test (***p≤0.001) showed a significant peak 
of p52 at day 1 significantly different to all later time points (2-10 days). H: 
Fluorescence intensity profiles measured at different time points (0, 1 and 5 days of 
differentiation), for different cells following transects as shown, to clearly expose the 
difference between nuclear and cytoplasmic fluorescence.  
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Figure 4-7. Immunocytochemical analysis of IκBα. A-F: ITSCs labeled against IκBα 
after 0, 1, 2, 5, 9.5 and 10 days of neuronal glutamatergic differentiation respectively. Each 
panel shows on the left c-Rel and co-localization with DNA on the right. Intensity scale 
indicates white as highest intensity level and black as lowest. G: Quantification of 
immunocytochemical analyses showing nuclear mean integrated density for IκBα during 
early differentiation (n=3, mean ± SEM). Normality of the data was refuted using Shapiro-
Wilk normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and Bonferroni 
corrected post-test (***p≤0.001) revealed a significantly increased nuclear translocation of 
IκBα at days 2 and 5. H: Fluorescence intensity profiles measured at three different time 
points (2, 5 and 9.5 days of differentiation), for different cells following transects as shown, 
in order to clearly reveal the difference between the nuclear and cytoplasmic fluorescence. 
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4.1.7 NF-κB subunit composition in early stages of 
glutamatergic differentiation of ITSCs 
In summary, we characterized the distribution pattern of all NF-κB 
subunits upon glutamatergic differentiation (Fig. 4-8A), and we found out 
that each subunit had a particular curve/activity. Among these, RelB and 
p52 appeared to have a similar behavior during the first days of 
differentiation, suggesting the presence of p52/RelB heterodimers at the 
initial time points. Shortly afterwards, c-Rel and IκBα presented a strong 
peak with a very similar temporary pattern, indicating that after RelB/p52 
dimers are inactivated, probably by IκBαup-regulation, c-Rel had a main 
role during the ongoing differentiation, being down-regulated immediately 
afterwards and also accompanied by IκBdown-regulation which could 
imply the inactivation of the pathway for a restoration of the internal 
balance. In contrast, the classical subunits RelA (p65) and p50 presented an 
extremely low level with almost no variation, indicating they have no role 
during this process. These data further indicated that glutamatergic 
differentiation is driven by the NF-κB subunits c-Rel and RelB. 
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4.1.8 NF-κB subunit c-Rel is important for cell survival during 
glutamatergic differentiation of ITSCs 
In order to establish the relevance of NF-κB-c-Rel during neuronal 
glutamatergic differentiation of inferior turbinate stem cells, we further 
analyzed what happened when we directly blocked c-Rel during 
differentiation. Thus, we initially confirmed that pentoxifylline (PTXF) was 
really inhibiting NF-κB-c-Rel2, by investigating whether PTXF induced a 
decrease in nuclear translocation of c-Rel during the peak of c-Rel at day 5 
of glutamatergic differentiation (Fig. 4-8C- D). Quantification of nuclear 
mean integrated density of c-Rel confirmed a significant decrease in nuclear 
c-Rel upon PTXF treatment (non-parametric Mann Whitney test, 
***p≤0.0001), compared to untreated cells (Fig. 4-8G). Thus we tested the 
hypothesis, that neural stem cells (NSCs) undergo an increase in nuclear 
NF-κB-c-Rel during early time points, which triggers differentiation towards 
a glutamatergic neuronal fate (Fig. 4-8H). For this, we treated ITSCs using 
PTXF during differentiation to block c-Rel nuclear activation, which should 
result in a shift in the cell fate or otherwise in the cell death (Fig. 4-8H). 
After 30 days of differentiation we first analyzed cell survival. Nonviable 
neurons were recognized by an increase in clived-caspase3, together with 
the nuclear condensation or fragmented chromatin observed (Fig. 4-8E,F). 
Quantification analyses confirmed a significant decrease in the survival of 
the treated differentiated-ITSCs, compared to untreated ones (Fig. 4-8B). 
These findings further suggested that NF-κB-c-Rel has an important role in 
cell survival during normal differentiation into this neuronal fate.  
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Figure 4-8. NF-κB subunit composition in early gluatamatergic differentiation and c-Rel 
potential function. A: Diagram summarizing NF-κB subunit distribution during early stages of 
glutamatergic differentiation. Nuclear mean integrated density shown as the median normalized to 
the range from 0 to 1, showing the curve for each NF-κB subunit as indicated. B: Quantification 
of survival of neuronal differentiated-ITSCs for 30 days in the presence or absence of 
pentoxifylline (PTXF; n=3, mean ± SEM). Non-parametric Mann Whitney test confirmed a 
significant decrease in survival of PTXF-treated differentiated cells (***p≤0.001), compared to 
untreated differentiated neurons. C-D: ITSCs differentiated for 5 days in the absence and presence 
of PTXF respectively, labeled against c-Rel shown with an intensity scale, merged with DNA 
staining. E-F: ITSCs differentiated for 30 days without and with PTXF, labeled against clived-
caspase-3 (cl.casp-3), merged with nuclear counterstaining. G: Quantification of 
immunocytochemical assay for c-Rel showing nuclear mean integrated density, after 5 days of 
differentiation with or without PTXF (n=3, mean ± SEM). Non-parametric Mann Whitney test 
confirmed a significant decrease in nuclear c-Rel after 5 days of differentiation with PTXF 
(***p≤0.0001), a known c-Rel inhibitor 2. F: Diagram showing neuronal differentiation mechanism 
and PTXF mode of action. Neural stem cells differentiating into neurons undergo an increase in 
nuclear NF-κB-c-Rel, which further induces differentiation into the glutamatergic neuronal fate. 
The treatment using PTXF during the early neuronal differentiation diminishes c-Rel activation 
leading to a decrease in the gene expression towards the neuronal fate resulting in a cell fate shift 
or in cell death. Intensity scale: White as highest intensity level, black as lowest intensity level. 
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4.1.9 c-Rel inhibition by pentoxifylline provokes a differentiation 
shift into the oligodendrocyte fate 
Furthermore, we investigated the cell fate by immunocytochemistry, 
which confirmed the presence of mature neuronal markers Neurofilament 
200 (41,44% ± 6.31%; Fig. 4-9A-C) and vGlut2 (47,97% ± 2,72%; Fig. 4-9D-
F) upon treatment with PTXF, showing however a strong decrease on the 
percentage of positive cells in comparison to the untreated-differentiated 
neurons (84,68% ± 7,70% NF200+ neurons; 85,37% ± 5,34% vGlut2+ 
neurons; Non-parametric Kruskal-Wallis test ***p≤0.0005). Further analysis 
revealed that differentiated-ITSCs treated with PTXF were robustly 
positive for different oligodendrocyte markers such as Olig2 (86,67% ± 
6,67%, Fig. 4-9J-L) and O4 (100%, Fig. 4-9M-O) an early and an 
intermediate marker respectively. Both differences were confirmed to be 
significantly relevant by non-parametric Kruskal-Wallis test (***p≤0.001, 
*p≤0.05 respectively) which indicated there was a shift of the cell fate into 
the oligodendrocyte fate. In addition, PDGFRA (Platelet derived growth 
factor receptor alpha) and NG2 (chondroitin sulfate proteoglycan type 4, 
CSPG4), two early oligodendrocyte markers, and MBP (Myelin basic 
protein) a mature marker of myelinating oligodendrocytes were also present 
at the mRNA level, which were completely absent in the untreated neurons 
(Fig. 7A-C). These findings also evidenced the clear shift into the 
oligodendrocyte lineage. Interestingly, differentiated-ITSCs treated with 
PTXF were totally negative for GFAP (0%, Fig. 6G-I), suggesting no 
astrocytes were present in the treated differentiated-ITSCs. Besides, 
differentiated-ITSCs treated with PTXF showed a slight tendency to 
express Nestin (stemness marker), compared to the untreated cells (Suppl. 
fig. 3A-C, p≤0.10). And a similar trend was observed for p75 (Neural crest 
marker, Suppl. fig. 3D-F, p≤0.10), suggesting that PTXF treated 
differentiated-ITSCs might be somewhat less differentiated compared to 
normal ITSC-derived neurons. In addition, treated and untreated 
differentiated-ITSCs were negative for αSMA (alpha smooth muscle), 
indicating the absence of mesodermal-derived cells (Suppl. fig. 3G-I). These 
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findings discarded a possible switch in the cell fate towards a non neuro-
ectodermal lineage.  
4.1.10 NF-κB-c-Rel drives neuronal glutamatergic differentiation 
of ITSCs 
Taken together our findings suggested that ITSCs undergo a high 
increase of nuclear c-Rel during early glutamatergic differentiation, which 
might induce the expression of a specific gene program towards the 
neuronal fate. That was evidenced by the enhanced expression of mature 
neuronal proteins such as NF200 and vGlut2, as well as a strong decrease in 
oligodendroglial marker proteins like O4 and Olig2, as well as an extremely 
low level of GFAP. In addition, neuronal differentiation was accompanied 
by a strong survival (87%, Fig. 4-10). However, when nuclear c-Rel 
activation was abolished using pentoxifylline, this strong inhibition 
produced a remarkable shift of the cell fate shift into the oligodendrocyte 
lineage. This shift was determined by an elevated increase in 
oligodendrocyte markers like Olig2 and O4 by imunodetection, as well as 
PDGFRA, NG2 and MBP at the mRNA level (Fig. 4-10A-C). Followed by 
a significant decrease in the neuronal protein markers NF200 and vGlut2, 
and also a strong reduction in cell survival (47%). Moreover, the switch in 
the differentiation program further produced a prominent change in the 
morphology of the treated-differentiated-ITSCs (Fig. 4-9, 4-10); cells 
acquired a polygonal-like shape, with an extension of the cell surface, and a 
reduction of the cellular processes, indicating that cells were unable to 
produce such cellular processes; further supporting the shift in the cell fate. 
These changes at the protein and mRNA levels together with the 
modification of the cellular morphology and the cell survival further 
demonstrate that the differentiation of neural stem cells into the neuronal 
phenotype is driven by NF-κB-c-Rel as previously suggested (Fig. 4-8F).  
Furthermore, myelination assay results showed that O4 expression was 
similar in female derived co-cultures of both ITSC-derived neurons and 
ITSC-derived OPCs, and of ITSC-derived neurons and ITSC-differentiated 
cells in the presence of PTXF, which were co-cultivated for 10 days, after 
20 days of differentiation (Suppl. fig 4I,J). Also, the expression of this 
oligodendrocyte marker was similar for these co-cultures and the ITSCs 
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differentiated in OPCs (Oligodendrocyte progenitor cells) and the neuronal-
differentiated ITSCs with PTXF, further supporting the shift into the 
oligodendrocyte fate (Suppl. fig. 4F-J). In addition, both male- and female-
derived co-cultures were positive for NF200, indicating neuron progenitors 
were present in the co-cultures, however these were also slightly positive for 
Myelin oligodendrocyte glycoprotein further indicating cells were 
differentiating into mature oligodendrocytes as well (Suppl. fig. 5D-E, I-J). 
These Findings strongly suggest that both co-culture systems had a mixture 
of neural progenitors that could further differentiate into neurons or 
oligodendrocytes, while co-differentiating together.  
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Figure 4-9. Immunocytochemistry against neuronal and glial markers, after glutamatergic differentation 
in the presence and absence of pentoxifylline (PTXF) and quantification. A-B: Neuronal differentiated-
ITSCs labeled against Neurofilament 200 (NF200). C: Quantification showing percentage of NF200+ 
neurons. Non-parametric Kruskal-Wallis test (***p≤0.0005) revealed a significant decrease of NF200+ 
neurons with PTXF, compared to untreated neurons. D-E: Neuronal differentiated-ITSCs labeled against 
vGlut2. F: Quantification showing percentage of vGlut2+ neurons. Non-parametric Kruskal-Wallis  test 
(***p≤0.0005) showed a significant decrease of vGlut2+ neurons in the differentiated-ITSCs treated with 
PTXF, compared to untreated neurons. G-H: Differentiated-ITSCs labeled against GFAP, an astrocyte 
marker. I: Quantification showing percentage of GFAP+ cells indicates a very low number of astrocytes in 
the untreated neurons and none in the PTXF-treated differentiated-ITSCs. No significant difference was 
observed. J-K: Neuronal differentiated-ITSCs labeled against Olig2, an early oligodendrocyte marker. L: 
Quantification of Olig2+ cells in percentage, no positive cells were present in the untreated neurons, while in 
the PTXF-treated differentiated-ITSCs almost all cells were Olig2+. Non-parametric Kruskal-Wallis  test 
(***p≤0.001) confirmed a significant increase of Olig2+ cells upon PTXF treatment, indicating a shift into 
the oligodendrocyte fate. M-N: Neuronal differentiated-ITSCs labeled against O4, an intermediate 
oligodendrocyte marker. O: Quantification of O4+ cells, showed a clear increase of O4+ cells in the neuronal 
PTXF-treated differentiated-ITSCs, confirmed by statistical non-parametric Kruskal-Wallis test (*p≤0.05). 
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Figure 4-10. Cell fate shift towards the oligodendrocyte phenotype due to c-Rel early 
inhibition. A-C: Real time polymerase chain reaction showing relative mRNA levels of 
Oligodendrocyte markers NG2, PDGFRA and MBP respectively. Levels for these 
Intermediate (NG2, PDGFRA) and mature markers (MBP) are only present in the 
differentiated-ITSCs treated with PTXF, indicating a shift into the oligodendrocytic 
lineage (n=2, mean ± SD). D: Summarizing scheme showing outstanding results obtained 
in this investigation. During neuronal differentiation of ITSCs into glutamatergic neurons, 
cells undergo a strong increase of c-Rel activation during early time points, which further 
induces the expression of a specific gene program towards the neuronal fate, which was 
confirmed by the increased expression of mature neuronal proteins NF200 and vGlut2, and 
a clear decrease in O4, as well as almost no GFAP and Olig2 accompanied by a strong 
survival. When ITSCs differentiating were treated in parallel with pentoxifylline, the 
increase of nuclear c-Rel was almost completely abolished, leading to a shift in the cell fate 
into the oligodendrocyte lineage, which was confirmed by a strong increase in 
oligodendrocyte markers Olig2 and O4 and a clear decrease in the neuronal markers 
NF200 and vGlut2, which was also accompanied by a strong reduction in cell survival. 
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4.2 Discussion 
The present study describes for the first time the main role of NF-κB-
Rel-B and c-Rel during glutamatergic neuronal differentiation of human 
inferior turbinate stem cells. Here, we successfully characterized the NF-κB 
subunit composition during early stages of differentiation, and we found out 
that RelB and p52 were activated during an early phase, suggesting 
RelB/p52 heterodimers had a part at the initial steps of differentiation. 
Interestingly, their inactivation was opposed to the increase observed for 
IκBα and c-Rel shortly afterwards, indicating their negative regulation was 
mediated by IκBα, while in parallel c-Rel was being highly activated, 
suggesting that c-Rel takes over afterwards. Furthermore c-Rel inactivation 
might also be mediated by IκBα, which wasdown-regulated with the 
restoration of the internal balance (Fig. 4-8A), indicating NF-κB activity is 
strictly regulated during differentiation. On the contrary, RelA and p50, the 
classical NF-κB subunits had no part during differentiation, although RelA 
had an early short significant nuclear increase immediately after seeding, 
and might be important for the attachment of the cells. In accordance to 
our findings, previous studies showed that NF-κB-p65 decreased upon 
differentiation of human embryonic stem cells (hESCs), and was involved in 
the maintenance of the undifferentiated state 153-154. Similarly during early 
differentiation of hESCs, upon inhibition of IKK using IKK small-inhibitor 
or p65 knockdown, p65 activity was high only during the initial days of 
differentiation and decreased shortly afterwards, together with the up-
regulation of endodermal and mesodermal markers which resulted in MSCs 
specification 155. Interestingly, in other hESCs a peak of RelB/p52 was 
characterized in the undifferentiated cells, and a strong decrease was 
observed upon 10 days of differentiation, which was further implicated in 
pluripotency maintenance and proliferation156. Whereas p65/p50 were 
increased upon differentiation and were required for the maintenance of 
viability and differentiation 156. These findings are in line with the initial 
activation of RelB/p52 dimers that we observed, which might be necessary 
for early neuronal differentiation.    
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Data presented here further confirmed that c-Rel has an important 
function in cell survival during neuronal differentiation. Initially we 
intended to use CRISPR/Cas9-mediated genome editing to delete c-Rel 
subunit, however it is difficult to apply this strategy in primary cells such 
as ITSCs, which are not easily transfected in comparison to HEK293 
cells157. Therefore, as shown by c-Rel inhibition using chronic pentoxifylline 
(PTXF) treatment, PTXF induced a significant decrease in nuclear c-Rel 
after 5 days of differentiation, as also observed in PTXF-treated T 
lymphocytes158; and extended treatment produced a strong decrease in cell 
survival as illustrated by an increase in clived-caspase-3+ cells and 
respective nuclear condensation and/or fragmentation after 30 days of 
differentiation. These results are in agreement with the known anti-
apoptotic effects of c-Rel in different cell types, such as neurons, 
keratinocytes, and B cells 159-161. Besides, NF-κB is known to regulate cell 
proliferation, being involved in the G2/M phase in certain cell types 112,162-
163. Furthermore, c-Rel inhibition generated a strong shift into the 
oligodendrocyte fate, evidenced by the increase in Olig2+/O4+-
differentiated-ITSCs after 30 days, suggesting the presence of immature 
pre-myelinating oligodendrocytes 164-165. The oligodendrocytes are cells 
responsible for the production of myelin in the central nervous system 
(CNS), which is required for the saltatory conduction of electrical impulses 
across axons. These cells extend multiple cellular processes that individually 
ensheath different segments of axons. Thus, myelin consists of loops of the 
oligodendroglial plasma membrane tightly wrapped around the axon. 
During early embryonic development oligodendrocytes are differentiated 
from oligodendrocyte progenitor cells, proliferative cells, which migrate and 
undergo differentiation into mature oligodendrocytes 48. However, immature 
oligodendrocytes differentiated from ITSCs also expressed NG2 (CSPG4) 
and PDGFRα at the mRNA level, known markers of oligodendrocyte 
progenitors, but they also expressed MBP, a mature marker of myelinating 
oligodendrocytes 48,166. Hence, our results suggest that in the absence of c-
Rel, ITSCs undergo the differentiation into the oligodendrocyte lineage, 
resulting in a mixed population of cells with different levels of maturity, 
from immature pre-myelinating to mature myelinating oligodendrocytes. 
Furthermore, these findings demonstrated that c-Rel is a key player in the 
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differentiation of ITSCs, being directly involved in the regulation of 
neuronal differentiation and survival.  
Demyelinating diseases including Multiple sclerosis (MS) are caused by 
loss of oligodendrocytes and concomitant loss of myelin 166-167. MS is a 
chronic inflammatory disease of the CNS acquired in young adults, due to 
an enhanced autoimmune response against myelin antigens that result in 
demyelinating lesions in the brain and spinal cord followed by axonal injury 
168-169. Treatments to ameliorate MS are based on decreasing the reactive 
autoimmune response, an example is Pentoxifylline, a methylxanthine 
derivative and phosphodiesterase inhibitor, which was used for the 
treatment of MS alone 170 or accompanying IFN-β1b (Interferon beta-1b) 171. 
Treatment using PTXF was shown to deviate the immune response in MS 
patients, by decreasing pro-inflammatory cytokines like TNF-α and 
interleukin-2, suggesting a modulation towards a Th2-like response instead 
of a Th1-like T cell response170. Moreover, when patients were treated with 
both IFN-β1b and PTXF, TNF-α and IFN-α (interferon alpha) were not 
detected, compared to patients treated with only IFN-β1b, which had an 
increase in both cytokines 171. However, during these studies only the 
inflammatory response was analyzed in detail, thus no relevant changes 
within the cellular populations within the CNS were analyzed. Nevertheless, 
new insights suggest that fibrinogen enters the brain when the blood-brain-
barrier is damaged due to MS and inhibits OPC differentiation into 
oligodendrocytes, while inducing their differentiation into astrocytes, further 
decreasing the oligodendrocyte population and therefore the 
remyelination172. In this work, our results confirmed that PTXF is directly 
inducing a shift towards the oligodendrocyte fate in vitro, due to the 
inhibition of nuclear c-Rel. Therefore, c-Rel might also have an important 
function in vivo during PTXF-treatment of demyelinating diseases such as 
multiple sclerosis. Further studies analyzing the modifications induced 
within the central nervous system upon treatment using pentoxifylline 
against these neurodegenerative diseases will be needed to elucidate a role 
in the remyelinating process within the adult ageing human brain. 
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and functionality. 
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A version of this chapter is in preparation to be published: 
Ruiz-Perera, L. M., Kaltschmidt, C., Kaltschmidt, B. in prep. 
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5.1 Results 
5.1.1 NF-κB subunit distribution in early stages of dopaminergic 
differentiation of ITSCs 
In order to study the role of NF-κB during dopaminergic differentiation, 
we characterized the NF-κB subunit composition during early stages of 
differentiation. ITSCs were cultivated following a directed dopaminergic 
differentiation procedure (Fig. 5-1A)40. Samples were taken at different time 
points (0, 2, 6, and 9 days of differentiation) and analysed by 
immunocytochemistry for NF-κB-p65 (RelA), RelB and c-Rel (Fig. 5-2, 5-3, 
5-4), and we further verified their ability to differentiate into the 
dopaminergic lineage, demonstrated by morphological changes into a 
neuronal phenotype (Fig. 5-1B) and by immunostaining analyses showing 
dopamine (DA) and tyrosine hydroxylase (TH) expression after 21 days of 
differentiation (Fig. 5-1C-D), further validating that ITSCs efficiently 
differentiate into mature dopaminergic neurons.  
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Figure 5-1. ITSCs effieciently differentiate into dopaminergic neurons. A: 
Diagram showing dopaminergic differentiation procedure. ITSCs were cultivated for 
at least 12 hours in DMEM high glucose supplemented with 10% FCS. For neuronal 
induction, media was changed to DMEM high glucose supplemented with 1% FCS, 
penicillin/streptomycin, β-mercaptoethanol (10 µM), B27 without retinoic acid, 
purmorphamine (10 µM), FGF8 (100 ng/ml), GDNF (5 ng/ml), BDNF (20 ng/ml), 
NGF (20 ng/ml), dibutyryl cAMP (1 mM), ascorbic acid (200 µM), SB-431542 
(10µM), LDN193189 (100 nM), and CHIR99021 (0.5µM). Afterwards media was 
modified as indicated in the scheme. Medium was replaced with prewarmed fresh 
medium daily. Modified from Nartnyk et al., 20144. B: ITSCs changed their 
morphology towards a neuronal phenotype during directed neuronal differentiation. 
C-D: Immunocytochemical analysis showing dopamine (DA) and tyrosine 
hydroxylase (TH) expression after 21 days of differentiation, indicating mature 
dopaminergic neurons derived from ITSCs. 
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5.1.2 RelA distribution during early dopaminergic differentiation 
Immunocytochemistry against RelA revealed that during the first days 
of differentiation there is a strong marked cytoplasmic signal and a lower 
nuclear level in most cells, being strong in some cells (Fig. 5-2A, 
arrowheads). During the first 4 days of differentiation both cytoplasmic and 
nuclear RelA decreased (Fig. 5-2A-C), while at day 6 both were slightly 
increased, having a faint nuclear intensity with a punctuated pattern (Fig. 
5-2D). Later, cytoplasmic and nuclear RelA intensity was further increased 
for donor 1 (Fig. 5-2E), while it decreased for the other two donors, keeping 
the punctuated pattern observed. Thus, due to the slight changes in nuclear 
activation observed, we further analyzed the fluorescence intensity profile 
(Fig. 5-2F), to discriminate the fluctuations in RelA subcellular localization 
for cells at the different timepoints analyzed. We also quantified nuclear 
fluorescence using the nuclear mean integrated density for the three female 
donors analyzed (Fig. 5-2G), that allowed us to determine the changes in 
nuclear RelA during early dopaminergic differentiation. Statistical analysis 
clearly demonstrated significant differences for nuclear RelA which had a 
higher level between day 0 and day 2 compared to day 4 (Non parametric 
Kruskal-Wallis test, ***p≤0.001, Tukey's test, ***p≤0.001, n=3), this could 
be due to cell attachment, that might be consolidated after day 4. Also 
there was a significant difference between day 4 and day 6, indicating that 
RelA increased afterwards, and that it might be important for the 
differentiation process during later timepoints. 
5.1.3 RelB distribution during early dopaminergic differentiation 
Immunostaining analyses also confirmed that RelB had a higher level in 
the cytoplasm than in the nucleus, although the intensity level observed 
was relatively low (Fig. 5-3A-E). Initially, RelB had a lower intensity level 
at the beginning of the differentiation and gradually increased over time 
(Fig. 5-3A-E), showing a peak at day 9, which could be maintained or 
increased later. However, for female donor 1 RelB level was slightly higher 
at the beginning and decreased gradually during differentiation. These 
differences were further analyzed with the fluorescence intensity profile 
(Fig. 5-3F), were a clear change in the nuclear intensity fluctuations is 
observed, among cells at different timepoints. In addition, to detect these 
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nuclear intensity changes, we quantified the nuclear mean integrated 
density (Fig. 5-3G). As shown by the range of the intensity scale (Fig. 5-
3A-E), both cytoplasmic and nuclear RelB levels are very low during the 
first 4 days of differentiation, however after day 6 there is a clear increase 
in RelB at both cytoplasmic and nuclear levels. Statistical analysis 
demonstrated a significant difference between day 0 and day 6 and 9 (Fig. 
5-3G, Non-parametric Kruskal-Wallis ***p≤0.001, Tukey's post hoc test 
***p≤0.001), suggesting that RelB has an important role during this later 
stage of early dopaminergic differentiation. Although there is a clear 
increase of nuclear RelB, as the peak observed is not too prominent, it is 
possible that RelB has an even stronger activation peak at later timepoints. 
In that case, later timepoints should be analyzed to determine whether 
RelB has a role during late dopaminergic differentiation. 
5.1.4 c-Rel distribution during early dopaminergic 
differentiation 
We further analyzed NF-κB-c-Rel by immunostaining, and determined 
that c-Rel is highly expressed at day 0 for two female donors (D1 and 2), 
especially at the cytoplasmic level, however it is highly expressed at the 
nuclear level (Fig. 5-4A, arrowheads). At day 2 both cytoplasmic and 
nuclear c-Rel remarkably decreased, however some nuclear activation 
remained in a lower degree (Fig. 5-4B). In the following timepoints a slight 
increase at both subcellular localizations was observed (Fig. 5-4C-E). 
Furthermore, the differences in c-Rel expression were illustrated by 
measuring the fluorescence intensity profile of cells at the different 
timepoints studied (Fig. 5-4F), showing a clear nuclear c-Rel increase 
between days 4 and 9. Quantification of nuclear mean integrated density for 
c-Rel confirmed this NF-κB-c-Rel activating peak, which was statistically 
relevant (Fig. 5-4G, non-parametric Kruskal-Wallis ***p≤0.001 and Tukey's 
test ***p≤0.001). As shown in the figure, there was a significant increase of 
nuclear c-Rel between days 4 and 6 compared to day 2, and also a clear 
decrease afterwards when comparing days 4 and 6 to day 9 (Fig. 5-4G, 
Non-parametric Kruskal-Wallis ***p≤0.001 and Tukey's test ***p≤0.001). 
Further, a significant difference was shown between day 0 and all later time 
points, which could be related to the cell attachment during the beginning  
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Figure 5-2. Immunocytochemical analysis of RelA (NF-κB-p65) during early 
dopaminergic diferentiation. A-E: ITSCs labeled against RelA after 0, 2, 4, 6 and 9 days 
of dopaminergic diferentiation. Each panel shows RelA on the left-side and DNA staining 
on the right-side. Intensity scale: white highest intensity level and black lowest intensity 
level. Arrowheads show high RelA nuclear activity, asterisks indicate cells further 
analyzed in F. F: Fluorescence intensity profiles measured at all time points analyzed, for 
the cells shown in A-E with asterisks, following transects as shown. Here the difference 
between the nuclear and cytoplasmic fluorescence is exposed. G: Quantification showing 
nuclear mean integrated density of RelA for all female donors analyzed (n=3, mean ± 
SEM) and the Statisic analysis performed. Normality was refuted using Shapiro-Wilk 
normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and Tukey's test 
(***p≤0.001) revealed significant differences in nuclear translocation of NF-κB-p65 as 
indicated.  
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Figure 5-3. Immunocytochemical analysis of RelB during early dopaminergic 
differentiation. A-E: ITSCs labeled against RelB after 0, 2, 4, 6 and 9 days of 
dopaminergic diferentiation. Each panel shows RelB on the left-side and DNA staining 
on the right-side. Intensity scale: white highest intensity level and black lowest 
intensity level. Arrows indicate cells with low RelB activity, Arrowheads show high 
RelB nuclear activity, asterisks indicate cells  further analyzed in F.  F: Fluorescence 
intensity profiles measured at all time points analyzed, for the cells shown in A-E with 
asterisks, following transects as shown. Here the difference between the nuclear and 
cytoplasmic fluorescence is exposed. G: Quantification showing nuclear mean integrated 
density of RelB for all female donor analyzed (n=3, mean ± SEM) and the statisic 
analysis performed. Normality of the data set was refuted using Shapiro-Wilk normality 
test. Non-parametric Kruskal-Wallis (***p≤0.001) and Tukey's test (***p≤0.001) 
revealed significant difference in nuclear RelB between day 0 and day 6 and 9. 
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Figure 5-4. Immunocytochemical analysis of c-Rel during early dopaminergic 
differentiation. A-E: ITSCs labeled against c-Rel after 0, 2, 4, 6 and 9 days of 
dopaminergic diferentiation. Each panel shows c-Rel on the left-side and DNA staining 
on the right-side. Intensity scale: white highest intensity level and black lowest 
intensity level. Arrows indicate cells with low c-Rel nuclear activity, Arrowheads show 
high c-Rel nuclear activity, asterisks indicate cells  further analyzed in F. F: 
Fluorescence intensity profiles measured at all time points analyzed, for the cells shown 
in A-E with asterisks, following transects as shown. Here the difference between the 
nuclear and cytoplasmic fluorescence is exposed. G: Quantification showing nuclear 
mean integrated density of c-Rel for all female donors analyzed (n=3, mean ± SEM) 
and the statisical analysis performed. Normality of the data set was refuted using 
Shapiro-Wilk normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and Tukey's 
post hoc test (***p≤0.001) revealed significant differences in nuclear c-Rel as indicated. 
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of differentiation in the early phase (Non-parametric Kruskal-Wallis 
***p≤0.001 and Tukey's post hoc test ***p≤0.001). These results strongly 
suggest the presence of a nuclear c-Rel peak during dopaminergic 
differentiation, indicating that c-Rel might have an essential function 
during early stages of dopaminergic differentiation. 
5.1.5 Dopaminergic differentiation capability of female and 
male-derived ITSCs 
We further analyzed the ability of female and male-derived ITSCs to 
differentiate into dopaminergic neurons (Fig. 5-6), and we observed that 
female-derived neurons had a multipolar neuronal morphology, exhibiting a 
higher amount of neurites, similar to the dopaminergic neuronal mature 
shape (Fig. 5-6A-C). However male-derived neurons possessed a less 
complex morphology with a smaller amount of neurites, being most cells 
bipolar and few of them multipolar. Also male-derived neurons had not a 
much defined soma, possibly corresponding to a different neuronal subtype 
or to an immature dopaminergic phenotype. This was supported by the low 
expression of tyrosine hydroxylase in male-derived neurons, as well as a 
higher number of cells with a remarkably smaller nucleus, indicating a 
 
Figure 5-5. NF-κB subunit composition in early dopaminergic differentiation. A: 
Overview of the NF-κB-Rel subunit distribution showing the nuclear mean integrated 
density plotted as the median with the median absolute deviation as the variance 
range. B: Diagram showing NF-κB subunit distribution during early stages of 
dopaminergic differentiation. Nuclear mean integrated density shown as the median 
normalized to the range from 0 to 1. The curve for each subunit is represented as 
indicated. 
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higher amount of cell death (Fig. 5-6E-F). These results further indicated 
the strong capability of female-derived ITSCs to efficiently differentiate into 
dopaminergic neurons, which was not so evident in male-derived neurons, 
indicating the existence of a sex-specific difference in dopaminergic 
differentiation of ITSCs.  
5.1.6 Stimulation of dopaminergic differentiated neurons of 
female and male-derived ITSCs 
Furthermore we studied the capability of the dopaminergic neurons to 
respond to chemical stimulation, specially focusing in the female ITSC-
derived neurons, which were shown to differentiate better into this neuronal 
subtype (Fig. 5-6). We stimulated dopaminergic neurons using TNF-α, 6-
hydroxydopamine (6-OHDA), and their combination, and compared to 
untreated neurons (Fig. 5-7A-F). Subsequently, we analyzed whether the 
stimulation resulted in the nuclear translocation of the NF-κB-p65 (RelA) 
by indirect immunodetection, to determine a possible role of p65 in 
dopaminergic neuronal functionality in vitro. 
 Upon 24h of 100 µM 6-OHDA stimulation, we observed a clear change 
in neuronal morphology, the cells exhibited an extended soma with a 
flattened cytoplasm, and enlarged neurites compared to control (Fig. 5-7A, 
C). We also observed an increase in nuclear NF-κB-p65 activation (Fig. 5-
7C, arrowheads) and in neuronal death, after treatment with 6-OHDA. 
These morphological changes were similar to the alterations observed after 
treatment with 10 ng/ml TNF-α for 2h (Fig. 5-7B), however in this case, no 
increase in neuronal death was observed. In contrast, when neurons were 
pre-treated with TNF-α for 2h upon 6-OHDA stimulation, some neurons 
maintained their multipolar morphology which was very similar to the one 
observed in untreated neurons (Fig. 5-7D, arrow), suggesting there was  
neuroprotection of some cells, although there was still a reduction of 
neurons observed per area that imply some level of neuronal death.  
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Figure 5-6. Immunocytochemical analysis against tyrosine 
hydroxylase (TH) performed after 21 days of dopaminergic 
differentiation of female and male ITSCs. A-C: Dopaminergic neurons 
differentiated from female ITSC-donors strongly positive for TH, 
showing multiple neurites. D-F: Dopaminergic neurons differentiated 
from male ITSC-donors less positive for TH. Male neurons show a 
lower number of neurites, being most cells bipolar in shape and few of 
them multipolar.  
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Due to the nuclear NF-κB-p65 activation observed after the stimulation 
of dopaminergic neurons, we quantified the nuclear fluorescence using the 
nuclear mean integrated density (Fig. 5-7E-H), where each female donor 
showed a particular nuclear p65 curve for the different treatments. 
Statistical analysis demonstrated that only TNF-α-stimulation showed a 
clear significant increase in nuclear RelA activation, compared to the 
untreated control, and it also showed a significant increase compared to 6-
OHDA stimulation alone and upon TNF-α-pretreatment (Fig. 5-7H, non-
parametric Kruskal-Wallis test, ***p≤0.001, Tukey's post hoc test 
***p≤0.001, n=3). In particular, this might be due to the high variance on 
the basal level of p65 observed between the different donors, and also to the 
variance of nuclear-p65 within 6-OHDA treatment. Thus, these results show 
that the basal activation of p65 is similar to its activation after treatment 
with 6-OHDA and TNF-α/6-OHDA. Thus, NF-κB-p65 function upon 6-
OHDA stimulation or TNF-α/24h 6-OHDA remains to be determined due 
to their similarity on p65 level to the untreated control.  
Due to the changes in neuronal morphology and death observed in the 
immunocytochemical assays, the death rate of female-derived dopaminergic 
neurons after the different stimulations were calculated (Fig. 5-8A), 
although there was a clear trend in the death rate to increase in neurons 
treated with 6-OHDA, no significant differences were observed between the 
treatments and the untreated neurons. Furthermore, in the case of male-
differentiated ITSCs, statistical analysis showed similar significant 
differences, as the ones obtained for female-differentiated dopaminergic 
neurons (Suppl. fig. 6H, non-parametric Kruskal-Wallis test, ***p≤0.001, 
Tukey's post hoc test ***p≤0.001, n=3). Therefore we analyzed the death 
rate for the different treatments of the male-derived neurons and compared 
to the female death rate (Fig. 5-8B). In this manner, we observed that 
male-derived neurons had a higher tendency to die in most treatments, 
compared to female dopaminergic neurons, with the exception of TNF-α 
treatment, however these differences were not statistically relevant. Male-
derived neurons showed a similar trend in the death rate of 6-OHDA 
treated and control neurons, in comparison to female neurons, and both 
female- and male-derived neurons showed some reduction in death rate 
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after pre-treatment with TNF-α before 6-OHDA treatment. These 
preliminary findings propose a possible neuroprotection induced by the 
activation of NF-κB-p65 mediated by TNF-α-pretreatment in both sexes. 
Nevertheless, more experiments need to be done to further prove this 
neuroprotection effect, and the sex-specific differences that might be 
related.  
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Figure 5-7. Stimulation of dopaminergic differentiated neurons of female-derived 
ITSCs. A-D: Immunocytochemical assays labeling p65 of female-derived dopaminergic 
neurons, after treatment with TNF-α, 6-hydroxydopamine (6OHDA), and their 
combination. Arrows: low endogenous p65 nuclear activity, arrowheads: strong p65 
activity. E-G: Quantification analysis of nuclear mean integrated density of p65 after 
stimulation of dopaminergic differentiated ITSCs shown for the three female donors 
analyzed. H: Quantiication showing nuclear mean integrated density of p65 after 
treatment of dopaminergic neurons shown for all female donors (n=3, mean ± SEM) 
and the statisical analysis performed. Normality was refuted using Shapiro-Wilk 
normality test. Non-parametric Kruskal-Wallis (***p≤0.001) and Tukey's test 
(***p≤0.001) revealed significant differences in nuclear p65 as indicated. 
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5.2 Discussion 
The present work describes the central function of NF-κB-Rel family 
members, Rel-A, c-Rel and RelB during dopaminergic neuronal 
differentiation of human inferior turbinate stem cells. In this work, we 
efficiently differentiated dopaminergic neurons reproducing and extending 
previous findings of our lab40, as verified by the morphological changes into 
a neuronal phenotype observed and the upregulation of dopamine and 
tyrosine hydroxylase after 21 days of differentiation. We further 
characterized the NF-κB subunit composition during early stages of 
differentiation, and we demonstrated that RelA (p65) was activated during 
an early phase and gradually decreased, having a strong nuclear increase at 
day 6. During RelA inactivation, an increase in nuclear c-Rel was observed, 
showing an activation peak between days 4 and 6. In contrast, RelB had an 
extremely low nuclear level until day 6, where a significant increase was 
observed indicating a function at later timepoints. These results strongly 
suggested that NF-κB activity is strictly regulated during dopaminergic 
differentiation. In this way, RelA was shown to have an important role 
during the initial phase that could be related to cell attachment, then, c-Rel 
seemed to take over during a medial phase of differentiation, showing a 
clear peak directly afterwards, suggesting a major function during early 
dopaminergic differentiation. Finally, RelA and RelB significantly increased 
at day 6, further demonstrating that these subunits are essential at later 
 
Figure 5-8. Death rate of dopaminergic differentiated ITSCs upon drug treatment. A: 
Death rate of female-derived dopaminergic neurons. B: Death rate of female versus male-
derived dopaminergic-differentiated ITSCs. Statistic analysis using non parametric 
Kruskal-Wallis test showed no significant differences in neuronal death between the 
treatments and the sexes.  
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timepoints, during a final phase (Fig. 5-5). Furthermore RelB increase at 
day 6 suggested that it might have an even higher peak at later timepoints, 
and thus it can have an important function during late differentiation.  
Interestingly, we further observed strong differences in the ability of 
female and male-derived ITSCs to differentiate into dopaminergic neurons. 
Neurons derived from female donors showed a complex neuronal 
morphology after 21 days of differentiation, and a higher expression level of 
tyrosine hydroxylase compared to neurons derived from male donors. In 
addition, male-derived neurons showed a lower neuronal complexity, 
evidenced by a minor number of neurites, indicative of the differentiation of 
these cells into an immature dopaminergic phenotype or into another 
neuronal subtype. Male-derived neurons also showed an extremely small 
nuclear size, supporting a higher death rate in comparison to female-derived 
neurons. This might be due to their lower capacity to differentiate into 
dopaminergic neurons, thus cells unable to proceed their differentiation 
undergo apoptosis. These findings confirm the existence of sex-dependent 
differences in the differentiation of ITSCs into the dopaminergic lineage.  
Furthermore, we evaluated the functionality of dopaminergic neurons by 
chemical stimulation. In the present work, ITSC-derived human 
dopaminergic neurons revealed a significant increase in nuclear 
translocation of NF-κB-p65 induced by TNF-α-treatment, indicating a 
crucial role of NF-κB-signalling in neuronal dopaminergic function, as we 
also demonstrated for ITSC-derived glutamatergic neurons (see chapter 3). 
TNF-α is a cytokine mediating the activation of the canonical NF-κB-
signalling pathway124-125, by binding to its receptors TNFR1 and TNFR2 
which are broadly expressed in the nervous system 128-130. TNF-α plays a 
dual role in neurodegenerative diseases, since stimulation via TNFR1 is 
predominantly associated with neurodegeneration, and stimulation via 
TNFR2 is involved in neuroprotection and tissue regeneration173. In 
addition, an in vitro model of Parkinson disease showed that induction with 
a human selective TNFR2 agonist was able to rescue neurons upon 
induction of cell death by 6-OHDA174.  
Stimulation of dopaminergic neurons using 6-hydroxydopamine, 
exhibited a strong alteration in the neuronal morphology regardless of the 
sex of the donor, providing evidence that these neurons respond to the 
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neurotoxin, however there was a higher tendency to die in male-derived 
neurons, compared to their female counterpart. Although the differences 
observed in the death rate between female- and male-derived neurons were 
not significantly different, our findings indicate a higher tendency in male-
derived neurons to die upon 6-OHDA-treatment, in comparison to female-
derived neurons. These results are in line with the gender differences 
observed in PD where more men are diagnosed with the disease than 
women (by a ratio of 2:1)175. Moreover, our results introduce a 
neuroprotection role induced by the activation of NF-κB-p65 mediated by 
TNF-α-pretreatment upon 6-OHDA-treatment of dopaminergic neurons 
derived from donors from both sexes. Indeed, additional analysis needs to 
be done to further demonstrate this neuroprotective effect, and also the 
possible sex-specific differences that might be related to it. Additionally, 
neuronal survival could be promoted using lowered oxygen levels during 
differentiation, that was shown to enhance proliferation and neuronal 
survival during dopaminergic differentiation on CNS precursors in vitro176.    
Furthermore, as the statistical analysis pointed out 6-OHDA-treated 
dopaminergic neurons and TNF-α/6-OHDA-treated neurons showed a 
similar nuclear RelA level compared to the basal state in untreated 
neurons. This is probably due to the high variance observed in nuclear p65 
level in control neurons among the different donors, this elevated 
heterogeneity might be masking the real differences between the treated 
and the untreated neurons. Therefore, to determine a real difference we 
should increase the N, by increasing the number of donors analyzed or the 
number of replicates used to diminish the variance observed. Besides, the 
concentration of 6-OHDA used, could have been too low to produce a 
strong neurotoxic effect, even if the neurons were stressed as shown by the 
morphological alterations observed. Moreover, these dopaminergic neurons 
were able to produce dopamine and tyrosine hydroxylase, which are 
essential for normal neuronal function. It is thus possible that endogenous 
dopamine masked in part the effect of 6-OHDA stimulation in nuclear-p65 
activation, however we used a higher level, probably saturated that makes 
this unlikely. Nonetheless, this could also be due to the timepoints analyzed 
and the dynamics in NF-κB-signaling. It is known that NF-κB-p65 nuclear 
dynamics upon TNF-α stimulation, is initially very high and decreases over 
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time, thus something similar might be happening upon 6-OHDA 
stimulation. Thus, if the signaling dynamics vary depending on the stimuli 
used, NF-κB-p65 peak might have a differential temporal pattern depending 
on the stimuli used. Therefore, the nuclear-p65 activation induced by TNF-
α could be completely different to the one induced by 6-OHDA. Hence, in 
order to determine a clear difference we should optimize the concentration 
of 6-OHDA utilized as well as the treatment duration.  
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6 Outlook 
6 
In the presented study, we efficiently differentiated and validated the 
functionality of glutamatergic neurons derived from inferior turbinate stem 
cells, and we further demonstrated a key role of NF-B-p65 in sex-specific 
neuroprotection during their maturation after oxidative stress insult. In this 
way, our findings showed a significantly elevated sensitivity of female-
derived neurons to oxidative stress-induced neuronal death and to NF-B-
dependent neuroprotection compared to male-derived neurons. These were 
accompanied by a differential expression of NF-B-p65 target genes in a 
sex-dependent manner. In addition, we further revealed TNF-α stimulation 
of glutamatergic neurons, induced NF-B-c-Rel nuclear translocation. Thus, 
an interesting study to be carried on in the near future is the analysis of the 
function of c-Rel during H2O2-mediated oxidative stress and TNF-α-
mediated neuroprotection in glutamatergic neurons. It is sensible to think 
that both subunits RelA and c-Rel are affected during TNF-α-mediated 
neuroprotection, and thus c-Rel might also induce the expression of a 
special set of genes that could also be sex-specific and complement the 
regulatory mechanism observed. Furthermore, as the entire mechanism 
involved in this process was not completely elucidated, sex-specific 
investigation is essential. An important point to follow up this research 
project is to study the mechanisms regulating TNF-α-mediated 
neuroprotection at the chromatin and DNA level. In this way, epigenetic 
regulation mechanisms such as DNA methylation, histone deacetylation, or 
other histone post translational modifications controlling chromatin 
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remodelling and DNA access by transcription factors should be further 
analyzed. 
In addition, we demonstrated for the first time a key role of NF-κB 
subunits during neuronal differentiation of human inferior turbinate stem 
cells. We were able to determine the NF-κB subunit composition present 
during early stages of glutamatergic and dopaminergic neuronal 
differentiation. In the case of glutamatergic differentiation, NF-κB subunit 
pattern showed a nuclear activation of RelB/p52 heterodimers during an 
early phase, and a c-Rel nuclear activation peak during a later phase of 
differentiation. While the classical NF-κB subunits, RelA and p50 had no 
part during this differentiation. In contrast, during dopaminergic 
differentiation RelA had an important role during the initial phase of 
differentiation, whereas c-Rel showed a clear activation peak during the 
medial phase of differentiation, and finally RelA and RelB were significantly 
increased at a later and final phase of dopaminergic differentiation. These 
results confirmed that NF-κB activity is strictly regulated during neuronal 
differentiation, and thus NF-κB-signalling might have a particular temporal 
pattern during the differentiation towards any cell fate. Therefore, it would 
be of outmost importance to further determine NF-κB subunit composition 
during early and late differentiation of inferior turbinate stem cells into 
different mesodermal lineages, such as osteoblasts, adipocytes and 
chondrogenic cells, to gain insight in the NF-κB regulatory network 
involved during human stem cell differentiation.  
Furthermore, here we confirmed that modifying the expression of the 
NF-κB subunits involved in a particular differentiation mechanism, we can 
shift the differentiation into a completely different cell fate, with the 
respective potential restrictions in the fate lineage. In this work we were 
able to switch the cell fate from the glutamatergic phenotype to the 
oligodendrocyte phenotype by the sole inhibition of c-Rel using 
pentoxifylline, during the differentiation procedure. These findings further 
implicate that the NF-κB regulatory network involved during stem cell 
differentiation is somehow interconnected. Therefore, another approach to 
continue the study of the role of NF-κB in the regulation during 
differentiation is the use of CRISPR/Cas9 to eliminate the different NF-κB 
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subunits and elucidate their role during different directed differentiations. 
This could be a particularly helpful tool to determine other possible shifts 
in cell fate during differentiation. However, it is a difficult task to apply 
this strategy in primary cells, which are not easily transfected especially 
with huge plasmids (>9Kb), unless the lentivirus approach for transduction 
is established and performed instead.  
Furthermore, the investigation of the mechanisms underlying 
differentiation could be studied from a different perspective. An interesting 
way to enlighten the changes observed during differentiation, could be to 
determine the methylation state of the cells before and after the 
differentiation. One would expect that DNA methylation has a particular 
pattern in undifferentiated stem cells and it becomes modified upon 
differentiation, making certain DNA regions accessible for transcription 
factors, with the concomitant expression of specific target genes for 
differentiation and specification into a particular lineage. Thus, this would 
be a very important hint to determine the mechanisms implicated during 
differentiation. 
Moreover, we further analyzed differences in the ability of female and 
male-derived ITSCs to differentiate into dopaminergic neurons, and we 
determined differences in neuronal complexity, in a sex-dependent manner. 
We also studied their capability to respond to stimulation using TNF-α, 6-
hydroxydopamine, and their combination. Hence, stimulation of 
dopaminergic neurons using 6-hydroxydopamine, evidenced a strong 
alteration in neuronal morphology, evidencing neurons were able to respond 
to 6-OHDA, however male-derived neurons had a higher tendency to die, 
compared to female-derived neurons. Although these differences were not 
significantly relevant, these results are in line with the gender differences 
observed in Parkinson's disease. Our results bring in a neuroprotection 
function, by NF-κB-p65 mediated activation induced by TNF-α-
pretreatment upon 6-OHDA-treatment of female- and male-derived 
dopaminergic neurons. Indeed, additional investigation in this direction 
needs to be done to demonstrate these preliminary results about this 
potential neuroprotective effect, and also the possible sex-specific differences 
that might be related to it. Therefore, insight into this line of investigation 
would help to improve our understanding about the characteristics of sex-
specific differences in neuronal differentiation and neurodegenerative 
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diseases as well as to further develop appropriate therapies for their 
treatment.    
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8.1 Supplementary Figures  
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Promotor analysis using the JASPAR Tool 
(jaspar.genereg.net) validated SOD2, PRKACA to be direct RELA, RELB and REL 
target genes. RELA binding sites are shown in red, RELB binding sites  in green, and 
REL binding sites  in brown. Common RELA and REL binding sites are shown in 
blue. One promoter is shown for each gene, for more detail see supplementary material. 
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Supplementary figure 2: Promotor analysis using the JASPAR Tool 
(jaspar.genereg.net) validated IGF2 to be direct RELA, RELB and REL target 
genes. Six promoters are shown for IGF2. RELA binding sites are shown in red, 
RELB binding sites in green, and REL binding sites in brown. Common RELA 
and REL binding sites are shown in blue. Sequences in the antisense strand are 
indicated with an arrow. 
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Supplementary figure 3. Immunocytochemistry assays showing different cell markers after 30 
days of glutamatergic neuronal differentation in the absence or presence of pentoxifylline (PTXF) 
and their respective quantifications. A-B) Neuronal differentiated- ITSCs labeled against Nestin, a 
stemness marker. C) Quantification of the percentage of Nestin+ cells shows a higher tendency on 
Nestin for the differentiated-ITSCs treated with PTXF, compared to the untreated differentiated-
ITSCs. However it is not significantly relevant difference. D-E) Neuronal differentiated- ITSCs 
labeled against alpha smooth muscle actin (αSMA). F) Quantification showing the percentage of 
αSMA+ cells which is cero for the differentiated-ITSCs treated with PTXF and it is 1% in 
untreated differentiated-ITSCs. No significant difference was observed. G-H) Differentiated-ITSCs 
labeled against p75, a neural crest marker. I) Quantification of the percentage of p75+ cells 
indicates a lower ammount of p75+ cells (10%), present in the untreated neuronal differentiated-
ITSCs and a higher tendency of positive cells in the differentiated-ITSCs treated with PTXF 
(40%). However it was not a significant difference. Non-parametric Kruskal-Wallis test (p≤0.10), no 
significant differences observed. 
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Supplementary figure 4. Myelination assay showing immunostainings against 
O4 and NF200, an oligodendrogilal and neuronal marker respectively.  A-E: 
immunocytochemical assays showing male-derived differentiated inferior turbinate 
stem cells (ITSCs), F-J: immunocytochemical assays showing female-derived 
differentiated ITSCs. A, F: ITSC-derived oligodendrocyte progenitor cells (ITSC-
OPCs), B, G: Neuronal differentiated ITSCs in the presence of pentoxifylline 
(PTXF).  C, H: Neurons differentiated from ITSCs. D, I: Co-cultures of ITSC-
derived neurons and ITSC-derived OPCs co-cultivated after 20 days of neuronal 
and oligodedrocyte differentiation. E, J: Co-cultures of ITSC-derived neurons and 
ITSC-differentiated cells in the presence of PTXF, co-cultivated after 20 days of 
neuronal differentiation. Whithin both co-cultivation assays, cells were co-cultured 
for 10 days in neuronal induction media supplemented with N2 at 37ºC in a 5% 
CO2 incubator. 
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Supplementary figure 5. Myelination assay. Myelination assay showing 
immunostainings against MOG (Myelin oligodendrocyte glycoprotein) and MAP-2 
(Microtubule-associated protein 2), an oligodendrogilal and neuronal marker 
respectively.  A-E: immunocytochemical assays showing male-derived differentiated 
inferior turbinate stem cells (ITSCs), F-J: immunocytochemical assays showing 
female-derived differentiated ITSCs. A, F: ITSC-derived oligodendrocyte progenitor 
cells (ITSC-OPCs), B, G: Neuronal differentiated ITSCs in the presence of 
pentoxifylline (PTXF).  C, H: Neurons differentiated from ITSCs. D, I: Co-cultures 
of ITSC-derived neurons and ITSC-derived OPCs co-cultivated after 20 days of 
neuronal and oligodedrocyte differentiation. E, J: Co-cultures of ITSC-derived 
neurons and ITSC-differentiated cells in the presence of PTXF, co-cultivated after 
20 days of neuronal differentiation. Whithin both co-cultivation assays, cells were 
co-cultured for 10 days in neuronal induction media supplemented with N2 at 
37ºC in a 5% CO2 incubator. 
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Supplementary figure 6. Stimulation of dopaminergic differentiated neurons of 
male-derived ITSCs. A-D: Immunocytochemical assays labeling p65 of male-derived 
dopaminergic neurons, after treatment with TNF-α, 6-hydroxydopamine (6OHDA), 
and their combination. Arrows: low endogenous p65 nuclear activity, arrowheads: 
strong p65 activity. E-G: Quantification analysis of nuclear mean integrated 
density of p65, after treatment of dopaminergic neurons shown for the three male 
donors analyzed. H: Quantification showing nuclear mean integrated density of p65 
(n=3, mean ± SEM) and the statisical analysis performed. Normality of the data 
set was refuted using Shapiro-Wilk test. Non-parametric Kruskal-Wallis 
(***p≤0.001) and Tukey's test (***p≤0.001) revealed significant difference in 
nuclear p65 as indicated. 
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8.2 Supplementary tables 
 
Supplementary table 1: ITSCs donors differentiated into dopaminergic 
neurons. 
Donor Internal code Gender Age 
1 K278N Female 20 
2 K325N Female 68 
3 K395N Female 61 
4 K272N Female 26 
5 K284N Male 23 
6 K243N Male 53 
7 NM4 Male 50 
 
8.3 List of Abreviations 
ESCs embyonic stem cells 
iPSCs induced pluripotent stem cells 
ASCs Adult stem cells 
SSEA-3 
stage specific embryonic antigen 3, cell surface antigen used to 
recognize human embryonic stem cells 
SSEA-4 
stage specific embryonic antigen 4, cell surface antigen used to 
recognize human embryonic stem cells 
TRA-1-60 
keratan sulfate antigen from human embryonic stem cells used as 
specific surface marker 
TRA-1-81 
keratan sulfate antigen from human embryonic stem cells used as 
specific surface marker 
OCT4 
octamer-binding transcription factor 4, also known as POU class 5 
homeobox 1 
SOX2 SRY(sex determining region Y) -box 2 
NANOG homeobox protein NANOG 
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KLF4 Kruppel like factor 4 
C-MYC MYC proto-oncogene, bHLH transcription factor 
NCSCs neural crest derived stem cells  
NC neural crest 
BMPs bone morphogenetic proteins 
RA retinoic acid 
FGF fibroblast growth factor 
ITSCs inferior turbinate stem cells 
S100 S100 calcium binding protein 
p75NTR low-affinity neurotrophin receptor, nerve growth factor receptor p75 
SOX10 SRY(sex determining region Y) -box 10 
NSCs neural stem cells 
PNS peripheral nervous system   
CNS central nervous system 
OPCs oligodendroglial progenitor cells   
NPCs neural progenitor cells   
BMP4 bone morphogenetic protein 4 
SHH sonic hedgehog  
OTX1 Orthodenticle homeobox 1 
OTX2 Orthodenticle homeobox 2 
BF1 brain factor 1 
FGF8 fibroblast growth factor 8 
FGF2 fibroblast growth factor 2 
PAX6 paired box 6 
TBR2 T-box brain protein 2 
NEUROD neuronal differentiation 1 
TBR1 T-box brain protein 1 
NGN2 Neurogenin2 
LMX1A LIM homeobox transcription factor 1 alpha 
FOXA2 forkhead box A2 
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EN1 Engrailed Homeobox 1 
WNT1 Wnt family member 1 
GBX2 Gastrulation brain homeobox 2 
NKX2-2 NK2 homeobox 2 
MSX1 msh homeobox 1 
NKX6-1 NK6 homeobox 1 
TH tyrosine hydroxylase 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B-cells 
RHD Rel homology domain 
IB inhibitor of B family 
IB IB-alpha subunit 
PD Parkinson’s disease 
AD Alzheimer’s disease 
TNF-α tumor necrosis factor alpha 
AMPA agonist α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
ROS reactive oxygen species 
H2O2 hydrogen peroxide 
O2
- superoxide 
OH hydroxyl radical 
HSCs hematopoietic stem cells 
NSCs neural stem cells 
BP blood plasma 
EGF epidermal growth factor 
NIM neuronal induction medium 
RT-PCR reverse transcription polymerase chain reaction 
GLU glutamate 
CSS buffered control salt solution 
CQNX 6-cyano-7-nitroquinoxaline-2,3-dione 
PFA paraformaldehyde 
PTXF pentoxifylline, a known inhibitor of c-Rel 
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OEM oligodendrocyte enrichment medium 
GDNF glial cell line-derived neurotrophic factor 
BDNF brain-derived neurotrophic factor 
NGF nerve growth factor 
6-OHDA 6-hydroxydopamine 
NF200 anti-neurofilament 200 
RPLP0 Ribosomal Protein Lateral Stalk Subunit P0 
qPCR Quantitative polymerase chain reaction 
IGF1  Insulin-like growth factor 1 
IGF2 Insulin-like growth factor 2 
PKAcatα c-AMP-dependent protein kinase catalytic subunit alpha 
SOD2 
Superoxide dismutase 2, also known as manganese superoxide 
dismutase , Mn-SOD 
cIAP1 Cellular inhibitor of apoptosis protein 1 
cIAP2 Cellular inhibitor of apoptosis protein 2 
NG2 
transmembrane proteoglycan nerve-glia antigen 2, also known as 
Chondroitin sulfate proteoglycan 4, CSPG4 
PDGFRA Platelet derived growth factor receptor alpha 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
ROI region of interest 
GLU glutamate 
AMPA 3-hydroxyl-5-methyl-4-isoxazole-propionate 
CQNX 6-cyano-7-nitroquinoxaline-2,3-dione 
MK-801 dibenzocyclohepteneimine 
TNFR1 tumor necrosis factor receptor 1 
TNFR2 tumor necrosis factor receptor 2 
IFN-β1b Interferon beta-1b 
IFN-α interferon alpha 
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OPEN NF-κB p65 directs sex-specific 
neuroprotection in human neurons 
 
Lucia M. Ruiz-Perera1, Lennart Schneider1, Beatrice A. Windmöller1, Janine Müller1, 
Johannes F. W. Greiner    2, Christian Kaltschmidt2 & Barbara Kaltschmidt1,2 
 
Protection of neurons against oxidative stress is crucial during neuronal development, maintenance
Accepted: 15 October 2018 and for treating neurodegenerative diseases. However, little is known about the molecular mechanisms 
underlying sex-specific maturation and survival of neurons. In the present study, we demonstrate 
NF-κB-p65 mediated neuroprotection in human glutamatergic neurons differentiated from inferior 
turbinate stem cells (ITSCs) in a sex-dependent manner. We successfully differentiated ITSCs into MAP- 
2+/NF200+/Synaptophysin+/vGlut2+-glutamatergic neurons in vitro and ex vivo and validated their 
functionality. TNF-α-dependent NF-κB-p65 activation was accompanied by significant neuroprotection 
against oxidative stress-induced neuronal death, which was surprisingly higher in neurons from female 
donors. Accordingly, sex-specific neuroprotection of female neurons was followed by an increased 
expression of special NF-κB target genes SOD2 and IGF2. Among these, SOD2 is a well known gene 
protecting cells against oxidative stress resulting in longevity. In addition, IGF2 is known to promote 
synapse formation and spine maturation, and it has antioxidant and neuroprotective effects against 
oxidative damage. In conclusion, we show that NF-κB-p65 is a key player in neuroprotection of human 
neurons, however the protective gene expression program beneath it differs between sexes. Our 
findings are in accordance with the increasing evidences pointing towards sex-specific differences in risk 
and severity of neurodegenerative diseases. 
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Results 
Inferior turbinate stem cells efficiently differentiate into glutamatergic neurons in vitro.    
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Integration and differentiation of ITSC-derived glutamatergic neurons after transplantation 
into ex vivo-cultivated murine organotypic hippocampal slices.    
in vitro
+ 
+ 
 
ITSC-derived glutamatergic neurons show AMPA or glutamate-dependent activation of 
NF-κB-p65.     
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Stimulation with TNF-α leads to significantly increased nuclear translocation of NF-κB-p65 
in ITSC-derived glutamatergic neurons.    
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TNF-α-pre-treatment of human ITSC-derived glutamatergic neurons leads to increased 
NF-κB-p65-activity upon oxidative stress insult.    
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Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000 
deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may 
also have great implications for finding new treatment strategies for other kinds of epithelial 
cancers. Although the transcription factor NF-κB is known as a key player in tumor forma- 
tion, the relevance of its particular subunits is still underestimated. Here, we applied 
CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit c- 
REL in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated 
a homozygous deletion in the c-REL gene, which we validated using sequencing, qPCR, 
immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On 
the functional level, we observed the deletion of c-REL to result in a significantly decreased 
cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired 
proliferative behavior of c-REL
-/- 
cells was accompanied by a strongly decreased amount of 
the H2B protein as well as a significant delay in the prometaphase of mitosis compared to c- 
REL+/+  HeLa Kyoto cells. c-REL-/- cells further showed significantly decreased expression 
levels of c-REL target genes in comparison to wt. In accordance to our proliferation data, we 
observed the c-REL knockout to result in a significantly increased resistance against the 
chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. In summary, 
our findings emphasize the importance of c-REL signaling in a cellular model of cervical can- 
cer with direct clinical implications for the development of new treatment strategies. 
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Target design and cloning 
 
Cell culture and transfection 
c-REL 
 
Genomic PCR and Native PAGE 
c-REL 5´-
TGCATTTTCATTTTCAGTGAATGGT-3´, 5´-ACCTGTGGAGATGACTGTGAAG-
3´
 
Quantitative real-time PCR 
1
5´-CTCCTGACTGACTGACTGCG-3´ c-REL 5´-
TACGGGTTATACGCACCGGA-3´ c-REL 5´-
CCTGGAGCAGGCTATCAGTC-3´ RELA 5´-CACTGTCACCTGGAAGCAGA-3´
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 RELA), 5´-ACATCAAGGAGAACGGCTTCG-3´( RELB 5´-GACACTAGTCG 
GCCCAGG-3´ RELB 5´-GCACCCTGACCTTGCCTATT-3´ NFKB1 5´-GCT 
CTTTTTCCCGATCTCCCA-3´ 5´-CAACCCAG GTCTGGATGGTA-3´ 
NFKB2 5´-CTGCTTAGGCTGTTCCACGA -3´ 5´-TGACAGTGA 
GCCCTGAAAGC-3´ ( IKBKE 5´-CCGGATTTCCCACACTCTGA-3´ IKBKE 5´-
CGGAGACCCGGCTGGTATAA-3´ TBK1), 5´-ATCCACTGGACGAAGGAAGC-3´ 
TBK1 5´-CTGAAAACGAACGGTGACGG-3´ A20 5´-TCCAGTTGCCAG 
CGGAATTT-3´ A20 5´-CAGGATAACGGAGGCTGGGATG-3´ BCL2 5´-
TTCACTTGTGGCCCAGATAGG -3´ BCL2 5´-GCTTGGATGGCCACTTACCT-3´ 
BCL-XL 5´-ACAAAAGTATCCCAGCCGCC-3´ BCL-XL 5´-GCAAGTGGAC 
ATCAACGGGT-3´ TGFB1 5´- TCCGTGGAGCTGAAGCAATA-3´ TGFB1 5´-
GTAGTGGAAAACCAGCAGCC-3´ MYC 5´-AGAAATACGGCTGCACCGAG-3´ 
MYC 5´-ATGGCAACGACTCCTTCTCG-3´ ICAM-1 5´-GCCGGAAAGCTGTA 
GATGGT-3´( ICAM-1 GAPDH 5´-
CATGAGAAGTATGACAACAGCCT-3´, 5´-AGTCCTTCCACGATACCAAAGT-3´
RPLP0 5´-TGGGCAAGAACACCATGATG-3´ , 5´-AGTTTCTCCAGAGCTGGG 
TTGT-3´ eEF2 5´-AGGTCGGTTCTACGCCTTTG-3´, 5´-TTCCCACAAGG 
CACATCCTC-3´).
 
Western blotting 
c-REL c-REL
α 
 
Electrophoretic mobility shift assay 
c-REL 5´-TCGAGGGCTCGGGCTTTCC 
ATCTCTCGA-3´ c-REL CGGGCTTTCC
 
Immunocytochemistry and fluorescence imaging of H2B-mcherry 
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c-REL is overexpressed in human cervical cancers 
c-REL c-REL 
c-
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Successful knockout of c-REL in HeLa Kyoto cells using 
CRISPR/Cas9n 
c-REL 
 
 
Fig 1. Assessment of c-REL overexpression in human cancers and target design of CRISPR/Cas9n-mediated c-REL knockout. A: 
Database mining revealed more profound overexpression of c-REL in cancers from human ovary, cervix and endometrium compared to 
oesophagus ([35], sancer. sanger.ac.uk; 02-14-2017 16:00; 02-21-2017 15:10). B: Target design showing the proposed c-REL knockout with an 
expected deletion around 450 bp targeting the intron 1-exon 2-boundary of the c-REL gene. The design was done with the CRISPR/Cas9n Target 
Online Predictor from the University of Heidelberg [36], crispr.cos.uni-heidelberg.de) and the gene sequence was taken from Ensembl Genome 
Browser (ensembl.org). 
 
https://doi.org/10.1371/journal.pone.0182373.g001
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Fig 2. Successful validation of the c-REL knockout in HeLa Kyoto cells on DNA, mRNA and protein level. A: Genomic PCR depicting a 
profound deletion of the c-REL gene in the c-REL knockout clone (band at 300 bp) compared to the wt clone (band at 700 bp). B: Sequencing analysis 
confirmed the knockout in exon 2 of c-REL. C: qPCR with specific primers in targeted deletion of exon 2 showed no expression of c-REL on mRNA 
level in the c-REL knockout clone in comparison to wt. D: Western blot analysis validated the knockout of c-REL on protein level. E: Electrophoretic 
mobility shift assays (EMSA) showed DNA-binding of c-REL in HeLa Kyoto wt cells (arrow), which was not observable in the c-REL KO clone. F: 
Immunocytochemistry 
depicted a nearly complete loss of c-REL-protein in c-REL knockout clone compared to HeLa Kyoto wt cells. 
 
https://doi.org/10.1371/journal.pone.0182373.g002 
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Fig 3. CRISPR/Cas9-mediated deletion of c-REL results in a decreased proliferation of HeLa Kyoto cell accompanied by strongly 
reduced amounts of histone H2B. A: Cell number assessed by Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) set against 
cultivation time showed a strongly increased population doubling time of c-REL knockout cells compared to wt HeLa Kyoto cells. PDT: 
Population doubling time. B: Flow cytometric DNA content measurements of DAPI-stained c-REL knockout cells showed a decrease in the 
amount of mitotic cells in c-REL knockout cells compared to wildtype. C: Flow cytometric analysis of Annexin V-stained c-REL-/- and wt HeLa 
Kyoto cells revealed only slightly increased amounts of apoptotic cells upon c-REL deletion in comparison to wt. D: Flow cytometric analysis of 
histone H2B-mCherry showed a strongly decreased amount of the H2B protein in 41.48% of c-REL-/- HeLa Kyoto cells, which was observable in 
only 8.67% of HeLa Kyoto wt cells. 
 
https://doi.org/10.1371/journal.pone.0182373.g003 
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Fig 4. Knockout of c-REL leads to a significantly delayed prometaphase or even complete arrest of the cell cycle. A-B: Live cell imaging 
of c- REL-/- and c-REL+/+  cells showed delayed duration of the prometaphase in c-REL-/- (arrows) in comparison to wildtype. Mitosis was visualized 
by H2B- mCherry and alpha-tubulin-EGFP. C: Quantification of life cell imaging validated the significant delay of c-REL-/- in length of the 
prometaphase 
(39.50 ± 9.96 min) in comparison to wt (18.42 ± 1.58 min) (n = 20). D: Exemplary images of c-REL-/- cells arresting during mitosis without entry of the 
G2 phase of the cell cycle. E: Fluorescence imaging of H2B-mCherry in fixed cells displayed a significantly increased amount of c-REL-/- HeLa 
Kyoto cells 
within the prometaphase compared to wt cells. (>1000 cells quantified per genotype, n = 3). Scale bar: 25 μm. 
 
https://doi.org/10.1371/journal.pone.0182373.g004
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Fig 5. c-REL knockout leads to significantly decreased expression levels of NF-κB family member and 
cell cycle-associated genes. A: qPCR analysis showing significantly decreased mRNA levels of NF-κB 
family members RELA, NFKB1 (p50), NFKB2 (p52), IKBKE and TBK1 in c-REL knockout cells compared to 
wildtype cells. B-C: Expression levels of cell cycle-related c-REL target genes A20, BCL2, BCL-XL and 
TGFB1 and c-REL target genes MYC and ICAM-1 were significantly decreased in c-REL knockout cells in 
comparison to HeLa Kyoto wildtype cells. D: Western blot analysis validated the reduced expression levels of 
RELA and A20 in c-REL-/- cells in comparison to wt on protein level. WB were performed after TNFα-
dependent stimulation of c-REL-/- and c- REL+/+ cells. E: Immunocytochemistry revealed a strongly decreased 
protein amount of ICAM in c-REL-/- cells in comparison to wt. 
 
https://doi.org/10.1371/journal.pone.0182373.g005 
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Fig 6. Significantly increased resistance against chemotherapeutic agents in HeLa Kyoto cells with c-REL deletion. A: 
Although both HeLa Kyoto wildtype and c-REL knockout cells showed cell death after treatment with 5-Fluoro-2’-deoxyuridine, the 
c- REL knockout clone showed significantly elevated cell numbers in comparison to wildtype cells. Cells were exposed to 
chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) 
after 
2 h of incubation. Cell number of untreated cells were set to 1 and used for comparison. B: Although cisplatin-treatment of 1–4 μM 
led to cell death of wildtype cells, survival of the c-REL knockout clone was significantly increased even in comparison to untreated 
control. Increasing concentrations of cisplatin (10–100 μM) affected survival of c-REL knockout cells, but cell numbers were still 
significantly elevated compared to wildtype. Cells were exposed to chemotherapeutic agents for 21 h, cell numbers were assessed 
using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) after 2 h of incubation. Cell number of untreated cells were set 
to 1 and used for comparison (n = 8). 
 
https://doi.org/10.1371/journal.pone.0182373.g006 
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Table 1. Overexpression of REL in human cancers. 
 
tissue type % of REL overexpression no. tested 
Ovary 7.52 266 
Lung 7.26 1019 
Urinary tract 7.11 408 
Endometrium 6.81 602 
Pancreas 6.7 179 
Haematopoietic and lymphoid 6.33 221 
Soft tissue 6.08 263 
Cervix 5.86 307 
Upper aerodigestive tract 5.75 522 
Kidney 5.5 600 
Thyroid 5.46 513 
Large intestine 4.92 610 
Stomach 4.91 285 
Liver 4.83 373 
CNS 4.73 697 
Prostate 4.62 498 
Breast 3.71 1104 
Skin 3.59 473 
Oesophagus 3.2 125 
Adrenal gland 2.53 79 
https://doi.org/10.1371/journal.pone.0182373.t001   
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TNF signaling is directly linked  to cancer development and  progression. A broad range of tumor cells is able  to 
evade cell death induced by TNF impairing the  potential anti-cancer value  of TNF in therapy. Although sensi- 
tizing  cells  to  TNF-induced death therefore has  great  clinical implications, detailed mechanistic insights into 
TNF-mediated human cell  death still  remain unknown. Here,  we  analyzed human cells  by  applying  CRISPR/ 
Cas9n  to  generate cells  deﬁcient of IKK1, IKK2, IKK1/2  and  RELA. Despite  stimulation with  TNF resulted in 
impaired NF-κB activation in all genotypes compared to wildtype cells, increased cell death was observable only 
in IKK1/2-double-deﬁcient cells. Cell death could  be detected by Caspase-3 activation and binding of Annexin V. 
TNF-induced programmed  cell  death in  IKK1/2−/−  cells  was  further shown to  be  mediated via  RIPK1 in  a 
predominantly apoptotic manner. Our  ﬁndings demonstrate the  IKK complex to protect from  TNF-induced cell 
death in human cells independently to NF-κB RelA suggesting IKK1/2  to be highly promising targets for cancer 
therapy.
 
 
1.  Introduction 
 
The tumor  necrosis factor (TNF) is a well-characterized pro-in- 
ﬂammatory cytokine known  to activate the  canonical NF-κB signaling 
pathway. A particular important regulatory factor  in NF-κB signaling  is 
the IκB kinase  (IKK) complex.  It consists  of the catalytic subunits IKKα 
(IKK1) and  IKKβ (IKK2) and  the  regulatory subunit NF-kappa-B essen- 
tial  modulator (NEMO; IKKγ). The IKK complex  is required for the  ac- 
tivation of the  transcription factor  NF-κB, which  ultimately results  in 
the  expression of NF-κB target  genes  involved  in cell growth, survival, 
but  also  inﬂammation and  cell  death  [1]. Deregulation of NF-κB sig- 
naling  is strongly   associated with  diseases,   in  particular with  tumor 
formation [2,3]. 
In the canonical NF-κB signaling  pathway binding of TNF to the TNF 
receptor 1 (TNFR1) results  in the  formation of the  so-called  complex  I 
consisting of  the  TNFR1 associated death   domain   protein (TRADD), 
TNF receptor associated factor  2 (TRAF2), cellular  inhibitors of apop- 
tosis  1 and  2 (cIAP1/2), linear  ubiquitin assembly  complex  (LUBAC) 
and   Receptor-interacting serine/threonine-protein  kinase   1  (RIPK1) 
[4].  Ubiquitination of  RIPK1  leads   to  the   recruitment  of  the   IKK 
complex  by binding of NEMO to M1-linked  ubiquitin chains  on the one 
hand  and  of the  TAK1/TAB2/3 complex  via K63-linked  chains  on the 
other  hand  [5,6]. Being phosphorylated by TAK1, IKK2 in turn  phos- 
phorylates IκBα at  Ser32/36. Phosphorylated IκBα will  be poly- 
ubiquitinated by  SCFβ-TrCP  E3 ubiquitin ligases  leading  to  its  protea- 
somal  degradation [7]. This  results  in  the  unmasking of the  nuclear 
localization sequence of NF-κB, in canonical signaling  mostly comprised 
of a p65/p50 dimer,  whereby p65  is the  transactivating subunit [8]. 
Due to the unmasked NLS, NF-κB is no longer retained in the cytoplasm 
and can enter  the nucleus  leading  to the expression of target  genes [9]. 
Tight regulation of the speciﬁcity of this process is achieved by a broad 
range of post-translational modiﬁcations (PMTs) potentially resulting in 
conformational changes  of NF-κB and  by this  specifying  the  subset  of 
target  genes  being  expressed [10,11]. 
Although  TNFR1 belongs  to the  death  receptor family  [12], under 
physiological conditions TNF signaling  will not  induce  cell death  in a 
broad  range  of cell types,  since TNF-mediated activation of NF-κB will 
result  in the  expression of anti-apoptotic genes  such as c-FLIP, cIAP-1, 
cIAP-2  and  Bcl-2 [13–16].  However, genetic  or  pharmacological  in- 
hibition  of  NF-κB is  known   to  increase   sensitivity  to  TNF-induced
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Fig. 1.  Strongly impaired NF-κB activation in knockout cells. (A) Immunocytochemical stainings of cells stimulated for 20 min with  10 ng/mL TNFα. Only in wildtype 
cells  a clear  nuclear translocation of p65  after  stimulation is observable. (B) Western blot  analysis of IκBα after  stimulation with  10 ng/mL TNFα for 20 min.  (C) 
Quantiﬁcation of the  nuclear intensity of cells stained against p65 (One-way ANOVA, Bonferroni post-test, three independent replicates (n = 3), at least  40 cells per 
replicate, genotype and  condition were  analyzed).(D) Quantiﬁcation of western blot  analysis (B). No degradation of IκBα after  TNFα stimulation was  observed in 
double-deﬁcient cells (One-way ANOVA, Bonferroni post-test, n = 3). (E) qPCR analysis of the NF-κB target genes  IκBα, A20 and IL-8 revealed reduced expression in 
the  knockout cells after  6 h of TNFα (10 ng/mL) treatment compared to wildtype cells (One-way ANOVA, Bonferroni post-test, n = 3). 
apoptosis [17]. Here,  cell death  is mediated via the  so-called  complex 
IIa  comprised of  TRADD, Fas-associated protein  with  death   domain 
(FADD) and  caspase-8, which  only  assembles  upon  NF-κB inhibition 
[18,19].  However, programmed cell  death  induced by TNF signaling 
can  also  be mediated via  an  NF-κB-independent manner [20].  In this 
context, cell  death   occurs  via  the  complex   IIb  [20]. In  contrast to 
complex  IIa, FADD and  caspase-8  are  recruited by RIPK1 in complex 
IIb.  Upon  inhibition of  caspase-8,  NF-κB-independent cell  death   via 
TNFR1 can also be necroptotic. Necroptosis is a more recently described 
way  of  programmed cell  death, which   is  independent on  caspase-8 
activation and  induced by RIPK3 and  the  pseudokinase mixed  lineage 
kinase  like  (MLKL) [21–23]. In 2015,  Dondelinger and  colleagues de- 
scribed  Ikk1 and Ikk2 to act directly on RIPK1 and thereby protect cells 
from TNF-induced  cell death  independently on NF-κB activation [24]. 
Most  studies   regarding  TNF-induced   cell  death   were   performed 
using mouse models,  in which members of the NF-κB signaling  pathway 
were  genetically depleted. Many  of  these  genetic   knockouts are  re- 
sulting  in  lethality during  embryonic development, e.g.  in  RelA- and 
Ikk2-deﬁcient  mice   [25–27].  In  both   cases,   embryonic  lethality  is 
caused  by  TNFα-induced  death   of  hepatocytes and  subsequent liver 
degeneration, which  can be rescued  by additional depletion of TNFR1 
[26,28]. In contrast to  this,  a frameshift mutation within  the  human 
IKBKB gene,  which  was  found  in patients suﬀering from  severe  com- 
bined immunodeﬁciency (SCID), had no eﬀect on embryonic survival  or 
liver constitution [29]. These ﬁndings suggest the presence of potential 
diﬀerences  in  the   regulation  of  TNFα-induced  cell  death   between 
mouse  and  human. Since  TNF signaling  is highly  elevated in a broad 
range  of cancer  cells, which  are resistant to cell death  induced by TNF 
[30], sensitizing these  cells to TNF-induced  cell death  appears to be a 
promising approach for cancer  therapy. Despite  this clinical  relevance, 
the detailed molecular mechanisms of TNF-induced  cell death  in human 
cells still remain unknown. 
Facing  this  challenge, we made  use of the  CRISPR/Cas9  system  to 
generate genomic  knockouts of several  members of the NF-κB signaling 
pathway in human cells. Originally  discovered as part  of the  bacterial 
adaptive immune system  [31,32], the  clustered regularly interspaced
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short  palindromic repeats (CRISPR) system  has  become  a state-of-the- 
art  tool  broadly applied for  eﬃcient genome  editing  [33,34]. In this 
study,  a nickase  mutant of the S. pyogenes Cas9 (D10A; Cas9n) has been 
used  minimizing potential oﬀ-target eﬀects  and  by this  increasing the 
speciﬁcity of genome  editing  [35]. We successfully  generated cells de- 
ﬁcient  for IKK1, IKK2, IKK1/2  and  RelA and  demonstrate that  TNFα- 
induced cell death  in human cells is mediated predominantly via RIPK1 
and  independently of NF-κB. Targeting the IKK complex  in tumor  cells 
genetically or  pharmacologically therefore  appears promising to  in- 
crease sensitivity to TNF-induced  cell death  with direct  implications for 
potential therapeutic approaches. 
 
2.  Results 
 
2.1.  Knockout of IKK1 and IKK2 leads to strongly impaired NF-κB 
activation 
 
To assess clinical  implications of IKK1 and IKK2 knockouts, we ﬁrst 
analyzed  levels  of  overexpression  in  human  cancer   with   database 
mining  using COSMIC [36]. Here, particularly IKBKB (IKK2) was found 
to be profoundly overexpressed in a variety  of tissues  including breast, 
endometrium, large  intestine and  skin (Fig. S1). 
We now aimed to analyze  the role of IKK1 and IKK2 in the context  of 
TNF signaling  and  activation of NF-κB. For this,  we utilized  the 
CRISPR/Cas9n system to generate IKK1- and IKK2-deﬁcient cells as well 
as  an  IKK1/IKK2  double   knockout  by  inducing  two  double-strand 
breaks  spanning an intron-exon border  (Fig. S2A). Deletions  within  the 
IKBK1 and   IKBK2 gene  of  clonally   grown   cells  were   validated  by 
genomic  PCR using primers ﬂanking the deletion (Fig. S2B) and by RT- 
PCR using  primer  pairs  with  one  primer  set  within  the  deletion (Fig. 
S2C). Absence of IKK1 and  IKK2 protein was ﬁnally  shown  on western 
blot  (Fig. S2D). Notably,  we did not  observe  a strong  reduction in the 
amount of the  NF-κB subunit p65  in the  knockout clones,  which  was 
described earlier  for  IKK2-deﬁcient   human ﬁbroblast [29].  Only  in 
IKK1-deﬁcient  cells, a slight reduction was detected (Fig. S3). Next, we 
examined  NF-κB activation  in  all  genotypes  after   stimulation with 
TNFα.  Nuclear  translocation of p65  was  signiﬁcantly impaired  com- 
pared  to  wildtype cells  (Fig.  1A, C). This  eﬀect  was  strongest in  the 
double-deﬁcient cells.  In  line  with  this,  qPCR analysis  of  the  NF-κB 
target   genes  IκBα,  A20  and  IL-8 after  TNFα  stimulation revealed a 
signiﬁcantly reduced expression in all genotypes compared to wildtype 
cells (Fig. 1E). In IKK1/2-double-deﬁcient cells, no increase  in expres- 
sion  upon  stimulation was detected at all (Fig. 1E). Moreover,  we de- 
tected  no signs of IκBα degradation upon  TNFα treatment in these  cells 
(Fig. 1B, D). We likewise observed no signiﬁcant degradation of IκBα in 
IKK2  single   knockout  cells,   although  IKK1−/−    cells   showed   
sig- niﬁcantly decreased protein  levels  of  IκBα  after  TNFα-
treatment in comparison to wildtype control  (Fig. 1B, D). 
 
2.2.  IKK1 and IKK2 double-deﬁciency results in TNFα-induced cell death 
 
We aimed  to analyze  TNFα-induced cell death  in our newly  gener- 
ated  knockout cells.  After long-term exposure  (24 h)  to TNFα,  a high 
number of dead  cells was observable only in the  double-deﬁcient cells 
(Fig.  2A; Fig.  S4),  while  there  was  hardly   any  diﬀerence detectable 
between the single knockouts and wildtype cells (Fig. 2A). Im- 
munocytochemical staining of TNFα-treated cells also revealed 32.1% 
of the  IKK1/IKK2−/−  cells  to  be  positive  for  activated Caspase-3.  In 
comparison, only 3.0% Caspase-3-positive cells were found  in wildtype 
cells  (Fig.  2B). Without  TNFα stimulation, in both  genotypes < 0.3% 
cells were positive  (Fig. 2B). We additionally detected the increased cell 
death   in  the  IKK1/2  double-deﬁcient  cells  using  DNA content  mea- 
surements (Fig.  S5).  In  the  IKK1 and  IKK2 single  knockout cells,  no 
diﬀerence in the amount of apoptotic cells upon  TNFα stimulation was 
observable compared to  wildtype cells.  However, in  IKK1/2-double- 
deﬁcient cells,  this  amount was  increased from  4.2%  (wildtype) to 
34.7%  (Fig. S5). Furthermore, increased cell death  of the  IKK1/2−/− 
cells within  24 h of TNFα stimulation could  be demonstrated using  an 
Annexin  V-based apoptosis assay.  Annexin  V-based luminescent signal 
was strongly  elevated in the  double-deﬁcient cells in relation to wild- 
type  (Fig. 2C). 
In  the  presence of Nescrostatin-1s (Nec-1s),  a  potent  inhibitor  of 
RIPK1,  cell  death   was  markedly  reduced  in  IKK1/2-deﬁcient  cells 
(Fig. 3A). Stainings  against  activated caspase-3  revealed 12.8% caspase- 
3-positive cells  (Fig.  3B),  a  strong  reduction when  compared to  the 
32.8%  positive  cells, which  were  stimulated only with  TNFα (Fig. 2B). 
Using the Annexin V-based apoptosis assay, the protective eﬀect of Nec- 
1s was further validated (Fig. 3C). 
 
2.3.  TNFα does not induce programmed cell death upon RelA deﬁciency 
 
Since  cells deﬁcient for either  IKK1 or IKK2 also  showed  strongly 
impaired NF-κB activation, we  speculated an  NF-κB-independent me- 
chanism  might  lead the cell death  observed. To further analyze  this, we 
generated cells  deﬁcient for  the  NF-κB-subunit  RelA (p65)   (Fig.  4). 
Using the  same  approach, we generated a genomic  deletion spanning 
the  intron-exon boundary of exon  2 (Fig. 4A), which  is present in all 
transcript variants listed  at  ENSEMBL.org. We validated the  designed 
deletion using  genomic  PCR and  qPCR (Fig.  4B, C) and  lack  of p65 
protein by immunocytochemistry (Fig. 4D). Analysis  of NF-κB activa- 
tion in these  cells was assessed  by qPCR of the NF-κB target  genes IκBα 
and  A20  showing  reduced expression in  the  RelA−/−  cells  after  sti- 
mulation with  TNFα  compared to  wildtype cells  (Fig.  4E).  This  im- 
pairment was validated by usage of an NF-κB-driven luciferase reporter 
demonstrating  reduced  activation  of  NF-κB  in  the   knockout  cells 
(Fig. 4F). 
Upon long-term exposure  to TNFα we detected no increased amount 
of dead  RelA-deﬁcient cells compared to wildtype cells (Fig. 5A). In an 
immunocytochemical analysis,  the  amount of cells positive  for the  ac- 
tivated form  of caspase-3  only  very  mildly  increased (Fig. 5B), being 
even  below  the  values  for  TNFα-stimulated wildtype cells  (Fig.  2B). 
Signals  for Annexin  V were  hardly  elevated in the  GloMax Annexin  V 
Apoptosis   Assay  in  RelA−/−   cells  within   24 h  of  TNFα  treatment 
(Fig. 5C). 
 
3.  Discussion 
 
In the  present study,  we successfully  generated genomic  knockouts 
for IKK1, IKK2, IKK1/2  and  RelA in HEK293 cells to initially analyze 
the  role  of IKK1 and  IKK2 in  the  context  of TNF-induced  cell  death. 
HEK293 cells are a broadly used cellular  model  for TNF-signaling  [18]. 
Upon stimulation with TNFα, a vast increase  in cell death  was observed 
only  in  cells  deﬁcient for  both  IKK1 and  IKK2. We further partially 
rescued  cell death  in these  cells using  the  RIPK1-speciﬁc  inhibitor  Ne- 
crostatin-1s indicating RIPK1 activity  to be the  predominant cause  of 
the  cell death  observed. 
Activation  of the death  receptor TNFR1 does not necessarily lead to 
death  but  often  results  in cell survival  or even  increased proliferation 
[37,38]. Downstream of TNFR1 two major  pathways – an NF-κB – de- 
pendent and  an  – independent one  – have  been  described to regulate 
and  control   cell  death   [39]. The  ﬁrst  one  is  well  characterized and 
demonstrates the activation of NF-κB by TNF-signaling  resulting in the 
expression of anti-apoptotic NF-κB target  genes  such as cIAP-1, cIAP-2 
or c-FLIP [13,14,17]. In contrast, signaling  via TNFR1 independently of 
NF-κB activation is far less well understood and just gained  attention in 
the  last  years  [39,40]. In the  present study,  we carefully  investigated 
NF-κB activation in  response to  TNFα  in  all  genotypes we  created. 
While diﬀerences between the diﬀerent knockouts were observable, all 
cells showed  signiﬁcantly reduced activation when  compared to wild- 
type  cells.  In  contrast, experiments conducted in  Ikk1-deﬁcient mice 
showed  no major  impairments in canonical NF-κB signaling, although 
strong  developmental aberrations and  death  shortly  after  birth  were
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Fig.  2.  IKK1/2-deﬁciency results in  profound TNFα-induced cell  death. (A) Light  microscopic images demonstrate  vastly  increased cell  death in  IKK1/2-double 
deﬁcient cells upon  24 h exposure to TNFα (20 ng/mL). (B) Immunocytochemical stainings of wildtype and  IKK1/2−/− cells revealed a huge  increase in caspase-3- 
positive cells in the double knockout after  24 h of TNFα stimulation (20 ng/mL) (n = 3; for each  genotype and  condition > 2500  cells were  analyzed). (C) RealTime 
Glo Annexin V apoptosis assay  of wildtype and  IKK1/2-deﬁcient cells.  Compared to wildtype cells,  a strong increase in apoptotic cells was  observed. 
observable [41]. Consequently, IKK2 is concluded to  be  the  catalytic 
subunit needed for  canonical NF-κB signaling   by  directly phosphor- 
ylating   IκBα.  However, in  IKK1-deﬁcient  cells  we  observed severely 
aﬀected NF-κB activation after  TNFα stimulation. In fact, most  experi- 
ments  demonstrated impairments within  the  same  range  as  in  IKK2- 
deﬁcient cells indicating that  IKK2 cannot  compensate loss of IKK1 in 
the cells we used. Interestingly, while no signiﬁcant increase  in nuclear 
localization of p65  after  TNFα stimulation was observable in IKK1-de- 
ﬁcient   cells,   IκBα  was   signiﬁcantly  degraded.  These   data   are   in 
accordance to  Ikk1−/−  mouse  hepatocytes showing  highly  decreased 
amounts of IκBα accompanied by a decreased nuclear translocation of 
p65 in comparison to wt after treatment with TNFα. In line with Luedde 
and  coworkers, we thus  suggest  IKK1 to control  NF-κB nuclear trans- 
location by a mechanism independent of IκB phosphorylation and  de- 
gradation [42]. Remarkably, although activation of NF-κB via  TNF is 
associated with  cell growth, especially in the  context  of tumor  forma- 
tion  and  progression, we detected no signs of reduced proliferation in 
any of the genotypes created (data  not shown).  Recently,  we generated
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Fig. 3.  TNFα-induced cell death is mediated via RIPK1. (A) Stimulation of IKK1/2-deﬁcient cells with  20 ng/mL TNFα and the RIPK1 inhibitor Nec-1s (10 μM; middle 
panel) (1 μM; bottom panel) resulted in a profound protection from  TNFα-induced cell death for Nec1s  (B) Upon  TNFα treatment immunocytochemistry revealed 
12.8% caspase-3-positive cells in the presence of Nec-1s (n = 3; for each  genotype and  replicate > 2500  cells were  analyzed). (C) RealTime Glo Annexin V apoptosis 
assay  of TNFα-stimulated wildtype and  IKK1/2-deﬁcient cells in the  presence of Nec-1s  (C). 
HeLa cells deﬁcient for the  NF-κB subunit c-Rel, which  showed  a sig- 
niﬁcantly lowered proliferation rate  [43].  However, although NF-κB 
activation was signiﬁcantly impaired in these  cells, no increase  in cell 
death  was observed after  treatment with  TNFα already suggesting  the 
presence of an  NF-κB-independent mechanism  to  prevent from  TNF- 
induced cell  death   in  human cells.  Dondelinger and  colleagues  de- 
scribed  a novel function  of both Ikk1 and Ikk2 in mice by demonstrating 
RIPK1 to  be  a bona  ﬁde  target  of the  Ikk complex  [24]. By directly 
phosphorylating  RIPK1,  Ikk1/2  inactivate RIPK1  and   prevent  from 
TNF-induced  cell death  independently of NF-κB. In this NF-κB-in- 
dependent pathway, RIPK1 will be required to recruit FADD into the so- 
called  complex  IIb  resulting in  apoptosis. Upon  caspase-8   inhibition 
RIPK1 can also be incorporated into  the necrosome, which  will lead  to 
the  activation of RIPK3 and  its substrate MLKL leading  to necroptotic 
cell death  [20]. Interestingly, deﬁciency of either  Ikk1 or Ikk2 was not 
suﬃcient to induce  cell death  upon  TNFα. However, in ﬁbroblasts de- 
rived   from  Ikk1/2-double  deﬁcient  mice,  cell  death   was  vastly  in- 
creased  when  cells were  exposed  to TNFα [24]. Extending  these  ﬁnd- 
ings, we observed no strong  increase  in cell death  when  either, IKK1 or 
IKK2 was genetically depleted. Only in cells deﬁcient for both, IKK1 and 
IKK2, signiﬁcant increase  in cell death  was detectable. We hypothesized 
that  cell death  predominantly occurred in an  NF-κB-independent way 
mediated via RIPK1. Conﬁrming this,  application of the RIPK1-speciﬁc 
inhibitor Nec-1s partially rescued  from  TNF-induced  cell death  in the 
IKK1/2-double deﬁcient cells. Previously, the IKK complex  particularly 
was  considered to  be  important in  regard   to  anticancer therapy.  In 
mice, Ikk1 and Ikk2 have been shown to control  liver cancer  by directly 
acting  on  RIPK1, extending the  initial   ﬁndings by  Dondelinger to  a 
tumor   environment [44].  Similar   results   were  obtained for  NEMO, 
which    controlled   RIPK1-mediated  hepatocyte   death    and   by   this 
formation  of  hepatocellular carcinoma [45].  Notably,   most   studies 
dealing  with  the  causes  of cell  death  induced by  TNFα  included the 
application of mouse  models  to  gain  their  ﬁndings. However, diﬀer- 
ences  between humans and  mice  have  been  reported in  the  past  in 
terms  of TNF and NF-κB signaling. Mice deﬁcient for either, RelA, Ikk2 
or NEMO were reported to die during  embryonic development, in each 
case  due  to  TNF-induced  death  of  hepatocytes resulting in  liver  de- 
generation [25–27,46]. In 2013,  Panicke  and  co-workers described a 
frameshift mutation in the human IKBKB gene to be the cause of severe 
combined immunodeﬁciency [29]. Patients carrying this  loss-of-func- 
tion  mutation did  not  show  any  signs of liver  degeneration indicating 
potential diﬀerences in TNF signaling  between humans and  mice.  This 
elucidates the  necessity  to analyze  TNF-mediated cell death  in human 
cells,  especially when  considering that  TNF signaling   is closely  con- 
nected  to  human diseases,  in  particular with  cancer.  Several  reports 
describe   TNF being  involved   in  all  parts   of  carcinogenesis, namely 
transformation of  healthy cells,  survival, proliferation,  invasion, an- 
giogenesis  and  metastasis of tumor  cells (reviewed in [30]). In a broad 
range  of tumorigenic tissues  or tumor  cells, TNF expression is strongly 
increased [47,48]. Consequently, many  types  of tumor  cells are  parti- 
cularly resistant to TNF-induced  cell death  [30]. A better understanding 
of  the  mechanisms, on  how  tumor   cells  evade  death   therefore is  a 
promising approach  to  increase   the  anti-cancer value  of  TNF.  Sup- 
porting our  ﬁndings of NF-κB-independent cell  death  in human cells, 
Legarda-Addison and co-workers demonstrated in Jurkat cells increased 
sensitivity to  TNF-induced  cell  death   upon  NEMO deﬁciency, which 
was  independent of NF-κB [49]. As was  observed from  Dondelinger, 
NEMO deﬁciency in mice  also  sensitized cells regarding TNF-induced 
cell  death, in  a similar  manner as  Ikk1/2 combined [24]. Studies  in 
mice depicted diﬀerences in RIPK1-mediated cell death, depending on
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Fig.  4.  Generation of RELA-deﬁcient  cells. (A) Target design  for the  CRISPR/Cas9-mediated knockout of RELA. Depicted in blue  are the  sgRNAs and  depicted in red 
are the ﬂanking primers used for genomic PCR. (B) Genomic PCR of clonally grown cells revealed genomic deletion within the RELA gene.  (C) qPCR analysis using  a 
primer  set,   where  one   primer  is  designed within  the   deletion  showed a  highly  signiﬁcant  downregulation  of  RelA  mRNA  (t-test,  two-tailed,  n = 3).  (D) 
Immunocytochemical stainings depicted almost complete loss  of RelA protein in  RelA-deﬁcient cells.  (E)  Expression of the  NF-κB target genes  IκBα and  A20  is 
markedly reduced in RelA−/−  cells after  6 h of TNFα stimulation (10 ng/mL) compared to wildtype cells (One-way ANOVA, Bonferroni post-test, n = 3). (F) An NF- 
κB driven luciferase reporter assay revealed a signiﬁcantly reduced NF-κB activation after  24 h TNFα stimulation in RelA-deﬁcient cells (One-way ANOVA, Bonferroni 
post-test, n = 3). 
the cellular  environment. While a mostly NF-κB-independent regulation 
of RIPK1 was demonstrated in the  liver  [45], in the  small  intestine an 
NF-κB-mediated  activation of RIPK1 was shown  to result  in the  loss of 
Paneth  cells [50]. Future  studies  on the  role of human IKK1 and  IKK2 
therefore have  to consider potential diﬀerences between diﬀerent cell 
populations. 
In summary, our ﬁndings demonstrate that  in human cells IKK1 and 
IKK2 have  an NF-κB-independent function  in preventing from  TNF-in- 
duced  cell death. Targeting – genetically or pharmacologically – both 
catalytic IKKs therefore appears to be a promising approach in cancer 
therapy, especially for tumor  cells resistant to TNF-induced  cell death.
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Fig.  5.  No increase in TNFα-induced cell  death upon  RelA deﬁciency. (A) After  24 h of TNFα stimulation  (20 ng/mL) no  diﬀerences in the  amount of dead  cells 
between RelA-deﬁcient and wildtype cells was observable. (B) Immunocytochemistry revealed only a small  increase in Caspase-3-positive cells after  TNFα treatment 
(n = 3; for each  condition > 5000  cells  were  analyzed). (C) RealTime Glo Annexin V apoptosis assay  of TNFα-treated RelA−/−  cells  showed no diﬀerence in the 
amount of apoptotic cells compared to untreated cells. 
4.  Materials and methods 
 
4.1.  Statistical analysis 
 
All  statistical  tests   were   performed  using   GraphPad  Prism   5 
(GraphPad Software,  La Jolla,  USA). Data is presented as the mean of at 
least  three  biological replicas  ± SEM if not  stated  otherwise. The sta- 
tistical  test  used  is mentioned in the  respective ﬁgure  legend.  ns, not 
signiﬁcant, *p < 0.05,  **p < 0.01,  ***p < 0.001. 
 
4.2.  Target design and cloning 
 
Single  guide  RNAs (sgRNAs) were  designed using  the  online  pre- 
diction  tool from the University  of Heidelberg [51]. Nicking pairs were 
chosen  as  described by  Ran  and  colleagues [35].  For  eﬃcient gene 
knockout we designed two nicking pairs creating a deletion spanning an 
intron-exon border  within  the  respective gene.  sgRNAs for  IKK1 and 
IKK2 knockout were  cloned  into  pSpCas9n(BB)-2A-Puro  (PX462)  V2.0 
(Addgene  plasmid  #62987) essentially as described [52], while sgRNAs 
for knockout of RELA were  cloned  into pX335_G2P (modiﬁed Addgene 
plasmid  #42335, kindly  provided by Boris Greber). 
 
4.3.  Cell culture and transfection 
 
HEK293   cells   were   cultivated  in   Dulbecco's   Modiﬁed    Eagle's 
Medium  (DMEM) (Sigma  Aldrich,  Taufkirchen, Germany) containing 
10%  (v/v)  heat-inactivated fetal  calf  serum  (FCS) (VWR, Darmstadt, 
Germany), 2 mM L-glutamine (Sigma Aldrich) and 100 U/mL Penicillin/ 
Streptomycin (P/S)  (Sigma  Aldrich)  at 37 °C and  5% CO2  at saturated 
humidity. 
Transfection was  performed either   using  standard  calcium-phos- 
phate  precipitation or TurboFect  transfection reagent (Thermo  Fisher 
Scientiﬁc) according to manufacturer's guidelines. 
 
4.4.  Genomic PCR 
 
Cells were harvested at 300 g for 5 min and resuspended in cell lysis 
buﬀer  (0.1 μg/mL  Gelatine,  50 mM KCl, 1.5 mM MgCl2, 0.45%  NP40, 
10 mM TRIS pH 8.3,  0.45%  TWEEN 20,  200 μg/mL  Protein  kinase  K). 
Lysate was incubated for 1 h at 55 °C and  5 min  at 95 °C before  being 
used  as template for genomic  PCR. The following  primers were  used: 
IKBKA-fwd 5′-GCCTTGGAACAACTGTGGAAC-3′, IKBKA-rev 5’-GGACG 
CACACATTCCCAAAG-3′,  IKBKB-fwd   5′-CCACCTTGTTTGCCTGC 
TTG-3′,     IKBKB-rev    5′-GTCTCCCCATCCCTCTTCCT-3′,   RELA-fwd 
5′-GGAGCAGAGGGAACCTTGAC-3′,  RELA-rev 5′-GTATCTGTGCTCCTC 
TCGCC-3′. 
 
4.5.  RT-PCR and quantitative  real-time PCR 
 
Total  RNA was  isolated using  TRI Reagent   (Sigmal-Aldrich)  ac- 
cording  to the manufacturer's protocol. 1 μg of RNA was used for cDNA 
synthesis. For RT-PCR, 1 μL cDNA was used  as template and  for quan- 
titative real-time PCR (qPCR), cDNA was diluted 1:100  and  2 μL/reac- 
tion  were  used.  qPCR was  carried out  with  SYBR Green  Master  Mix 
(Thermo  Fisher Scientiﬁc). The following  primers were used: IKK1-fwd 
5′-CTTCGGGAACGTCTGTCTGTA-3′, IKK1-rev 5′-TTGGCATGGTTCAAC 
TTCTTCAT-3′,  IKK2-fwd  5′-GCTGACCCACCCCAATGTG-3′, IKK2-rev 
5′-TAAGCGCAGAGGCAATGTCA-3′, RelA-fwd 5′-CTGTTCCCCCTCATC 
TTCCC-3′,   RelA-rev    5′-GCCATTGATCTTGATGGTGGG-3′, IκBα-fwd 
5′-CCCTACACCTTGCCTGTGAG-3′, IκBα-rev  5′-TAGACACGTGTGGCCA 
TTGT-3′, A20-fwd  5′-CTGAAAACGAACGGTGACGG-3′, A20-rev  5′-TCC 
AGTTGCCAGCGGAATTT-3′, IL8-fwd   5′-TCTGTGTGAAGGTGCAGTT 
TTG-3′, IL8-rev 5′-TTTCTGTGTTGGCGCAGTGT-3′. Ct values  obtained 
in qPCR were  normalized to the  reference genes  GAPDH (fwd  5′-CAT 
GAGAAGTATGACAACAGCCT-3′; rev    5′-AGTCCTTCCACGATACCAA 
AGT-3′), eEF2 (fwd  5′-AGGTCGGTTCTACGCCTTTG-3′; rev 5′-TTCCCA 
CAAGGCACATCCTC-3′)  and  RPLP0 (fwd  5′-TGGGCAAGAACACCATG 
ATG-3′; rev 5′-AGTTTCTCCAGAGCTGGGTTGT-3′). 
 
4.6.  Western blotting 
 
Protein  extracts were made using RIPA buﬀer (1 mM EGTA, 150 mM 
NaCl, 1 mM Na2EDTA, 1 mM Na3VO4, 1% (w/v) NP-40,  1 μg/mL  leu- 
peptin, 1% (w/v) sodium  deoxycholate, 2.5 mM sodium  pyrophosphate, 
20 mM   Tris-HCl   (pH 7,5),    1 mM   β-glycerophosphate)   and    equal 
amounts of protein were  separated by SDS-PAGE and  transferred to a 
PVDF  membrane.  Membranes  were   blocked   using   PBS  containing 
0.05%  Tween  20 and  5% milk powder, followed  by probing with  pri- 
mary  antibodies (rabbit anti-IKK1 (#7182; Santa-Cruz  Biotechnology, 
Dallas,  USA), rabbit anti-IKK2 (#2370; Cell Signaling,  Danvers,  USA), 
rabbit anti-p65 (#8242; Cell Signaling), mouse  anti-IκBα  (#4814;  Cell 
Signaling)    overnight   at    4 °C.   Horseradish   peroxidase-conjugated
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secondary antibodies were  applied for 1 h at room  temperature.  Blots 
were developed using enhanced chemiluminescence. GAPDH (#32233; 
Santa-Cruz  Biotechnology) served  as loading  control. 
 
 
4.7.  Immunocytochemistry 
 
For immunocytochemical stainings cells were  cultivated on cover- 
slips. Fixation  was done with 4% paraformaldehyde (PFA) for 10 min at 
RT.  Prior  to  application of  the  primary antibodies (rabbit  anti-p65 
(#8242; Cell  Signaling), rabbit  anti-cleaved caspase-3   (#9661;  Cell 
Signaling)) cells were permeabilized and blocked  using PBS containing 
0.02%   Triton   X-100  and  5%  goat  serum.   After  repetitive  washing, 
secondary ﬂuorochrome-conjugated antibodies (goat anti-rabbit/mouse 
Alexa Fluor  555,  Thermo  Fisher  Scientiﬁc) were  applied, followed  by 
nuclear  counterstaining  with   DAPI (1 μg/mL)   and  ﬁnally   mounting 
using Mowiol/DABCO. Imaging was done by confocal laser scanning 
microscopy (LSM 780,  Carl  Zeiss,  Oberkochen, Germany) and  image 
processing was  performed using  Fiji [53] and  Corel Draw  (Corel  Cor- 
poration, Ottawa, Canada). 
 
 
4.8.  Dual luciferase reporter assay 
 
Cells were transiently transfected with TK (NF-κB)6 LUC vector [54] 
and  pRL-CMV (Promega Cooperation) using  TurboFect   Transfection 
Reagent  (Thermo  Fisher  Scientiﬁc) according to manufacturer's guide- 
lines.  24 h after  transfection, cells were  stimulated with  TNFα or left 
untreated. The  next  day,  cells  were  lysed  in  1 × Passive  Lysis buﬀer 
(Promega Corporation) and Luciferase  activity  was measured using the 
Dual-Luciferase® Reporter Assay  System  (Promega Corporation). Sig- 
nals were  normalized as a ratio  of Fireﬂy  luciferase activity  to Renilla 
luciferase activity. 
 
 
4.9.  RealTime Glo Annexin V apoptosis assay 
 
Apoptosis   was   analyzed  using   the   RealTime-Glo™  Annexin   V 
Apoptosis  Assay  (Promega Corporation) according to  manufacturer's 
guidelines. One day  prior  to stimulation, 10.000 cells were  seeded  in 
white,  tissue  culture-treated 96-well  multiwell plates  (BRAND, 
Wertheim, Germany). Cells were  stimulated as indicated and  simulta- 
neously  detection reagent – prepared according to the  manufacturer's 
protocol – was added. Annexin  V-based luminescence was measured at 
the   times   indicated  using   a  GloMax®-Multi  Plus  Detection  System 
(Promega Corporation). No-cell controls  were used for background 
subtraction. 
 
 
4.10.  Flow cytometric analysis 
 
DNA content was  measured essentially as described [55]. Brieﬂy, 
1 × 106 cells – treated as indicated – were harvested and ﬁxed for 5 min 
using 70% (v/v) ethanol. After centrifugation at 300 g cells were stained 
with staining solution  (PBS containing 1 mg/mL  glucose (Roth),  50 mg/ 
mL propidium iodide  (Partec, Sysmex Deutschland GmbH, Bornbarch, 
Germany) and  100  Kunitz units  RNaseA (Thermo  Fisher  Scientiﬁc) for 
60 min under  exclusion  of light.  PI-staining was analyzed using  a Gal- 
lios™ 10/3 ﬂow  cytometer (Beckman  Coulter,  Brea,  CA, USA). Data 
analysis   was  done  using  FlowJo  Software   (TreeStar, Olten,  Switzer- 
land),  doublet discrimination was assured  by gating  FL3-A- versus FL3- 
W signals. 
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